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Important definitions of terms
Pre-study phase:
The preparations for the study was performed prior the start of clinical investigations.
During this phase:
 information about the components of 5-FU was collected
 the protocol and the patient information and informed consent form were drawn up,
 the blank CRF was drawn up
 the opinion of the relevant ethics committee was requested
 relevant SOPs were put together, and specific SOPs were drawn up
 the relevant state authorities (“Regierungspräsidium”) were notified of the study,
 the subjects were insured.
Start of the study, enrolment:
The study started with obtaining the informed consent by signing the informed consent
form by the first patients. A patient was enrolled for the study when all results of the
clinical screening examination necessary for eligibility were available to the clinical
investigator and the patient was considered eligible according to inclusion and exclusion
criteria.
End of the study:
The regular termination of the study for a subject was the signing of the case report form
by the principal investigator after the final examination, which is approximately 28 days
after the last blood sampling or – in the case ongoing adverse events – after restitution of
adverse events or when the adverse events could be explained satisfactorily.
The study ends as a project when the final report is signed and a joint publication has been
accepted by an international journal.
Drop out:
A subject, who has prematurely been withdrawn from the study within the time of
enrolment until last blood sampling, was considered a drop out.
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1. Introduction
5-Fluorouracil (5-FU) is an analogue of uracil that was synthesized by Heidelberger and
colleagues in 1957 (Grem, 2000), which differs from uracil by virtue of a fluorine atom
in place of hydrogen at the carbon-5 position of the pyrimidine ring (fig. 1). Over the
years, 5-FU has continued to be useful in the treatment of solid tumors, including breast
cancer, gastrointestinal (GI) adenocarcinoma, and squamous cell carcinomas arising in
the head and neck (Anonymous, 1997; Decatris et al, 2004; Ilson, 2003; Rich, et al.,
2004; Wilke & Custem, 2003).
Figure 1: Chemical structure of 5-FU
5-FU therapy is characterized by considerable interpatient variability in
pharmacokinetics, toxicity, and responses. The routes of administration currently used
are i.v. bolus or continuous intravenous infusion (CVI) for up to 5 days and usually
administered along with folinic acid (FA) or other chemotherapeutic agents and/or
radiation to increase the anticancer activity of 5-FU and decrease host toxicity.
Blood dyscrasias, especially leukopenia, are the most common adverse effects of 5-FU
therapy. Cardiac toxicities including chest pain, tightness of the chest, dyspnea, and
cardiogenic shock have also occurred (2-5% of cases). Other frequent reactions include
stomatitis, GI disturbance (nausea, vomiting, and diarrhea) and hand foot-syndrome
(i.e., dermal pain in hands and feet) (Grem, 2000). The toxicity profile of 5-FU is
schedule dependent: reducing the rate of injection to a slow infusion over several hours
causes less myelosuppression but often lead to more severe stomatitis, diarrhea, and
hand-foot syndrome (Meta-Analysis Group in Cancer, 1998).
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1.1 Metabolic activation and catabolism of 5-FU
5-FU is a prodrug that requires an anabolic conversion into cytotoxic nucleotides, using
several enzymes of the pyrimidine metabolic pathway. These nucleotides can be formed
by three routes as illustrated in fig. 2: (1) conversion of 5-FU to 5-fluorouridine-5´-
monophosphate (5-FUMP) by orotate phosphoribosyl transferase (OPRT); (2)
sequential conversion of 5-FU to FUMP by uridine phosphorylase and uridine kinase;
(3) sequential conversion of 5-FU to 5-fluoro-2´-deoxyuridine-5´-monophosphate (5-
FdUMP) by thymidine phosphorylase and thymidine kinase (Grem, 2000; Longley et
al., 2003). The anti-tumor activity results from inhibition of thymidylate synthase (TS),
an enzyme required for de novo pyrimidine synthesis, by 5-FdUMP, as well as from
incorporation of 5-FU active metabolites into RNA and DNA (fig. 2).
Only a small part of the 5-FU dose is activated via these routes, as in humans 80-90% of
the administered dose is degraded mainly in the liver to 5,6-dihydro-5-fluorouracil (5-
FUH2) by dihydropyrimidine dehydrogenase (DPD) (Diasio & Harris, 1989), the rate-
limiting step in 5-FU catabolism. 5-FUH2 is further cleaved to form -fluoro--
ureidopropionic acid (FUPA) by dihydropyrimidinase. FUPA appears to be a transient
intracellular catabolite and is then converted to -fluoro--alanine (FBAL), carbon
dioxide (CO2), and ammonia (NH2) by -ureidopropionate. Other than the release of
small amounts of free fluoride anion (F-) from FBAL, further metabolisms of FBAL has
been found, including N-carboxy--fluoro--alanine (CFBAL), three conjugates of
FBAL with bile acids, two metabolites of FBAL by transamination (2-fluoro-3-
hydroxypropanoic acid (FHPA) and fluoroacetate (FAC) (fig. 3).
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Figure 2 Pathways for the anabolic metabolism of 5-FU
5-FU = 5-fluorouracil; 5-FUrd = 5-fluorouridine; PRPP = 5´-phosphoribosyl-1-pyrophosphate; 5-FUMP =
5´-flourouridine-5´-monophosphate; 5-FUDP = 5´-fluouroruidine 5´-diphosphate; 5-FUTP = 5´-
fluorouridine-5´-triphosphate; 5-FdUrd = 5-fluoro-2´-deoxyuridine; 5-FdUMP = 5-fluoro-2´-
deoxyuridine-5´-monophosphate; 5-FdUDP = 5-fluoro-2´-deoxyuridine-5´-diphosphate; 5-FdUTP = 5-
fluoro-2´-deoxyuridine-5´-triphosphate; CH2-THF = 5,10-methylenetetrahydrofolate
 CH2-THF
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Figure 3 Pathways for the catabolic metabolism of 5-FU
5-FU = 5-fluorouracil; 5-FUH2 = 5,6-dihydro-5-fluorouracil; FUPA = -fluoro--ureidopropionic acid; FBAL = -
fluoro--alanine, NADPH = nicotinamide adenine dinucleotide phosphate (reduced form); NADP+ = nicotinamide
adenine dinucleotide phosphate (oxidized form)
1.2 Clinical pharmacokinetics
1.2.1 Absorption and distribution
Oral administration of 5-FU gives rise to erratic and unpredictable plasma
concentrations due to the great variability in bioavailability (0-80%) (Iyer & Ratain,
1999). The unpredictable and significant interpatient variation in 5-FU absorption after
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oral administration may be partially due to differences in 5-FU catabolism by DPD
enzyme in the intestines and liver. This effectively rules out oral treatment with 5-FU.
Whether given by i.v. bolus or infusion, 5-FU readily distributes in tissue and
extracellular fluid, including intestinal mucosa, bone marrow, liver, brain, cerebral
spinal fluid, and neoplastic tissue. Reported volumes of distribution (Vd) ranged from 13
to 18 L (Iyer & Ratain, 1999; Diasio & Harris, 1989).
1.2.2 Plasma pharmacokinetics
The pharmacokinetic profile of 5-FU, as shown in table 1 and 2, varies according to
dose and schedule of administration. After i.v. bolus of doses of 400-600 mg/m² once a
week for 6 weeks, peak plasma concentration (Cmax) values of up to 500 µM have been
reported (table 2). The plasma half-life (t1/2) of 5-FU is extremely short, about 6-22 min.
The clearance (CL) of 5-FU is much faster with CVI than with i.v. bolus administration
and increases as the dose rate decrease (table 1 & 2). Concentration of 5-FU in bone
marrow were much lower and maintained for a shorter period after CVI administration
than after bolus dosing, which is consistent with the reported decrease of
myelosuppression of CVI (Fraile et al., 1980).
In addition to dose- and schedule-dependent variations in 5-FU pharmacokinetics, 5-FU
clearance varies considerably between individuals on a given schedule. A number of
studies indicated that the elimination of 5-FU are nonlinear (Wagner et al., 1986; Schaaf
et al., 1987). The following nonlinear pharmacokinetic characteristics are noted with
increasing doses of 5-FU: an increase in bioavailability, area under the plasma
concentration-time curve (AUC), and plasma t1/2 and a decrease in hepatic extraction
ratio and total CL (CLtot) (Iyer & Ratian, 1999). Although the change in 5-FU CL or
AUC with increasing 5-FU dosage on a given schedule may be linear over a certain
dose range, with higher dosages the decrease in clearance and increase in AUC may
change disproportionately. This nonlinear behavior represents saturation of metabolic
processes at higher drug concentrations, leading to difficulty in predicting plasma levels
or toxicity at higher doses.
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Table 1 Pharmacokinetics of 5-FU given by i.v. bolus
Investigator Dose(mg/m2/d) n t1/2 (min) CL (L/h) Cmax (µM) Vd (L)
Di Paolo et al., 2001 370 110 21.6  3 87.19  5.05 285.9  31 35.8  3.6
Bocci et al., 2000 370 20 12.6  1.2 25.43  2.3 372.1  59.0 7.2  1.3
Macmillan et al., 1978 400 8 11.4  1.5 75.9  14.8 469  85 18  3.2
Casale et al., 2004 400 18 20 52.09 425.8 32.55
Heggie, et al., 1987 500 10 12.9  7.3 60.6  0.74 420  102 14  6.2
Van Groeningen, et al., 1988 500 15 1.9-18.7 56.92 Not stated 17.4  6.7
Zhu et al., 2004 500 22 10.6  1.3 58.65  23.46 456.6  199.1 13.2  5.3
Coustère et al., 1991 500 10 6.9  3.9 48.6  12.6 Not stated Not stated
Larsson et al., 1996 500 82 15 122.71 341  34 18.05
Larsson et al., 1996 600 18 9.3-19.5 41.21 Not stated 14.4  3.8
Sandström et al., 1996 600 21 11 79 Not stated 24
t1/2 = half-life, CL = clearance, Cmax = peak plasma concentration, Vd = volume of distribution
Table 2 Pharmacokinetics of 5-FU given by continuous infusion
Investigator Duration ofinfusion
Daily dose
(mg/m2) n Css (µM) CL (L/h) Vd (L)
Fraile et al., 1980 96 h 1000-1100 6 1.3  0.1 - -
Erlichman et al., 1986 120 h 1250-2250 15 3.4  0.4 182.58-245.82 -
Spicer et al., 1988 120 h 300-500 25 0.005-0.01 - -
Grem et al., 1993a 120 h 64-200 24 0.30  0.04 311.1  33.66 -
Grem et al., 1993b 120 h 2000 19 6.5  0.9 270.40  33.05 -
Harris et al., 1990 120 h 300 7 0.13  0.01 - -
Fleming et al., 1992 120 h 1000 57 2.1 257.35  69.77 -
Petit et al., 1988 120 h 450-996 7 2.6  0.2 - -
Jodrell et al., 2001 Protracted 300 58 0.23-2.0 - 18.0  3.3
Yoshida et al., 1990 Protracted 190-600 19 1.15  0.15 207.37 -
Anderson et al., 1992 Protracted 176-300 3 0.32 - -
CL = clearance, Css = steady-state plasma concentration, Vd = volume of distribution
1.3 Special populations
Several studies have investigated the influence of body surface area (BSA), weight,
gender, and age on 5-FU CL (Chansky et al., 2005; Etienne et al., 1998; Fleming et al.,
1992; Lu & Diasio, 1995; Milano et al., 1992; Port et al., 1991; Sloan et al., 2002).
Multiple linear regressions have confirmed a moderate relationship between BSA and 5-
FU CL and BSA (r2 = 0.602, p <0.001; Port et al., 1991). In 26 cancer patients with an
equal 5-FU dose/m², the average CL in males was by 0.22 L/min higher than that in
females (Port et al., 1991). In another study, women had a 10% lower 5-FU CL than
men (p = 0.0005; Milano et al., 1992). Additionally, a pharmacokinetic study in 22
cancer patients showed that the mean AUC0-∞) was 72% greater in female patients than
in males (p = 0.002; Zhu et al., 2004). This may in part explain why women experience
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toxicity more frequently and with more severity than men (Chansky et al., 2005; Sloan
et al., 2002).
Concerning the effect of increased age on 5-FU CL, both a moderate decrease (in one
study by 0.072 L/min with every 10-year increase of age) (Port et al., 1991; Etienne et
al., 1998) and no change (Milano et al., 1992) have been reported. This discrepancy may
also reflect different methods of statistical analysis: age was considered as a continuous
variable in some studies, while age classes were examined both alone and in covariance
matrices in others. Similarly, DPD activity was not correlated with age (Etienne et al.,
1994; Lu et al., 1993) but appears to be influenced by gender. The hepatic in vitro DPD
activity in women seems to be higher than in men (Lu et al., 1995). In contrast, the DPD
activity in PMBC was found to be 15% lower in women than in men (Etienne et al.,
1994). The significant interpatient variability in 5-FU CL, tumor response, and toxicity
may be explained in part by genetic differences in the activity of DPD (see section 1.7)
(Milano & Etienne, 1994; Terret et al, 2000).
In a study in 187 head and neck cancer patients, no association between 5-FU CL and
hepatic function (AST, ALT, AP, GGT, LDH, bilirubin) or nutrition status (albumin,
prealbumin, transferrin) following 5-day CVI of 5-FU was found (r <0.25; Fleming et
al., 1992). The influence of liver metastases on 5-FU pharmacokinetics after an i.v.
bolus administration was studied in comparing between metastatic (n = 16) and
nonmetastatic GI cancer patients (n = 18). Both groups displayed similar
pharmacokinetics. No effect of liver metastases on 5-FU CL was observed. Ten (66%)
and 13 (72%) patients with and without liver metastases, respectively, experienced any
kind of 5-FU related toxicity (Maring et al., 2003).
Similarly, a trial on 24-h CVI of 5-FU with FA in patients with elevated serum bilirubin
or mild renal dysfunction (n = 64) showed that 5-FU toxicities did not appear to be
related to (mild) organ dysfunction. There was also no relationship between 5-FU CL
and either serum bilirubin (p = 0.517) or serum creatinine (p = 0.396) (Fleming et al.,
2003). In a colorectal carcinoma patient with end-stage renal insufficiency on
maintenance hemodialysis therapy, pharmacokinetics of 5-FU and its metabolite, 5-
FUH2, were in the ranges reported in literature for patients with normal renal function,
implying no need for dose adjustment (Rengelshausen et al., 2002). However, the
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terminal inactive metabolite FBAL excreted renally accumulated in this patient.
Whether this accumulation may have any clinical consequences is unknown to date.
Because renal elimination of unchanged 5-FU accounts for only 10% of dose (Diasio &
Harris, 1989), renal dysfunction should have, a priori, a minimal effect on 5-FU
pharmacokinetics. There does not seem to be a need for 5-FU dose adjustments in
patients with liver metastases or mild to moderate hepatic and renal dysfunction.
1.4 Pharmacodynamics
Measurements of systemic exposure towards 5-FU have been correlated with the
incidence of toxicity, tumor response, and survival (table 3). Equivocal findings exist
regarding the relationship between 5-FU plasma concentrations or exposure and
response (table 3). In some studies, no relationship (Findley et al., 1996; Grem et al.,
1993b; Thyss et al., 1986) was found, others suggested that improved responses occur
with a target 5-FU AUC of approximately 30 mgh/L during CVI (Hillcoat et al., 1978;
Gamelin et al., 1996; Milano et al., 1994; Vokes et al., 1996).
Several investigators have described a significant correlation between 5-FU
pharmacokinetics and toxicity (table 3). Despite the differences in 5-FU schedules,
serious toxicity (leukopenia, diarrhea, stomatitis, and HFS) tends to increase with AUC
values greater than 25-30 mgh/L during CVI (Au et al., 1982; Milano et al., 1988;
Milano et al., 1994; Santini et al., 1989; Thyss et al., 1986). Lower “critical” AUC
values around 8-9 mgh/L have been determined for i.v. bolus administrations (Di Paolo
et al., 2001, 2002). These findings suggest that pharmacokinetic monitoring might be
used to adjust 5-FU doses in order to avoid or minimize serious toxicity. This approach
has been used successfully in patients receiving infusional 5-FU in several clinical trials
(Gamelin et al., 1998; Santini et al., 1994; Ychou et al., 2003). However, not all patients
with relatively high 5-FU systemic exposure experience serious 5-FU toxicity, and some
patients have toxicity despite relatively low 5-FU systemic exposure (Gamelin et al.,
1996; Milano et al. 1988; Thyss et al., 1986), suggesting that other factors also
contribute to clinical toxicity.
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Table 3 Summary of clinical pharmacokinetic studies with 5-FU
Drug effect (s) investigated
5-FU regimen Co-med. n PK parameter
Groups compared or correlation studies PK parameter in the groups (mean) or PDrelationship p value
Ref.
Weekly 8 h CVI: initial dose 1
g/m2, individually increased every 3
wk by 250 mg/m2 steps according
to toxicity.
FA 43
152
Css
Css, AUC0-8h
OR vs. NR
Toxicity and 5-FU plasma levels
1,800-2,000 µg/L vs.< 1,800 µg/L
Css >3,000 g/L (AUC0-8h 24 mgh/L
correlated to acute toxicity
< 0.01
= 0.0001
Gamelin et al., 1996
Gamelin et al., 1998
72 h CVI: dose 2 g/m2/day PALA & FA 27 Css Incidence (ICD) of serious toxicity (GI,
granulocytopenia, thrombocytopenia) at
Css  8.9 M vs. Css > 9 M
ICD of GI toxicity: Css 8.9 M = 1% vs. Css
> 9 M = 14%
ICD of granulocytopenia: Css 8.9 M = 14%
vs. Css > 9 M = 41%
ICD of thrombocytopenia: Css 8.9 M = 0%
vs. Css > 9 M = 14%
= 0.02
= 0.01
= 0.07
Grem et al., 1993b
72 h CVI 185-3500 mg/m2/day Dipyridamole 42 Css Risk of leukopenia and mucositis and Css Css > 2 M associated with risk of toxicity - Trump et al., 1991
5-day CVI 2-6 cycles: mean daily
dose: 960 mg/m2 (650-1,300)
None 26 Total cycle AUC High vs. low probability of toxicity 30 vs. < 30 mgh/L < 0.01 Milano et al., 1988
5-day CVI: dose 1 g/m2/day CDDP 170 AUC0-5days and AUC0-3days AUC0-5days for toxic vs. non-toxic cycles
AUC0-3days for toxic vs. non-toxic cycles
34 vs. 26 mgh/L
11 vs. 5.5 mgh/L
< 0.001
< 0.01
Santini et al., 1989
5-day CVI: 1 g/m2/day, dose
adaptation on day 3 based on
AUC0-48h. Dose reduction 15-100%
for AUC0-105h <30 mgh/L
CDDP 186 Average AUC per cycle CR vs. PR >75% vs. PR <75% vs. NR
Overall survival
29.66 ± 4.9 vs. 28.68 ± 5.9 vs. 27.41 ± 4.7 vs.
27.21 ± 4.7 mgh/L
longer overall survival at AUC > 29 mgh/L
0.05
0.001
Milano et al., 1994
5-day CVI 500 mg/m2/day, 3 cycles CDDP & FA 39 Css NR vs. CR or PR
Toxicities and 5-FU concentration
0.67 M vs. 1.00 M
5-FU concentration > 1 M associated with
all grade 4 toxicities.
= 0.007
-
Schneider et al., 1995
5-day CVI 1.2 g/m2, not > 2 g CDDP 27 AUC NR vs. PR + stable
Toxic ( grade 2) vs. non-toxic group
36.1 mgh/L vs. 19.2 mgh/mL (median)
14.5 mgh/L vs. 27.6 mgh/mL (median)
= 0.05
NS
Hillcoat et al., 1978
CVI = continuous intravenous infusion, Co-med = co-medication, FA = folinic acid, CDDP = cisplatin, INF = interferon, PALA= N-phosphoroacetyl-L-aspartic acid, PK = pharmacokinetic, PD = pharmacodynamic,
Css = steady-state plasma concentration, Cmax = peak plasma concentration, CL = clearance, AUC = area under the plasma concentration-time, OR = objective response, CR = complete response, PR = partial response,
NR = no response, ICD = incidence, - = not stated
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Table 3 continued
Drug effect (s) investigated
5-FU regimen Co-med. n PK parameter
Groups compared or correlation studies PK parameter in the groups (mean) or PDrelationship p value
Ref.
5-day CVI 640 mg/m2/day IFN, FA &
CDDP
89
Css and AUC
CR vs. all other
Toxicity and Css
2.01 m (31.2 mgh/L ) vs. 1.54 µM (23.9
mgh/L)
Css associated with leukopenia and mucositis
= 0.02
= 0.01,
= 0.04
Vokes et al., 1996
5-day CVI: dose 1 g/m2/day CDDP 29 AUC Toxic vs. non-toxic cycles  30 vs. < 30 mgh/L < 0.001 Thyss et al., 1986
5-day CVI: dose 7.5-15 mg/kg/day Thymidine 24 CL and Css Toxic vs. non-toxic group
Change in WBC count
CL: 72.0  37.3 vs. 32.0 16.8 L/kg/day
Leukopenia more frequent with Css >1.5 M
(25 mgh/L)
= 0.001 Au et al., 1982
7-28 days CVI: 190-600 mg/m2/day None 19 Css and AUC0-72h Toxic vs. non-toxic group
Effective vs. non-effective
0.198 ± 0.088 (AUC0-72h 12.53 ± 5.55) vs.
0.106 ± 0.059 mg/L (AUC0-72h 6.32 ± 3.84
mgh/L )
0.163 ± 0.097 (AUC0-72h 10.12 ± 6.05) vs.
0.134 ± 0.074 mg/L (AUC0-72h 8.31 ± 5.21
mgh/L)
< 0.05
NS
Yoshida et al., 1990
PVI 200 mg/m2/day 12 wk
followed by a 2-wk rest period
CDDP &
FA
22
Css
Grade 0-1 vs. grade 2 GI toxicity
PR vs. stable
0.23 M vs. 0.54 M
0.27 M vs. 0.23 M
= 0.02
NS
Grem et al., 1993a
PVI 300 mg/m2/day until the tumor
response become refractory to
treatment
± INF 30
Plasma concentration
defined as C5-FU
Non-toxic vs. toxic group
Tumor response and C5-FU
 5 m vs. < 5 M (650 g/L)
No correlation
- Findley et al., 1996
PVI 300 mg/m2/day for 26 wk None 64 Css Css and PD endpoints (response, toxicity)
- Css and diarrhea
- Css and hand-foot syndrome
- Css and stomatitis
- Css and tumor response
No relationship
= 0.164
= 0.41
= 0.949
= 0.182
Jordrell et al., 2001
PVI = protracted venous infusion, CVI = continuous infusion, Co-med = co-medication, FA = folinic acid, CDDP = cisplatin, INF = interferon, PK = pharmacokinetic, PD = pharmacodynamic, Css = steady-state
plasma concentration, Cmax = peak plasma concentration, CL = clearance, AUC = area under the plasma concentration-time, PR = partial response
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Table 3 continued
Drug effect (s) investigated
5-FU regimen Co-med. n PK parameter
Groups compared or correlation studies PK parameter in the groups (mean) or PDrelationship p value
Ref.
Weekly i.v. bolus: initial dose 500
or 600 mg/m2, individually
escalated by 20% every wk until
dose limiting toxicity developed
None 21 AUC0-90 min Risk of toxicity and AUC0-90 min Slightly higher risk of toxicity at AUC0-90 min >
18 mgh/L
- Van Groeningen et
al., 1988
i.v. bolus 5 consecutive days every
5 wk: 370 mg/m2/day
FA 110 CL, Cmax, AUC of 5-FU
AUC of 5-FUH2
GI toxicity: grade  2 vs.  grade 1 toxicity
GI toxicity: grade  2 vs.  grade 1 toxicity
CL: 35.28 ± 3.31 vs. 56.30 ± 3.60 L/h/ m2
Cmax: 55.97 ± 12.51 vs. 31.48 ± 3.45 mg/L
AUC: 13.59 ± 2.05 vs. 7.91 ± 0.44 mgh/L
AUC: 12.91 ± 0.85 vs. 10.51 ± 1.02 mgh/L
< 0.005
< 0.01
< 0.001
> 0.05
Di Paolo et al., 2001
i.v. bolus for 5 consecutive days
every 5 wk: 370 mg/m2/day.
FA 26 CL, Cmax, AUC of 5-FU
Cmax, AUC of 5-FUH2
Grade  3 vs.  grade  2 toxicities
Grade  3 vs.  grade 2 toxicities
CL: 21.73 ± 4.81 vs. 48.86 ± 5.11 L/h/ m2
Cmax: 34.56 ± 5.48 vs. 18.80 ± 1.98 mg/L
AUC: 25.80 ± 10.15 vs. 8.51 ± 0.69 mgh/L
Cmax: 4.78 ± 0.39 vs. 4.36 ± 0.23 mg/L
AUC: 8.74 ± 1.29 vs. 8.09 ± 0.95 mgh/L
< 0.05
< 0.05
< 0.05
> 0.05
> 0.05
Di Paolo et al., 2002
i.v. bolus 500 mg/m2/day once a wk
for 6 consecutive wk followed by a
2-wk rest period.
FA 22 AUC Grade 0-2 vs. grade 3 or 4 toxicity 14.5  6.3 mgh/L vs. 14.8  mgh/L < 0.899 Zhu et al., 2004
Mayo regimen: 425 mg/m2 repeated
on days 2 to 5, every 4 wk for 6
courses
FA 30 Cmax and AUC in plasma
Cmax and AUC in saliva
Plasma:
- Overall toxicity and AUC
- Overall toxicity and Cmax
- Mucositis and AUC
- Mucositis and Cmax
Saliva:
- Overall toxicity and AUC
- Overall toxicity and Cmax
- Mucositis and AUC
- Mucositis and Cmax
No correlation either between AUC or Cmax
and toxicity
No correlation either between AUC or Cmax
and toxicity
= 0.346
= 0.863
= 0.987
= 0.162
=0.882
= 0.746
= 0.896
= 0.154
Jansman et al., 2002
Co-med = co-medication, FA = folinic acid, CDDP = cisplatin, EPI = epirubicin, CP = cyclophosphamide, PK = pharmacokinetic, PD = pharmacodynamic, Css = steady-state plasma concentration, Cmax = peak plasma
concentration, CL = clearance, AUC = area under the plasma concentration-time
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1.5 Pharmacogenetics
1.5.1 Dihydropyrimidine dehydrogenase (DPD)
Severe 5-FU-related toxicity is seen in DPD-deficient patients, which can be fatal
(Diasio et al., 1998; Houyau et al., 1993; Lyss et al., 1993). Pharmacokinetics of 5-FU
were modified in a patient with a low DPD activity, with 90% of the administered dose
being recovered unchanged in urine, a prolonged t1/2 of about 160 min, and a markedly
decreased CLtot of 71 mL/min/m2 already after a 5-FU test dose (25 mg/m2; Diasio et
al., 1988). Corresponding values in patients with normal DPD activity are <20%, 13  7
min, and 594  198 mL/min/m2, respectively (Diasio & Lu, 1994; Heggie et al., 1987).
A comparable AUC threshold (25-30 mgh/L) was also observed for severe toxicity
(section 1.6). Hence, a low DPD activity leads to a marked reduction in 5-FU CL with
an increased likelihood of developing severe 5-FU induced toxicity.
The DPD enzyme is encoded by the polymorphic DPYD gene which is located on
chromosome 1p22 and consists of 23 exons (Johnson et al., 1997; Wei et al., 1998;
Meinsma et al., 1995). To date, more than 30 mutations have been identified in cancer
patients (table 4: Ploylearmsaeng et al., 2006). DPYD*2A is the most common one seen
in cancer patients with severe 5-FU associated toxicity (van Kuilenburg et al., 1999,
2001, 2002). This allele carries a G to A point mutation in the 5-splicing site of intron
14 (exon 14-skipping mutation, IVS14+1G>A), leading to skipping of exon 14
immediately upstream of the mutated splice donor site in the process of DPD pre-
mRNA splicing (fig. 4). The mature DPD*2A mRNA lacks a 165-nucleotide segment
encoding the amino acids 58-635 (Wei et al., 1996; van Kuilenburg et al., 2001),
resulting in a loss of enzyme activity. When this mutation is present in a heterozygote, a
50% reduction of the normal activity leads to a roughly 50% reduction in 5-FU CL
(Maring et al., 2002). In patients homozygous for this variant allele, DPD activity is
completely lacking, and the 5-FU toxicity may become life-threatening. Other DPYD
aberrations associated with DPD deficiency have been reported (table 4), but their
clinical consequences are less clear and sometimes equivocal (table 5, reviewed in
Ploylearmsaeng et al., 2006).
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Table 4 The mutations of DPYD and their reported relationship to DPD*
DPD enzyme activityDPYD* Exon Genotype Effect
Normal Reduced Unclear
- 2 61C>A Stop codon
*12 2 62G>A AA exchange 
- 2 74G>A AA exchange 
*9A 2 85T>C AA exchange  
- 3 100 del A Truncated protein 
- 4 257C>T AA exchange 
*7 4 Del TCAT 295-298 Truncated protein 
- 6 496A>G AA exchange  
- 6 545T>A AA exchange 
- 6 601A>C AA exchange 
- 6 632A>G AA exchange 
*8 7 703C>T AA exchange 
- 7 731A>C AA exchange 
- 8 775A>G AA exchange 
- 8 812 del T Truncated protein 
*11 10 1003G>T AA exchange 
- 10 Del TG 1039-1042 Truncated protein 
- 10 1097G>C AA exchange 
- 10 1108A>G AA exchange 
- 11 IVS11+1G>T Exon 11 skipping 
*12 11 1156G>T Stop codon 
- 11 1217T>C AA exchange 
- 11 1218G>A AA exchange 
- 11 1236G>A - 
- 12 1475C>T AA exchange 
*4 13 1601G>A AA exchange  
*5A 13 1627A>G AA exchange  
- 13 1651G>A AA exchange 
*13 13 1679T>G AA exchange 
- 13 1714C>G AA exchange 
*2A 14 IV14+1G>A Exon 14 skipping  
- 14 1896T>C AA exchange 
*3 14 1897 del C Truncated protein 
*2A 14 IV14+1G>A Exon 14 skipping  
- 13 1714C>G AA exchange 
- 19 2303C>A AA exchange 
- 19 2329G>A AA exchange 
- 21 2657G>A AA exchange 
- 22 2846A>T AA exchange 
- 23 2921A>T AA exchange 
- 23 2933A>G AA exchange 
*10 23 2983G>T AA exchange 
- 23 3067C>T AA exchange 
*9B 2/21 85T>C + 2657G>A AA exchange 
*5B 13/Intron 13 1627G>A+Intron 13 39C>T AA exchange 
*2B 13/14 1627A>G + IV14+1G>A AA exchange + truncated protein 
- Intron 10 Intron 10 15T>C - 
- Intron 13 Intron 13 40G>A - 
* reviewed in Ploylearmsaeng et al. (2006), AA = amino acid
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Table 5 Variant DPYD alleles and patients characteristics suffering 5-FU toxicity*
DPYD alleles Sex Age* Cancer Chemotherapy Toxicity (grade)
DYPD*2A M 76 Basal cell 5% 5-FU cream diarrhea (severe), mucositis (severe), skin rash
F 44 Rectal 5-FU/FA mucositis (4), leukopenia (4), thrombocytopenia (4),
pancytopenia (4)
M 73 rectal 5-FU leukopeina (4)
F 48 Breast CMF leukopenia (4)
M 63 Colon 5-FU/FA leukopenia(4), diarrhea (3)
F 50 Rectal 5-FU leukopenia (4), diarrhea (3)
M 78 Colon 5-FU/FA leukopenia (4), thrombocytopenia (4)
F 72 Colon 5-FU/FA leupenia (4), mucositis (3)
F 59 Breast 5-FU/tamoxifen diarrhea (4), N/V, leukopenia, cardiotoxicity,
thrombocytopenia, hyperpigmentation,
F 60 Colon 5-FU/FA leukopenia (4), hair loss, thrombocytopenia (4), fever
(40C), diarrhea, mucositis
M 65 Colon 5-FU pancytopenia (4), mucositis (4)
F 66 Breast 5-FU Severe toxicity
F 57 Colon 5-FU Severe toxicity
M 79 Colon 5-FU Severe toxicity
M 54 Colon 5-FU Severe toxicity
F 44 Colon 5-FU/FA/IRI diarrhea (4), neutropenia (4) and death
DPYD*2A, DPYD*5,
R21X & DPYD*9A
F 42 Ovarian 5-FU/FA mucositis (4), anemia (3), thrombocytopenia (3),
leukopenia (3), alopecia, erythrodermaia of skin
DPYD*2A, DPYD*5,
M166V & D949V
M 73 Colorectal 5-FU/FA neutropenia, mucositis, exfoliation of the skin,
diarrhea, AF and death
DPYD*2A, DPYD*5 F 60 Colon 5-FU Severe toxicity
DPYD*2A, A777S,
D949V
F 58 Colon 5-FU/FA neutropenia, N/V, mucositis (4) and death
DPYD*2A, DPYD*9A F 40 Colon 5-FU Severe toxicity
DPYD*2A, DPYD*13A F 40 Breast CMF neutropenia, ataxia and deteriorate neurologically
DPYD*4A - - - 5-FU Severe hematopoietic toxicity
DPYD*4, DPYD*6,
DPYD*13,
IVS10+15T>C
- - - 5-FU Severe toxicity
DPYD*4, DPYD*5B,
DPYD*9A,
IVS13+40G>A
M 35 Colon 5-FU/FA cardeogenic with severe insufficient left ventricular,
reduced renal function, hepatic encephalopathy with
somnolence, myclonus & seizure
DPYD*5 F 49 Breast 5-FU Severe toxicity
DPYD*5, M182K,
A77S
F 53 Rectal 5-FU/Rx N/V (4), disoriented, somnolent, arrhythmia and death
DPYD*5,DPYD*9A, F 66 Colon 5-FU Severe toxicity
DPYD*6 M 53 Rectal 5-FU Severe toxicity
DPYD*9A F
F
M
M
-.
-
-
-
Gastric
Gastric
Gastric
Rectal
MTX/5-FU
MTX/5-FU
MTX/5-FU
5-FU/FA
nausea (1)
nausea (2)
nausea (2)
no toxicity (0)
DPYD*9A, 496A>G,
2846A>T
M 51 Rectal 5-FU Severe toxicity
DPYD*9A, 496A>G M 63 Colon 5-FU Severe toxicity
DPYD*11, DPYD*12 F 57 Breast 5-FU leukopenia, mucositis (4), thrombocytopenia
812delT M - Colon MTX/5-FU nausea (1)
I543V M - Esophageal 5-FU/CDDP/Rx nausea (2)
L572V F - Gastric MTX/5-FU arrhythmia (2)
* reviewed in Ploylearmsaeng et al. (2006)
F = female, M = male, CMF = cyclophosphamide, methotrexate and 5-fluorouracil, FA = folic acid, IRI = irinotecan, MTX =
methotrexate, Rx = radiotherapy, AF = atrial fibrillation, *age in year, - = data not show, N/V = nausea and vomiting
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Figure 4 The effect of the IVS14+1G>A mutation
The wild-type DPYD gene contains a GT nucleotide sequence at exon 14(wt), required for normal catabolism of 5-
FU to 5-FUH2. A G-to-A transition at the exon 14 splice site leads to skipping of exon 14 of the mutated splice donor
site in the process of DPD pre-mRNA splicing (mut). Patients with low hepatic DPD activity cannot efficiently
metabolize 5-FU and its accumulation causes toxicity (Relling & Dervieux, 2001)
Considering the common use of 5-FU in cancer patients and the relatively high
prevalence of DPYD mutations associated with a decrease or lack of DPD activity in
the normal population, patients who are to receive 5-FU should theoretically benefit
from genetic screening. It has been suggested to analyze the DPD activity (various
phenotyping methods) and to screen the DPD mutations (use allele-specific polymerase
chain reaction-based methods), at least for carriers of DPYD*2A, to identify persons at
risk for toxicity prior to 5-FU therapy (Omura 2003; van Kiulenburg et al., 2003), to
reduce doses in heterozygotes or to avoid the use of 5-FU in homozygotes.
However, the presence DPYD*2A is not the only reason for severe 5-FU-related
toxicity. Indeed, studies on populations of individuals phenotypically deficient in DPD
activity and of patients with 5-FU toxicity detected DPYD*2A in only 14 of 22 (64%:
van Kuilenburg et al., 2002) and in 6 of 25 (24%: van Kuilenburg et al., 1988) subjects,
respectively. In a prospective study carried out in 351 patients receiving 5-FU (± FA) as
a bolus or infusional therapy to assess the impact of DPD mutations on 5-FU toxicity,
there was no evidence for a pivotal role of this mutation (Kollmannsberger et al., 2001).
In 14 patients with severe 5-FU-related toxicity sequencing of ten DPYD exons
containing most of the known mutations was carried out, and in 3 patients no mutations
have been detected at all (Collie-Duguid et al., 2000). Furthermore, the complexity of
the DPYD gene with 23 exons, the still increasing number of sequence variations, and
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the mostly unclear clinical relevance of the majority of mutations reported to date limit
the usefulness of single mutation genotyping tests.
1.5.2 Thymidylate synthase (TS)
In addition to the enzyme catabolizing 5-FU, far more information is available
regarding polymorphisms of the target enzyme thymidylate synthase (TS). Genetic
polymorphisms in the gene encoding TS (called TYMS) have also been shown to
influence response (Marsh et al., 2001; Pullarkat et al., 2001) and toxicity (Lecomte et
al., 2004) of 5-FU-based therapy, although protein expression levels were not linked to
5-FU pharmacodynamics (Tomiak et al., 2001; Westra et al., 2005).
The TYMS is located on chromosome 18p11 (Hori et al., 1990). The polymorphisms
have been identified, characterized by variable numbers of a 28-bp tandem repeat
sequence in 5-promoter enhancer region (TSER), with double (2R) and triple repeats
(3R) being the predominant alleles (Pullarkat et al., 2001; Villafranca et al., 2001). The
3R/3R genotype is associated with higher tumor TS mRNA compared to either 2R/2R
(p = 0.004) or 2R/3R (p = 0.05) (Pullarkat et al., 2001). In 24 metastatic colorectal
cancer patients, the 2R/2R genotype was nearly twice as common in responders to a 5-
FU therapy compared to non-responders (40% vs. 22%, respectively). A decrease in
median survival was also linked to increasing numbers of TSER repeats (median
survival 16, 14 and 12 months for 2R/2R, 2R/3R and 3R/3R, respectively) (Mash et al.,
2001). This is confirmed in a study in 50 metastatic colorectal cancer patients receiving
5-FU, a higher response rate was observed in patients with lower numbers of TSER
repeats (50% for 2R/2R, 15% for 2R/3R, and 9% for 3R/3R: Pullarkat et al., 2001).
The associations between polymorphisms in the TYMS promoter and 5-FU toxicity
were investigated in 90 patients with colorectal cancer treated with 5-FU (Lecomte et
al., 2004). Patients with a 2R/2R, 2R/3R, or 3R/3R genotype had grade 3 or 4 toxicities
in 43% (6 of 14), 18% (8 of 44), and 3% (1 of 28), respectively (p < 0.02). In this study,
response to 5-FU and survival of patients did not differ between the TYMS genotype
groups.
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1.5.3 Methylenetetrahydrofolate reductase (MTHFR)
Directly linked to the 5-FU-mediated inhibition of TS is the presence of intracellular
folate. Methylenetetrahydrofolate reductase (MTHFR) also plays an important role in
the intracellular action of 5-FU. The substrate of MTHFR is necessary for the formation
of the cytotoxic inactive ternary complex between the active metabolite of 5-FU and
TS. Folic acid, a precursor of this substrate, is therefore added in various 5-FU
containing regimens to increase the intracellular reduced folate pool.
So far, two MTHFR polymorphisms have been recognized but most of them concerned
to the response of 5-FU. A common C677T transition in exon 4 of the MTHFR gene
results in a thermolabile enzyme variant with lower specific activity (Stern et al., 2000).
In 2 studies with 45 and 51 colorectal cancer patients, respectively, the C677T genotype
appeared to affect the folate pool (Wisotzkey et al., 2000; Kawakami et al., 2001). In
the latter study, no effect of the C677T genotype on overall survival after an oral 5-FU-
based chemotherapy was seen (Karakamie et al., 2001). In a recent study of 98
colorectal cancer patients, the C677T mutation was also associated with higher
response rates after 5-FU/FA chemotherapy (Etienne et al., 2004). The effect of the
single point mutation was small, and results were ambiguous, so that further studies
would be useful to elucidate the exact role of the MTHFR polymorphism and to
identify patient groups who would benefit from genotyping.
1.6 Conclusion
A major problem in 5-FU therapy is the prediction of the outcome of therapy, both in
terms of tumor response and host toxicity. 5-FU forms an integral part of the many
chemotherapy regimens. However, its use has been marred by variable
pharmacokinetics, unpredictable response rates and seemingly random toxicity.
Pharmacogenetic variability in drug metabolizing enzyme systems is a major
determinant of variations in these outcomes. Unpredictable disposition of drugs may
result in an undertreatment failing to provide therapeutic effects, or an overtreatment
leading to excessive toxicity. The current practice in 5-FU therapy is to dose patients
based upon BSA, which may be imprecise. Numerous attempts have established
relationships between the concentration of 5-FU and its desired or undesired effects.
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The majority of studies has focused on the toxic effects of 5-FU. AUC values between
25-30 mgh/L should be achieved, but not exceeded during 5-day CVI. For other
regimens, therapeutic plasma concentration or AUC ranges are not as well defined.
They should be established and used in prospective studies to adjust doses a posteriori.
Pharmacogenetically derived dosing regimens may offer an alternative to the above-
mentioned approaches in 5-FU therapy. Despite the many studies that focused on
potential genes interfering with 5-FU therapy, only few factors indeed have been
proven to affect 5-FU efficacy and/or toxicity. Most consistent data are available
regarding the role of DPD in 5-FU chemotherapy. The impact of DPD deficiency on 5-
FU pharmacokinetics and the development of severe toxicity are obvious. Whether or
not to screen patients on DPD deficiency before starting chemotherapy is, however, an
issue of debate (Behnke et al., 2002; Innocenti & Ratain, 2002; Raida et al., 2001).
Since genetic aberrations in the DPYD gene explain less than half of all cases of
extreme 5-FU-related toxicity, costly screening will only be partially preventive.
Therefore, a solid cost-benefit analysis, preferentially embedded in a large prospective
clinical trial, will be needed to establish the benefit of DPYD genotyping. Screening (by
means of genotyping or phenotyping) might become standard clinical practice as soon
as a rapid, sensitive, and cheap test becomes available.
Since TS is the important target enzyme of 5-FU, and since genetically controlled
expression of this enzyme varies considerably between individuals, genotyping of the
promoter of TYMS may prove useful to identify patients who are likely to respond to 5-
FU, but results from protein level quantification studies challenge the genotype-effect
relationship. The combination of a functional DPD activity test and of genotyping of
DPYD, perhaps also genotyping of TYMS, before 5-FU administration may be valuable
for the identification of patients who are likely both to tolerate and to respond to 5-FU.
However, the validity of these assumptions and the clinical usefulness remain to be
established in larger clinical trials.
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2. Rationale and objectives
2.1 Rationale
It is now well recognized that the pharmacogenetic syndrome DPD deficiency,
associated with severe or lethal toxicity after 5-FU administration, is primarily caused
by molecular defects in the DPYD gene that result in complete or partial loss of DPD
activity (van Kuilenburg, 2004). At least 30 variant alleles have been identified in DPD
deficient patients (van Kuilenburg 2004), with DPYD*2A being most frequently
implicated in patients suffering from severe 5-FU toxicity (van Kuilenburg, 2004).
However, the presence of DPYD*2A is not the only reason for severe 5-FU toxicity
(van Kuilenburg et al., 2002, Kollmannsberger et al. 2001). Besides, the known variant
DPYD alleles do not entirely explain the polymorphic DPD activity and toxic response
to 5-FU (Collie-Duguid et al., 2000). Hence, other factors, including novel mutations,
may contribute to DPD deficiency.
Although the relationship between DPD phenotype and DPYD genotype is not entirely
elucidated, it is well recognised that one of the major risk factors in cancer patients for
developing severe and life-threatening toxicity after 5-FU therapy is represented by
mutations in DPYD (Collie-Duguid et al., 2000; Johnson et al., 2002). Complete and
partial DPD deficiency affect around 0.1 and 3-5% of the general population,
respectively (Etienne et al., 1994). These individuals have no symptoms in the absence
of drug treatment, but are at risk for developing toxicity if exposed to 5-FU (Diasio &
Lu, 1994). Thus, the Association of Medical Oncology (AIO) of the German Cancer
Society has recommended to pre-screen patients for DPD activity and/or DPYD
genotype before 5-FU therapy and to modify therapy accordingly (Köhne et al., 2002).
However, neither all mutations leading to an altered enzyme function are identified nor
are therapeutic drug monitoring (TDM) schemes for 5-FU established which would be
suitable for use in clinical routine.
Additionally to the 5-FU-catabolizing enzyme, genetic polymorphisms in the TS gene
(TYMS) have been shown to influence response (Mash et al., 2001; Pullarkat et al.,
2001) and toxicity (Leconte et al., 2004) of 5-FU-based therapies. Another enzyme,
MTHFR, also plays an important role in the intracellular action of 5-FU. A
polymorphism that may influence the efficacy of 5-FU by influencing folate pools is
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that of the MTHFR gene (Etienne et al., 2004; Wisotzkey et al., 1999). Otherwise, a
large-scale assessment of the role of each TYMS and MTHFR polymorphism
individually is now required to determine whether prospective assessment is warranted
in patients prior to 5-FU-based chemotherapy.
However, no clear studies have quantified the extent and variability of influence of
DPD genotype/phenotype, of TS genotype and of MTHFR genotype on 5-FU
pharmacokinetics. Since 5-FU pharmacokinetics show high individual variability
causing difficulties in predicting efficacy and toxicity, it is important to elucidate other
factors influencing this variability. To estimate their extent of influence on
pharmacokinetics and/or pharmacodynamics would help to optimise cancer therapy.
Additionally, since DPD catalyzes the metabolic transformation of 5-FU to 5-FUH2,
investigations have been carried out to correlate pharmacokinetic parameters of these
two analytes in plasma to the occurrence and severity of 5-FU toxicity (Di Paolo et al.,
2001, 2002). The results of these studies showed that the increased 5-FU/5-FUH2 AUC
ratio was related to the severity of 5-FU toxicity in patients treated with adjuvant bolus
5-FU plus FA. These suggest that the AUC5-FU/AUC5-FUH2 ratio may be a useful
parameter to assess the metabolic activity of patients during 5-FU administration.
However, further studies will be required to prove and validate the usefulness of the
AUC ratio in various regimens.
Thus, in this study, DPD activity, DPD, TS, and MTHFR genotype and other factors
were correlated to 5-FU, and 5-FUH2 pharmacokinetics and 5-FU toxicity.
2.2 Objectives
1. Identification of the DPD, TS and MTHFR genotype and of the DPD phenotype
in 30 patients before start of 5-FU administration
2. Investigation of 5-FU pharmacokinetics and its metabolite, 5-FUH2, and toxicity
of 5-FU in these patients
3. Correlation of individual factors including DPD phenotype, genotyping of DPD,
TS, and MTHFR to 5-FU pharmacokinetics and adverse events.
4. Establishing a method based on individual factors and 5-FU pharmacokinetic
parameter allowing reliable prediction of clinical 5-FU effects (if applicable).
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3. Patients and methods
3.1 Study design
An open, non-randomized, consecutive period phenotyping study design in patients
with colorectal, gastric, or locally advanced esophageal cancer treated with 5-FU was
used in this pilot study. Phenotyping and genotyping for enzymes related 5-FU
metabolism was carried out before the initiation of the chemotherapy. Then, 5-FU
plasma concentrations were monitored during and after the first administration of 5-FU
during the first chemotherapy cycle (table 6).
3.2 Patients
This study was approved by the Ethics Committee of the University of Cologne,
Germany, and was conducted according to the Declaration of Helsinki in its amended
version of Edinburgh, Scotland, 2000, and national and international legal stipulations
and guidelines. Patients to be treated with 5-FU at the radiologic oncology department
(Klinik und Poliklinik für Strahlentherapie: KST), University of Cologne, were eligible
to participate in this study.
Patients were informed about the procedures and the aims of the study both verbally
and in written form, and they were enrolled after giving written informed consent to
participate. Inclusion and exclusion criteria were taken into consideration.
3.2.2 Sample size
The number of patients was calculated by sample size estimation using WinBiAS
(version 7.01, epsilon Verlag, Darmstadt, Germany) under the following conditions:
interindividual variability in 5-FU pharmacokinetics is determined to at least 30% by
DPD activity. Hence, in order to test between various parameters for a linear coefficient
of correlation  = 0.5477 with a power of 90% on a level of significance of p = 0.05, n
= 30 patients were required.
3.2.1 Patient selection
Eligibility requirements for this study included:
 Caucasian
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 Histologically and/or cytologically proven colorectal, gastric, or locally
advanced esophageal cancer
 age 18-70 years
 Karnofsky performance status  70%
 life expectancy  3 months (as assessed by the attending physician)
 adequate hematopoietic reserve (leukocyte count  3,000 cells/L, absolute
neutrophil count  1,500 cells/L, platelet count  100,000 cells/L and
hemoglobin level  10 g/dL)
 chemotherapy regimen containing i.v. bolus administration (450 mg/m2/day
within 5 min) or continuous long-term infusion of 5-FU (2 to 2.6 g/m2/24 h and
650-1000 mg/m2/24 h for 5 days), besides, other regimens will be considered by
the investigator, too
 normal hepatic function (total bilirubin level  2.0 mg/dL, aspartate
aminotransferase and alanine aminotransferase  2.5 times upper limit of
normal range)
 normal renal function (serum creatinine  1.5 mg/dL)
 willing and capable to confirm written consent to enrolment after thorough
information has been provided
 normal finding in the medical history and physical examination unless the
investigator considers an abnormality to be related to the neoplastic disease or
clinically irrelevant.
Exclusion criteria included the following:
 hypersensitivity against 5-FU and/or related drugs
 hypersensitivity against inactive ingredients of the preparation
 history of drug allergy
 acute hay fever
 present or past serious infection
 malnutrition (BMI < 18.5 kg/m2)
 females only: pregnancy, lactation
 history of relevant hepatic disorders or diseases
 history of relevant gastrointestinal disorders or diseases
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 history of treatment with 5-FU or other chemotherapeutic agents or radiotherapy
 acute or chronic diseases which could affect absorption and/or metabolism
 drug and/or alcohol dependence
 concomitant treatment with drugs known to interfere with 5-FU
pharmacokinetics and/or –dynamics, which are not part of the chemotherapeutic
regimen, such as cimetidine, levamisol, metronidazole, warfarin, allopurinol and
thiazide diurectics.
 history or suspicion of HIV infection, active or chronic viral hepatitis
 subjects who were known or suspected not to be capable of understanding and
evaluating the information that is given to them as part of the formal
information policy (informed consent), in particular regarding the discomfort to
which they will be exposed.
 subjects who known or suspected not to comply with the study directives and/or
known or suspected not to be reliable or trustworthy.
3.3 Treatment plan and evaluations
Patients underwent a physical examination, performance status determination,
electrocardiogram (ECG), complete blood count with platelet and differential counts,
serum chemistry profile, and urinalysis within 1-14 days before initiating therapy.
Chemotherapy was delivered on an inpatient basis. Prior to the initiation of 5-FU
therapy, all patients were required to obtain a central vascular catheter through the
subclavian vein. 5-FU was administered via a device pump in 24-h CVI for 5 days in a
mixture of 0.9% saline.
For patients with colorectal cancer, each cycle of treatment consisted of 5-FU 650 or
1,000 mg/m²/day for 5 days and radiotherapy, while the patients with oesophageal
cancer were treated with 5-FU 650 or 1,000 mg/m²/day and cisplatin 20 mg/m²/day for
5 days with radiotherapy. Cisplatin was administered in a mixture of 0.9% saline
The administration of anti-emetic agents was permitted at any time as an intervention or
a prophylaxis. Concurrent treatment with drugs known to interfere with 5-FU
pharmacokinetics and/or –dynamics (see exclusion criteria) was prohibited.
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Toxicity was evaluated with particular attention to diarrhea, mucositis, hand-foot
syndrome and hematologic effects. After 5-FU administration, blood was taken 2 or 3
times/week for controlling hematologic parameters (hemoglobin, white blood cell
count, platelet count). The toxic events were prospectively recorded, evaluated and
graded during the period of blood sample collection and thereafter, up to the following
cycle of chemotherapy according to Center for Disease Control and Prevention (CDC)
toxicity criteria. A patient history update, physical examination (including ECG, blood
pressure, heart rate, body temperature and body weight) and evaluation of clinical
chemistry tests were also performed at the end of study evaluation and long-term follow
up data were also obtained for the patients.
Table 6 Overview: study procedures
Study phase Pre-study Phenotypingperiod PK period
(1) Post study(2)
Period 1 2
Study day relative to day of drug intake -14 - - 1 - 14 - 0 0 - 5 +28
Informed consent 
Medical history 
Medical history update and re-check for
inclusion and exclusion criteria   
Physical examination  * * *
Check for inclusion/exclusion criteria  ** ** 
Determination of adverse events    
Serology (Hepatitis & HIV)*** 
Hematology  
Clinical chemistry  
12-lead ECG at rest  
Recumbent blood pressure/pulse rate   
A spot urine sampling for phenotyping 
Administration of chemotherapy  Depended onschedule
Blood sampling for genetic analysis 
Blood sampling for PK analysis of 5-FU 
Hematologic parameters (3 times/week) 
Check for CDC toxicity criteria  
(1), (2)Chemotherapy cycle 1 and 2, respectively, *short physical check up, **short physical check up, patients were asked about their
well-being, *** in case of suspicion or knowledge of infection, PK = pharmacokinetic
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3.4 Urine and blood sample collection
3.4.1 Urine samples
Single spontaneous urine samples,  20 mL, for DPD phenotyping were collected from
patients after an overnight fast (at least 10 h) between 09:00 and 10:00 a.m. before the
start of the chemotherapeutic period. The urine samples were stirred and 4 aliquots of 5
mL each were drawn and stored at -80C until analysis.
3.4.2 Blood samples
Blood samples were drawn from a peripheral vein by venipuncture for DPD, TS, and
MTHFR genotyping, and for 5-FU plasma pharmacokinetics. For genotyping, 8 mL of
blood (2 aliquots of 4 mL each) was drawn from each patient in EDTA containing tubes
(Sarstedt, Nümbrecht, Germany). This whole blood was stored at -20°C until assayed.
For 5-FU pharmacokinetics, 4.5 mL of blood were drawn and collected in Li+-
heparinized tubes (Sarstedt, Nümbrecht, Germany) before dosing (pre-dose), and at the
following times relative to the beginning of 5-FU infusion of the first cycle: 36, 48, 108
h and at the end of infusion, and at the following times relative to the end of infusion: 5,
30, 60 and 90 min. Samples were mixed by inversion, immediately placed on ice, and
centrifuged at 3500 rpm for 10 min at +4°C. Two aliquots of the resulting plasma were
stored at -80°C until analyzed.
3.5 Phenotyping analysis
DPD phenotyping was evaluated by using the dihydrouracil-uracil concentration ratio
(UH2/U) in urine. U and UH2 were quantified with liquid chromatography-tandem mass
spectrometry (LC-MS-MS).
3.5.1 Chemical and reagents
Standards: Uracil (U) (Acros Organics, Ort, New Jersey, USA) and dihydrouracil (UH2)
(Sigma-Aldrich, Steinheim, Germany) were purchased as crystalline form, pure >95%.
Other reagents: Formic acid (98-100%) and sodium chloride (NaCl) were of analytical
grade and were supplied by Merck, Darmstadt, Germany. Methanol (Roth, Karlsruhe,
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Germany) was of HPLC grade. All water used was filtered and deionized with a Milli-
Q-UF system (Millipore, Milford, MA, USA).
3.5.2 Stock solutions, calibration standard samples
Standard solutions of U and UH2 were prepared by dissolving U and UH2 powder in
methanol-water (1:1) at a concentration of 1,905.26 µM and 1,696.91 µM, respectively,
and stored at -20°C. The working solutions for quantification in urine were prepared
with 0.9% NaCl. Analytical standards in the concentrations of U/UH2 of 210.56/115.16,
104.80/57.32, 20.90/11.43, 10.49/5.71, 2.08/0.90, and 1.04/0.57 µM, were prepared by
diluting the stock solutions with 0.9% NaCl solution. QC samples (QC1-3) were also
prepared in the same way containing the following concentrations of U/UH2:
116.04/258.72, 61.04/136.09, and 12.20/2.05 µM.
3.5.3 Urine sample preparation
Urine samples were centrifuged at 18,600 g for 10 min at 4C, and 200 µL of the
supernatant was transferred into HPLC glass vials (give manufacturer here). Twenty µL
of the sample was injected into the LC-MS-MS system for detection.
3.5.4 LC-MS-MS analytical conditions
The LC-MS-MS system consisted of a Surveyor® MS pump (Firmware 1.1), a Surveyor
autosampler (Firmware 2.1), fitted with a tempered tray and a column oven, coupled to
a TSQ® Quantum triple quadrupole mass spectrometer (Thermo Finnigan, San José,
CA, USA).
Separation was achieved by gradient elution with a mobile phase A (0.1% formic acid)
and mobile phase B (pure methanol), programmed as follows: 0-0.5 min 97% A : 3% B,
0.5-1 min the conditions were changed gradually to the second mixture of mobiles
phase, 1-4 min 90% A : 10% B, and 4-5 min 97% A : 3% B, at a flow rate of 0.3
mL/min through an Aquasil analytic column (100 x 3 mm, 5 µm particle size, Thermo
Electron, Runcorn, UK) maintained at 20°C, preceded by a guard column (10 x 3 mm,
5 µm particle size) of the same material. Subsequent to sample injection, the
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autosampler syringe and injection needle were repeatedly rinsed with methanol. Total
duration of each sample analysis was 5 min.
The flow from the column was directed into a Thermo Finnigan TSQ® Quantum
electrospray interface using nitrogen as both the sheath and auxiliary gas. The sheath
gas was set at 60 instrument units, and flow-meter reading of auxiliary gas was set at 2
instrument units. A source collision-induced dissociation (CID) energy of 1.0 eV was
applied in order to break up elution solvent clusters. Analytes were ionized by positive
electrospray ionization (3500 V), and detected by tandem mass spectrometry (MS-MS)
using the selected reaction monitoring (SRM) mode. The scan rate of the mass
spectrometer for each SRM scan was set at 0.5 sec/scan. Integration of the detector
output was performed using LC-Quan (rev. 1.3) software (Thermo-Electron, San José,
USA) to determine peak areas.
3.5.5 Mass spectra and assay validation
Various procedures were performed to validate the assay according to the FDA
guideline (U.S. FDA, 2001). Mass spectra of target compounds are shown in fig. 5. The
ions used in the quantification were m/z 113 → 70.48 for U (RT: 3:94 min) and m/z
115.15 → 74.24 for UH2 (RT: 3.70 min).
To quantify the compounds of interest in urine samples, calibration curves were
obtained from mass chromatograms of calibration standards. The calibration standards
and QC samples were processed as described above and analyzed by LC-MS-MS.
The lower limit of quantification (LLOQ) for U was 2.9 µM, with an accuracy and
precision of 3.1% and 2.9%, respectively (n = 5). The LLOQ of UH2 was 1.8 µM, with
an accuracy and precision of 7.3% and 1.8%, respectively.
The r2 of the calibration curve was 0.999 for U and 0.998 for UH2. The intra-day
variability of LC-MS-MS measurement was obtained by analysis of five QCs of each
concentration on the same day. The intra-day precision of U varied between 2.6 and
3.1%, while for UH2, this value varied between 1.1 and 6.2%. The accuracy at the
tested concentrations ranged from 99.08-114.90% for U and 97.2-116.3% for UH2
(table 7). Further validation, including inter-day assessment, did not carried out because
this assay could be done in the one day.
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Figure 5 Mass spectra of U and UH2
Table 7 Intra-day accuracy and precision for U and UH2
Theoretical concentration
(M)
n Experimental concentration (µM)
(mean ± SD) CV (%)
% deviation
(accuracy)
Intra-day variability of U
116.14 5 118.91 ± 3.14 x 10-3 6 2.5
61.09 5 60.93 ± 2.71 x 10-3 4.4 -0.2
12.21 5 14.02 ± 4.37 x 10-4 3.1 14.9
Intra-day variability of UH2
258.72 5 290.37 ± 3.33 x 10-3 1.1 12.4
136.09 5 139.92 ± 0.72 x 10-3 6.2 2.8
27.20 5 31.62 ± 8.59 x 10-4 2.9 16.3
3.6 Genetic analyses
3.6.1 Isolation of genomic DNA
DNA was isolated from EDTA-anticoagulated blood using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany), following the manufacturer’s instructions.
Briefly, 200 µL of blood and 200 µL of buffer AL were added to 20 µL of proteinase K
in a 2 mL microcentrifuge tube. The mixture was mixed by pulse-vortexing for 15 sec,
U
UH2
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incubated at 56°C for 10 min, and briefly centrifuged to remove drops from the inside
of the lid. Then, 200 µL of ethanol (96%) was added to the sample; the mixture was
mixed by pulse-vortexing for 15 sec and briefly centrifuged. Then the samples were
applied to the QIAamp column (in a 2 mL collection tube) and centrifuged at 8000 rpm
for 1 min.
After centrifugation, the QIAamp column was placed in a clean 2 mL collection tube,
and the tube containing the filtrate was discarded. 500 µL of buffer AW1 was given
onto the QIAamp column, and the sample was centrifuged at 8000 rpm for 1 min, again
the QIAamp column was placed in a new collection tube and the tube containing the
filtrate was discarded. Thereafter, 500 mL of buffer AW2 was given onto the QIAamp
column, and the sample was centrifuged at 14000 rpm for 5 min. The QIAamp column
was placed in a clean 1.5 mL microcentrifuge tube and the collection tube containing
the filtrate was discarded. Finally, 200 µL buffer AE was added onto the QIAamp
column, the sample was incubated at room temperature for 1 min, and then centrifuged
at 8000 rpm for 1 min. After centrifugation, the filtrate contained the DNA, and the
QIAamp column was discarded. In average, a 200 µL of a whole blood sample
typically yielded 6 µg of DNA in 200 µL in eluting buffer (30 ng/µL), which was in
accordance with the value indicated by the manufacturer.
3.6.2 Analysis of the DPYD gene
3.6.2.1 Polymerase Chain Reaction amplification of DPYD genomic DNA
The polymerase chain reaction (PCR) was used to amplify 23 exonic regions of the
DPYD gene from genomic DNA. The specific primers used to amplify each exon are
listed in table 8.
The PCR amplification of all exons (except exon 1, see below) was performed in a 50-
µL reaction mixture consisting of 5 µL PCR-buffer (10x), 4.6 µL MgCl2 (25 mM), 2
µL dNTPs (10 mM), 1 µL of each primer (25 µM), 0.5 µL HotStarTaq DNA-
polymerase (5 U/µL) (Qiagen, Hilden, Germany), 100 ng of genomic DNA of each
patient used as the template (except for exon 3 and 8, 300 ng of genomic DNA were
used in these cases), and purified water for molecular biology analysis (Sigma-Aldrich)
was added to make 50 µL reaction volumes.
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Amplification of exon 1 was carried out with 5 µL PCR-buffer (10x), 1 µL MgCl2, 2
µL dNTPs, 1 µL of each primer, 2.5 µL DMSO (5%), 0.5 µL HotStarTaq DNA-
polymerase, 100 ng of genomic DNA of each patient, and purified water was added to
make 50 µL reaction volumes.
The PCR amplifications were run in a MultiCycler programmable thermal cycler-200
(MJ Research Laboratories, Waltham, MA, U.S.A). The PCR amplification program
was as follows: denaturation at 95°C for 15 sec, 34 cycles of 30 sec at 94°C, 1 min at
50-60°C (the exact annealing temperature used for each exon is given in table 8) and 1
min at 72°C, and a final elongation step of 10 min at 72°C.
3.6.2.2 Gel documentation and purification of the PCR amplification product
After the PCR amplification, 5 µL of glycerol blue was added to each PCR product.
The PCR product was separated by 80 mV electrophoresis on a 1.6% agarose gel
containing 5 mM cytidine (Fluka) and visualized with ethidium bromide staining. An
appropriate basepair marker was included into each gel electrophoresis run. The PCR-
fragments were identified on the agarose gel by comparing the length of the fragment to
the marker ladder, and photographically documented under UV transilluminator with
UV light at a wavelength of 302 nm. The length of each PCR product that contained the
exon investigated is listed in table 8.
Subsequently, the PCR product was purified using the QIAquick gel extraction kit
(Qiagen). Briefly, the gel slice containing the DNA band of interest was excised and
weighed in a vapor sterilized 2 mL tube. Three volumes of buffer QG were added to 1
volume of gel. The sample was incubated at 50°C for 10 min in a thermal block and
mixed by vortexing the tube. One gel volume of isopropranol was added to the sample
and the sample was mixed. The mixture was applied onto a QIAquick column (in a 2
mL containing tube) and centrifuged for 1 min at 13,200 rpm. The flow-through was
discarded, and the QIAquick column was placed back into the same collection tube. For
purification, 500 µL QG buffer was added to the QIAquick column, the sample was
centrifuged for 1 min at 13200 rpm, and the flow-through was discarded.
After placing the QIAquick column into the same collection tube, 750 µL of buffer PE
was added to QIAquick column for washing. The sample was incubated at room
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temperature for 5 min, centrifuged at 13,200 rpm for 1 min, followed by discarding the
filtrate. The QIAquick column was centrifuged again at 13,200 rpm for 1 min, the
eluent was discarded, and the column was placed on a clean, sterile 1.5 mL tube.
Finally, the DNA was eluted with 30 µL of buffer EB (10 mM TrisCl, pH 8.5)
applying the buffer directly on the silica membrane of the QIAquick column. The
QIAquick column was discarded. The eluent contained purified DNA which was either
directly used for sequencing or stored at -20°C until analysis.
3.6.2.3 DNA sequencing
The DNA sequencing of each exon was carried out by the dideoxynucleotide chain
termination method (enzymatic method) using BigDye Terminator kit V. 1.1 (Applied
Biosystems). The sequencing reactions were prepared to analyze the 23 coding exons of
the DPYD gene using sequencing primer sets as specified in table 9. The sequencing
reactions were carried out in 10 L reaction mixtures in microtubes containing 7 µL of
purified PCR products used as the template, 1 L of specific sequencing primer (3.2
M), 1.5 L of BigDye Terminator kit V.1.1, and buffer for BigDye Terminator Kit
V.1.1 added to reach a total volume of 10 L. However, for exon 1 this reaction
consisted of 7 µL of purified PCR products, 1 L of specific sequencing primer (3.2
M), 4 L of BigDye Terminator kit V 1.1, and deionized water added to reach a total
volume of 20 L.
Amplification of the sequencing reactions was performed in a MultiCycler PTC 200
(MJ Research) thermocycler, programmed for 25 temperature-step cycles of 96°C (10
s), 50-60°C (30 s; see annealing temperature for each exon in table 9), and 60°C (4
min) at a ramp speed of 1°C/s.
3.6.2.4 Purification of sequencing products
To generate high quality DNA sequence data, the sequencing products were purified
under filtration procedure with MultiScreen HV plate (MAHVN45, Millipore).
Briefly, the dry G50 Superfine grade Sephadex (G-50-50, Sigma-Aldrich) was filled
into all wells of MultiScreen column loaders (Millipore). Then, 300 L of distilled
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water were added to the Sephadex powder within each well. The plates were allowed
to incubate at room temperature for 3 hours with no agitation, and then centrifuged at
910 rpm for 5 min 2 times for packing the mini-columns, and the filtrates were
discarded.
Subsequently, the Sephadex-columns were placed in the MultiScreen HV plate with 15
L of distilled water and followed by adding the sequencing reaction product to the
center of each column. By centrifugation at 910 rpm for 5 min, the filtrate containing
the purified sequencing products was collected in 96-well plates which were analyzed
directly or stored at -20°C until analysis.
3.6.2.5 Sequence analysis
Ten µL of the purified sequencing product was filled in a MicroAmp Optical 96-well
plate (Applied Biosystems) with 10 L distilled water. The MicroAmp optical 96-well
plate was closed with septa strip (Applied Biosystems) and briefly centrifuged at 910
rpm to ensure that each sample was positioned correctly at the bottom of the well.
Sequence analysis was carried out using an ABI Prism 3100 Genetic Analyzer 16
capillary sequencer (Applied Biosystems, Foster City, CA, U.S.A.).
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Table 8 Oligonucleotides and annealing temperatures used to amplify genomic DNA for DPYD genotyping
Exon Forward-Primer 5´3´ Reverse-Primer 5´3´ Annealing temperature (°C) Fragment (bp)
1 F3x1DPD GCGGACTGCTTTTACCTTTG Rx1DPD TGCTCTGCGGGTAGGTG 58 493
2 Fx2DPD GTGACAAAGTGAGAGAGACCGTGTC Rx2DPD GCCTTACAATGTGTGGAGTGAGG 60 284
3 F2x3DPD ATTTTTATTCCTCCAAACTTA R2x3DPD CCCAAATAATGAAGAATGACT 55 473
4 Fx4DPD GGTAGAAAATAGATTATCTC R2x4DPD GATTTGCTAAGACAAGCTG 55 245
5 Fx5DPD GTTTGTCGTAATTTGGCTG Rx5DPD ATTTGTGCATGGTGATGG 55 284
6 Fx6DPD GAGGATGTAAGCTAGTTTC Rx6DPD CCATTTGTGTGCGTGAAGTTC 50 357
7 Fx7DPD GTCCTCATGCATATCTTGTGTG Rx7DPD GCTTCTGCCTGATGTAG 55 360
8 Fx8DPD GCCCCACATCGTGCTATGAAC Rx8DPD GTCTGAAGGCAGTCATTCTG 57 461
9 Fx9DPD CCCTCCTCCTGCTAAT R2x9DPD GAACAATGTGCTGCTGAG 55 242
10 Fx10DPD GATAGTGACACTTCATCCTG Rx10DPD CTGTTGGTGTACAACTC 55 340
11 Fx11DPD ACTGGTAACTGAAACTCAG Rx11DPD CAATTCCCTGAAAGCTAG 52 442
12 F2x12DPD ACGACTCACTATAGGGCA Rx12DPD GAAGCACTTATCCATTGG 55 453
13 Fx13DPD CGGATGACTGTGTTGAAGTG Rx13DPD TGTGTAATGATAGGTCGTGTC 57 439
14 F2x14DPD TCCTCTGCAAAAATGTGAGA Rx14DPD CAGCAAAGCAACTGGCAGATTC 60 415
15 F2x15DPD GTTTTGCTATCTTACCCTGCTA R2x15DPD AAAGAGTGTATGGATTCAGAGA 55 504
16 Fx16DPD AACGGTGAAAGCCTATTGG Rx16DPD TAGTAACTATCCATACGGGGG 50 223
17 Fx17DPD CACGTCTCCAGCTTTGCTGTTG Rx17DPD CGGGCAACTGATTCAAGTCAAG 55 269
18 Fx18DPD TGGGATGTGAGGGGGTGAATG Rx18DPD TTCAGCAACCTCCAAGAAAGCCAC 60 247
19 Fx19DPD TGTCCAGTGACGCTGTCATCAC Rx19DPD CATTGCATTTGTGAGATGGAG 60 300
20 Fx20DPD GAGAAGTGAATTTGTTTGGAG Rx20DPD CACAGACCCATCATATGGCTG 60 424
21 F3x21DPD GCGAAGTACCTTTGCTATT R3x21DPD TGCTGGTTGTGTTATCATACTATA 50 1287
22 Fx22DPD GAGCTTGCTAAGTAATTCAGTGGC Rx22DPD AGAGCAATATGTGGCACC 60 291
23 F2x23DPD CCCCAAAATCCACAGGTAGAAGAC Rx23DPD GGTGACATGAAAGTTCACAGCAAC 60 269
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Table 9 Sequencing primers and annealing temperatures used to sequence DPYD
Exon Sequencing Primer 5´3´ Annealing temperature(°C)
1 F2x1DPD CTCTACTCCCTCCCTCCCTTCT 60
2 SeqFx2DPD AAACAAATGCCAACATATTTC 55
3 SeqF2x3DPD CCATGATCAATATAATC 50
4 SeqRx4DPD CCCACAGATAATAGAGAA 55
5 SeqRx5DPD TGCATGGTGATGGTAGTG 55
6 SeqRx6DPD ATTGTTTTGCTCCATCATTTCT 55
7 SeqFx7DPD ATTTTTCTACTGATGCCTGTT 55
8 SeqFx8DPD TAATGACACTGGCTTTTCTTC 55
9 SeqRx9DPD GCTGAGCTTGATTTTGA 55
10 SeqFx10DPD TAGTGACACTTCATCCTGGA 55
11 SeqFx11DPD CTGCATATTGACTTAATATCA 55
12 SeqFx12DPD CGTTAGCTTTTCATTTTTATAG 55
13 SeqFx13DPD ATGCTGTGTTGAAGTGAT 55
14 SeqFx14DPD TCTGCAAAAATGTGAGAAG 55
SeqRx14DPD GCAAAGCAACTGGCAGATTCTT 55
15 SeqFx15DPD ATCTTACCCTGCTATTTTCTA 55
16 SeqFx16DPD GGTGAAAGCCTATTGGTATAT 55
17 SeqFx17DPD CCAGCTTTGCTGTTGTTCCAGTAC 55
18 SeqFx18DPD GAGGGTTTGAATGGGTTTTAAC 55
19 SeqFx19DPD CAAGTGGTCAGTGTGCTAAC 55
20 SeqRx20DPD TGGCTGTAATCAAGTCTC 55
21 SeqRx21DPD GCAGTAAATAAACATTTTAAC 55
22 SeqRx22DPD GCCATAAAAACAAGAAGAAAC 55
23 SeqFx23DPD CCTTTGTGGTCAGTGACATC 55
3.6.3 Analysis of thymidylate synthase (TS) gene
PCR analysis of thymidylate synthase (TS) gene polymorphism was performed as
previously described by Iacopetta et al. (2001). PCR amplification of the TS promoter
enhancer region containing the double and triple tandem repeats was carried out using
the following primers: Forward 5´ AAAAGGCGCGCGGAAGGGGTCCT 3´
Reverse 5´ TCCGAGCCGGCCACAGGCAT 3´
PCR reactions were carried out in 42 µL volumes containing 4 µL of DNA preparation,
0.2 µL of Rapidozym Polymerase (5U/µL) (Rapidozym, Berlin, Germany), 0.5 µL of
each primer at a final concentration of 10 µM, 3.0 µL MgCl2 at a final concentration of
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50 mM, 4 µl DMSO, 4.2 µL of 10 x buffer without Mg2+, and 1.0 µL of dNTPs (2 mM),
finally, purified water for molecular biology analysis (Sigma-Aldrich) was added to
make 42 µL reaction volumes.
Following hot-start denaturation at 94°C for 4 min after which time DNA was added, a
total of 32 PCR cycles were performed in a MultiCycler programmable thermal cycler-
200 (MJ Research) under the following conditions: denaturation at 94°C for 40 s,
annealing at 62°C for 40 s and extension at 72°C for 1 min. Final extension was at 72°C
for 5 min.
PCR products containing triple repeats (144 bp) were distinguished from those
containing double repeats (116 bp) by electrophoretic separation on 3% agarose gels.
Patients who were homozygous for the triple repeat (3R/3R) displayed only the 144-bp
PCR product; those homozygous for the double repeat (2R/2R) displayed only the 116-
bp PCR product, while heterozygous individuals (2R/3R) showed both 144- and 116-bp
PCR products.
3.6.4 Analysis of methylenetetrahydrofolate reductase (MTHFR) gene
Genotyping for the methylenetetrahydrofolate reductase (MTHFR) C677T
polymorphism was performed using a polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method reported by Shrubsole et al. (2004) with
minor modifications.
The PCR reactions were run in a MultiCycler programmable thermal cycler-200 (MJ
Research). Each 40 µL of PCR mixture contained 2 µL of DNA, 4 µL of 10 x PCR
buffer without Mg2+, 1 µL of MgCl2 (50 mM), 1 µL of dNTPs (2 mM), 0.5 µL of each
10 mM primer (forward primer 5´ TGAAGGAGAAGGTGTCTGCGGGA 3´ and
reverse primer 5´ AGGACGGTGCGCTGAGAGTG 3´), 1.2 µL of Rapidozym
Polymerase, and purified water for molecular biology analysis was added to make 40
µL reaction volumes.
The reaction mixture was initially denatured at 94°C for 2 min. The PCR was carried
out in 38 cycles of 94°C for 20 s, 64°C for 10 s and 72°C for 10 s. The PCR was
completed by a final extension cycle at 72°C for 7 min.
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After complete PCR amplification, PCR products were separated electrophoretically in
a 3% agarose gel. Each positive PCR product (198 bp fragment) was digested with Hinf
I (Fermentas) in a 10-µL reaction volume, containing 5 µL PCR product, 3.5 µL
purified water for molecular biology, 1 µL 5 x Tango buffer, and 0.5 µL (10 units) of
Hinf I, at 37°C for 12 hours. The products of the incubations with the restriction
enzyme from each patient were loaded with 10 µL bromphenol blue on a 3.2% agarose
gel and detected by ethidium bromide staining. The C→T substitution at nucleotide 677 
creates a Hinf I digestion site. The PCR product (198 bp) with the T allele was digested
to two fragments (175 bp and 23 bp), whereas the PCR product with the wild-type C
allele was not digested by Hinf I.
3.7 Analytical assay for pharmacokinetic studies
3.7.1 Chemical and Reagents
Analytical standards: 5-FU (Sigma, Steinheim, Germany) was purchased as crystalline
form, pure >95.0%, and its metabolite, 5-fluoro-5,6-dihydrouracil (5-FUH2), (26.5%
pure) was supplied by Syncom (Groningen, the Netherlands). 5-Chlorouracil (5-CU),
the internal standard, was obtained from Acros Organics, New Jersey, USA.
Other reagents: Potassium dihydrogenphosphate (KH2PO4) and orthophosphoric acid
were of analytical grade. Ethyl acetate, acetonitrile, and isopropranol were of HPLC
grade. These reagents were purchased from Merck (Darmstadt, Germany). All water
used in the study was filtered and deionized with a Milli-Q-UF system (Millipore,
Milford, USA). Pooled drug-free plasma samples from healthy volunteers were used for
the validation of the method.
3.7.2 Stock solutions and standards
The drugs were dissolved in Milli Q water to yield a stock solution of 1 mg/mL each.
Working solutions of 5-FU, 5-FUH2 and 5-CU were prepared by dilution of the stock
solution in KH2PO4 (50 mM, adjusted to pH 4 with 85% orthophosphoric acid). All
solutions were stored at -20°C.
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3.7.3 HPLC instrumentation and conditions
The HPLC system consisted of a Water 2690 Separations Module (Waters, Milford,
MA, USA) with a PDA Waters 996 photodiode array detector. Detection of 5-FU, 5-
FUH2 and 5-CU were carried out at 265, 220 and 270 nm, respectively. Separation of
compounds was performed on an Ultrasphere ODS C18 analytical column (5 m, 250 x
4.6 mm, Beckman CoulterTM, Fullerton, CA, USA), operating at 25˚C (column heater).
Elution was performed under gradient condition controlled by a gradient proportioning
valve. The elution program was: mobile phase A (50 mM K2HPO4) for 17 min, mobile
phase B (pure acetonitrile) 0-50% over 1 min and maintained at 50% for 5 min. Initial
conditions were restored by decreasing mobile phase B to 0% over 1 min, and the
column was equilibrated with 100% mobile phase A for 5 min. For 5-FU analytics, the
pumps were run at a flow rate of 1.0 mL/min, while for 5-FUH2, a flow rate of 0.8
mL/min was chosen. Analytical run-time was 25 min. Instrument control,
chromatogram recording and peak integration was performed with the Millennium 2.1
software (Waters).
3.7.4 Sample preparation
Plasma samples were allowed to thaw at room temperature and vortexed briefly. The
plasma sample (700 µL) was pipetted into a 15-mL glass tube with a PTFE-lined screw
cap. After addition of the internal standard (20 µL 5-CU, 100 µg/mL), 7 mL of ethyl
acetate-isopropranol (95:5) were added as extraction solvent and then vortexed for 30 s.
Following centrifugation (10 min, 3000 rpm) to separate the phases, the entire organic
layer was transferred into a conical glass centrifuge tube and evaporated to dryness in a
vacuum rotation evaporator (Jouan GmbH, St. Herbleain, France) at room temperature.
The dried residue was dissolved in 100 µL of 50 mM KH2PO4, vortexed for 30 s, and
40 L were injected into the HPLC system.
3.7.5 Calibration and calculation
Standard plasma calibration samples of 5-FU were prepared by spiking blank plasma
with an appropriate volume of working solution to give concentrations in the range
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0.005-75.0 g/mL. Similarly, calibration curves for 5-FUH2 were prepared by adding 5-
FUH2 in concentrations of 0.01-7.5 g/mL.
Four quality control samples (QC1-4) of 5-FU were prepared in plasma at concentrations
of 0.015, 0.15, 1.0 and 75.0 g/mL, and for 5-FUH2 the QC1-4 were 0.03, 0.15, 1.0 and
3.5 g/mL. These samples were subjected to the same sample preparation procedure as
described above.
Calibration curves were constructed by plotting peak area ratios of each analyte to that
of the internal standard (y) versus the nominal plasma drug concentration (x). The line
of best fit was determined using weighted (1/x) linear least-squares regression analysis.
5-FU and 5-FUH2 concentrations of controls and unknown samples were calculated
from the calibration curves using the software. To evaluate linearity of the calibration
curves, 5 calibration curves were prepared and analyzed. The curves were judged linear
if the correlation coefficient r was >0.99 as calculated by weighted linear regression.
3.7.6 Analytical method validation
The analytical method validation employed for the quantitative determination of 5-FU
and 5-FUH2 in plasma was performed according to the guidance proposed by Shah et
al. (1992) and according to the FDA guideline on analytical method validation (2001).
5-FU and 5-FUH2 were validated separately.
3.7.6.1 Validation of 5-FU
Specificity and retention time
Several human plasma samples from different healthy subjects were tested for the
absence of interfering compounds. The retention times of endogenous compounds in
plasma were compared with those of 5-FU and the internal standard (5-CU). Under the
conditions of the assay, 5-FU and 5-CU were eluted at about 5.4 min and 10.7 min,
respectively. No significant interfering peaks that could affect the compounds of
interest were observed (fig. 6).
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Figure 6 Chromatographic separation of 5-FU and internal standard 5-CU
(a) blank plasma; (b) blank plasma spiked with 5-FU (1.0 µg/mL) and 5-CU eluted at 5.4 and 10.7 min, respectively
Extraction recovery
The overall recoveries of 5-FU, expressed as the ratio peak heights of the validation QC
samples low (0.015 µg/mL), middle (1.0 µg/mL) and high (75.0 µg/mL) concentrations
to those in corresponding standard solutions, was 65.16 ± 2.67% (n = 9): mean
recoveries of 5-FU was 61.72 ± 0.56, 65.60 ± 0.13 and 68.15 ± 0.29% for the low,
middle and high concentrations, respectively. The recovery of internal standard (5-CU)
measured at the concentration used in the analysis (100 g/mL) was 72.73% (n = 3).
Determination of the lower limit of quantification (LLOQ)
The LLOQ is the lowest concentration of the standard curve that can be measured with
acceptable accuracy and precision (CV ≤20%). The LLOQ of 5-FU was 0.005 µg/mL
(n = 5); the signal-to-noise ratio at this concentration was about 5. The precision and
the accuracy were 6.32% and 104%, respectively.
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Linearity, accuracy and precision
The standard curve for 5-FU over the range 0.005-75 µg/mL exhibited good linearity
with average of correlation coefficient (r2) = 0.999295 (table 10). The deviation of the
interpolated concentrations of standards in the daily calibration curves of 5-FU were
within the acceptable range of 85-115%. The suitability of the calibration model was
confirmed by back-calculating the concentrations of the calibration standards (table 11).
Table 10 Calibration standard concentrations of 5-FU (5 analytical runs)
Experimental concentration (µg/mL)Theoretical concentration
(µg/mL) Day 1 Day 2 Day 3 Day 4 Day 5 Mean  SD
0.005 0.0044 0.0044 0.0052 0.0045 0.0046 0.0047  2.73 x 10-4
0.0075 0.0074 0.0074 0.0073 0.0074 0.0074 0.0074  4.76 x 10-5
0.01 0.0101 0.0097 0.0094 0.0092 0.0104 0.0098  4.39 x 10-4
0.1 0.107 0.108 0.101 0.110 0.0977 0.105  4.62 x 10-4
5.0 5.16 5.21 5.17 5.30 5.28 5.22  0.06
25.0 26.03 26.24 26.00 26.13 25.61 26.00  0.21
75.0 73.80 73.55 73.82 73.56 74.11 73.77  0.21
r2 (a) 0.999360 0.999060 0.999381 0.999066 0.999606 0.999295  2.08 x 10-4
r2 = correlation coefficient of the linear regression analysis, (a) = linear weighted regression, formula: y = a + bx
Table 11 Calibration standards of 5-FU (5 analytical runs)
Calibration standard (g/mL)
Parameter
0.005 0.075 0.01 0.1 5.0 25.0 75.0
Mean 0.00467 0.0074 0.0098 0.105 5.22 26.00 73.77
%CV 5.89 0.65 4.50 0.44 1.11 0.81 0.28
%deviation -6.34 -1.81 -2.36 +5.0 +4.5 +4.01 -1.64
CV = coefficient of variation
To assess the accuracy and the precision of the method, five replicates per
concentration of QCs were analyzed on the same day and once a day during 5 days to
determine the intra- and inter-day reproducibility, respectively.
The precision of the method at each concentration was calculated as the coefficient of
variation (CV). A CV of less than 15% was accepted, except for the LLOQ, where it
should not be more than 20%. The accuracy of the procedure was evaluated by
calculating the relative difference (% deviation) between the measured mean
concentrations and the theoretical concentrations. The method was considered accurate
when the deviation from the theoretical concentration was less than 20% at the LLOQ
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and less than 15% at the remaining levels. The data for the validation of intra- and
inter-day accuracy and precision of the method are presented in table 12. The results
show CVs which were within the acceptable range.
Table 12 Intra-day and inter-day accuracy and precision of the method for 5-FU
5-FUTheoretical concentration
(g/mL) n Experimental concentration (g/mL)
(mean ± SD) CV (%)
% deviation
(accuracy)
Intra-day variability
0.015 5 0.015 ± 1.09 x 10-3 7.15 0
0.15 5 0.1498 ± 3.12 x 10-3 2.07 0.13
1.0 5 1.06 ± 0.016 1.50 5.60
75.0 5 75.01 ± 0.26 0.34 0.011
Inter-day variability
0.015 5 0.0144 ± 4.9 x 10-4 3.40 4
0.15 5 0.151 ± 1.63 x 10-3 1.08 0.4
1.0 5 1.078 ± 9.96 x 10-3 0.92 7.8
75.0 5 74.99 ± 0.052 0.07 9.33 x 10-3
Stability
Stability testing of the 5-FU was performed on both in plasma and stock solution. For
stability in plasma, QCs of 0.015 and 75 g/mL were analyzed in replicate (n = 3) for
determination of long-term stability, short-term temperature stability, freeze thaw
stability and post-preparative stability.
Three aliquots of each QCs were thawed at room temperature (20C at day-light
exposure) and kept at this temperature for 6 hours and analyzed. The long-term
stability in frozen human plasma (-80C) was determined by storing 3 aliquots of each
QCs under the same conditions as the study samples (at -80C ) and periodic analysis
over 3 months. Prior to their analyzes, samples were brought to room temperature and
vortex-mixed well. Samples were analyzed immediately after preparation (reference
values or freshly prepared QCs) and after storage.
The freeze-thaw stability was determined after 3 refreeze and thaw cycles. Three
aliquots at each of QCs were stored at the -80C for 24 h and thawed unassisted at room
temperature. When completely thawed, the samples were refrozen for 24 h under the
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same conditions. The freeze-thaw cycles were repeated two more times, and then
analyzed immediately on the third cycles.
The stability of processed samples (extracted plasma samples), including the resident
time in the autosampler, was also determined by analyzing three aliquots at each QC
over a period of 24 h. The stored samples in autosampler (4C) were determined
concentrations on the basis of original calibration standards (freshly prepared samples).
For the stability of stock solution of 5-FU, three aliquots of were injected into the
chromatograph immediately after preparation (time 0) and at 6 h after bench-top storage
at room temperature.
The drug was considered stable if more than 90% of the intact drug was retained at the
end of the study period. 5-FU is quite stable under the conditions of storage chosen in
this study (-80C). It was found to be stable during three freeze thaw cycles and during
incubation after 6 hours at room temperature. The long- term stability of 5-FU in
plasma samples stored at -80°C was investigated for 3 months. Compared to the
reference values, there was no statistical difference. Processed plasma samples
containing 5-FU and 5-CU in mobile phase were also found to be stable at room
temperature in the autosampler for 24 h. Stock solution of 5-FU was also stable for at 3
months if stored at -20°C (table 13).
Table 13 Stability of 5-FU (n = 3)
Stability condition Time Concentration (g/mL) % recovery (mean ± SD)
5-FU in plasma
0.015 103.12 ± 2.25
75.0 101.60 ± 3.08Storage, -80˚C 3 months
Overall % recovery 102.36 ± 2.80
0.015 100.76 ± 0.05
75.0 95.87 ± 1.79Bench top, 20˚C 6 hours
Overall % recovery 98.32 ± 2.75
0.015 101.26 ± 1.52
75.0 100.43 ± 2.43Freeze and thaw (x3)
Overall % recovery 100.71 ± 1.95
5-FU in extracted samples
0.015 92.49 ± 1.64
75.0 93.90 ± 2.46On-system (4˚C) 24 hours
Overall % recovery 93.20 ± 2.21
5-FU in stock solution
Bench top, 20°C 6 hours 1.00 mg/mL 99.47 ± 0.28
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3.7.6.2 Validation of 5-FUH2
The analytical method validation employed for the quantitative determination of 5-
FUH2 in plasma was performed according to the guidance proposed by Shah et al.
(1992) and according to the FDA guideline on analytical method validation (2001). The
validation method of 5-FUH2 were determined in a similar way to the validation of 5-
FU, this part presents only the result of validation of 5-FUH2.
Specificity and retention time
The retention time of 5-FUH2 and 5-CU (internal standard) was approximately 5.49
min and 12.89 min, respectively (fig. 7).
Figure 7 Chromatographic separation of 5-FUH2 and internal standard 5-CU
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(a) Blank plasma extract
(b) blank plasma sample spiked with 5-FUH2 (1.0 µg/mL) and 5-CU which eluted at 5.48 and 12.89 min, respectively
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Figure 7 Cont.
(c) blank plasma sample spiked with 5-FUH2 (1.0 µg/mL), 5-FU (1.0 µg/mL) and 5-CU which eluted at 5.49, 6.7 and 12.89 min,
respectively, the chromatogram was recorded at 220 nm
Extraction recovery
The overall recovery of 5-FUH2 averaged 70.93 ± 1.8 (n = 9): mean recoveries at low
(0.03 µg/mL), middle (1.0 µg/mL), and high QCs (3.5 µg/mL) was 71.17 ± 2.2%, 70.40
± 1.63%, and 71.23 ± 1.35, respectively.
Determination of the lower limit of quantification (LLOQ)
The LLOQ of 5-FUH2 was 0.01 µg/mL (n = 5); the signal-to-noise ratio at this
concentration was about 5. The precision and the accuracy were 1.96% and 93.78%,
respectively.
Linearity, accuracy and precision
The calibration curves of 5-FUH2 were linear (average r2 = 0.99905; table 14). The
deviation from 5 validation analytical runs (5 days) was within the acceptable range of
85-115% (table 15).
The intra-day and inter-day precisions at the concentrations of the four QCs were <8%
and <4%, respectively, and the average accuracy showed values ranging within the
acceptable range of 85-115%. A summary of the analysis is presented in table 16.
(c)
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Table 14 Calibration standard concentrations of 5-FUH2 (5 analytical runs)
Experimental concentration (µg/mL)Theoretical concentration
(µg/mL) Day 1 Day 2 Day 3 Day 4 Day 5 Mean  SD
0.01 0.0094 0.0114 0.0091 0.00814 0.0081 0.0093  1.20 x 10-3
0.025 0.0275 0.0278 0.0260 0.0260 Excluded 0.0258  2.31 x 10-3
0.05 0.0490 0.0510 Excluded 0.0520 0.0540 0.0525  1.80 x 10-3
0.1 0.0870 0.0864 0.1143 0.1021 Excluded 0.0974  0.011
0.5 0.5313 0.4369 0.5281 0.5142 0.5600 0.514  0.041
1.0 1.0334 0.9963 1.0255 1.0249 1.00 1.016  0.015
7.5 7.4462 7.5762 7.4363 7.4570 7.4380 7.47  0.053
r2 (a) 0.999389 0.99755 0.999410 0.999787 0.9991 0.99905  7.8 x 10-4
r2 = correlation coefficient of the linear regression analysis, (a) = linear weighted regression, formula: y = a + bx
Table 15 Calibration standards of 5-FUH2 (5 analytical runs)
Calibration standard (g/mL)Parameter
0.01 0.025 0.05 0.1 0.5 1.0 7.5
Mean 0.0093 0.0258 0.0525 0.0974 0.514 1.016 7.47
%CV 12.93 8.95 3.43 11.29 7.98 1.48 0.71
%deviation -7.2 +3.2 +5.0 +2.6 +2.8 +1.6 -0.4
CV = coefficient of variation
Table 16 Intra-day and inter-day accuracy and precision of the method of 5-FUH2
5-FUH2Theoretical
concentration (g/mL) n Experimental concentration (g/mL)
(mean ± SD) CV (%)
% deviation
(accuracy)
Intra-day variability
0.03 5 0.0322 ± 1.72 x 10-3 0.53 7.33
0.15 5 0.149 ± 4.12 x 10-3 2.76 -0.67
1.0 5 1.009 ± 0.017 1.68 0.9
3.5 5 3.461 ± 0.071 2.05 -1.11
Inter-day variability
0.03 5 0.033 ± 2.50 x 10-3 7.58 10
0.15 5 0.150 ± 5.84 x 10-3 3.89 0
1.0 5 1.03 ± 0.052 5.05 3
3.5 5 3.48 ± 0.052 9.20 0.57
Stability
We assumed that 5-FUH2 might not be stable because instability of 5-FUH2 had been
observed previously under various conditions (van den Bosch et al., 1987; Ackland et
al., 1997; Casale et al., 2002; Maring et al., 2005). Thus, in this study the stability
testing of 5-FUH2 was not performed. However, to avoid the degradation of 5-FUH2
during analysis, the optimum requirements for storage and processing during the
analysis was followed as described below according to the previous reports.
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 Due to the instability of 5-FUH2 in plasma at room temperature (Maring et al., 2005;
van den Bosch et al., 1987), thus the samples were placed on ice immediately after
the collection, separate the plasma as quickly as possible and freeze it (-28C or -
80C) until analysis.
 5-FUH2 appears stable only 2 freeze-thaw cycles (Maring et al., 2005; van den Bosch
et al., 1987), once-thawed samples were used and thawing was proceed to 4-5C.
 At low concentration of 5-FUH2 in extracted and reconstituted plasma sample
appears stable for no longer than 20 h at ambient temperature (Maring et al., 2005;
Ackland et al., 1997), therefore each analytical run was not longer than 20 h and the
cooling of the autosampler compartment was set at 4C.
 For all standards, controls, stock solution and standard solution of 5-FUH2 was
diluted with K2HPO4 and prepared weekly and stored at -20C in the dark when not
in use as recommended by Casale et al (2002). Besides, the QCs samples and
standard calibration samples were prepared freshly for every analytical run.
3.7.7 Application to clinical pharmacokinetic studies
As shown above, the present method fulfilled the requirements for validation of
bioanalytical methodologies (Shah et al., 1992; FDA, 2001), making this method
suitable for the quantification of plasma concentrations of 5-FU and 5-FUH2. For
routine use, separate calibration samples for 5-FU and 5-FUH2 were included in each
analytical run in duplicate (in the beginning and at the end of each sample queue). An
analytical run consisted of 8 QC samples, twice 9 calibration standards (including blank
plasma and a zero sample), and all processed unknown samples of two patients of the
study (9 samples/patient) to be analyzed as one batch. After each 4th sample with
unknown 5-FU or 5-FUH2 content, 2 QCs were analyzed. Each analytical run took
about 20 h.
For accepting the results of an analytical run, at least 2/3 of the QC samples had to be
within 15% of their respective values; 1/3 of the QC sample (not all replicates at one
concentration) were allowed to be outside the 15% range of the nominal value. If the
QC sample of the particular run did not meet these criteria, the run was repeated.
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In case a single patient sample with unknown content of the analytes deviated from the
theoretical level to be expected according to the individual concentration versus time
profile, this sample was verified by repeating the analysis. When the initial result was
confirmed (difference <15%), the first value was reported. If the difference between
two determinations ranged between 15-30%, the mean of these two values was
reported. If the difference was >30%, a third determination was performed. If the
difference between any two of these three values was <15%, the median of these values
was reported.
Analysis of plasma concentrations in the samples of the 30 patients of the study was
performed as described above. Figure 8 depicts the chromatograms of a plasma sample
at t = 36 h after the beginning of continuous infusion over 5 days of 5-FU.
Figure 8 Representative Chromatograms of a patient plasma sample at 36 h after
the start of a continuous infusion over 5 days of 5-FU
(a) Chromatogram of a patient plasma sample of 5-FU monitored at 265 nm (flow rate of 1.0 mL/min); (b) Chromatogram of a
patient plasma sample of 5-FUH2 monitored at 220 nm (flow rate of 0.8 mL/min).
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3.8 Data analysis
3.8.1 Population pharmacokinetic model development
The NONMEM program version V, level 1.1 (NONMEM Project Group, UCSF, San
Francisco, CA, U.S.A.) was used to develop a compartmental population
pharmacokinetic model to describe the pharmacokinetics of 5-FU and its main
metabolite (5-FUH2) and their variability (interindividual and residual), as well as the
influence of covariates on disposition of 5-FU and 5-FUH2. Fitting was performed with
the “first-order conditional estimates” algorithm, taking interaction between the
parameters into account. Additional statistical analysis was done with Statistical
Product and Service Solutions (SPSS) for Windows, version 11.0 (SPSS Inc. Chicago,
IL, U.S.A.) to confirm the results obtained from the NONMEM analysis.
3.8.1.1 Algorithm of model building:
Step 1: building a basic model without covariates, including
- development of a structural pharmacokinetic model for 5-FU
- development of a combined structural pharmacokinetic model for 5-FU and
5-FUH2: the dataset included concentrations of both 5-FU and 5-FUH2;
model parameters allowed the simultaneous estimation of 5-FU and 5-FUH2
pharmacokinetics
Step 2: building the final model including all relevant covariates
Step 3: model assessment
In order to characterize that the present model is representative of the data in hand, the
following criterias were taken into account:
a) Difference in minimum value of objective function (OFV)
The goodness-of-fit (GOF) of the model to the data was evaluated based on changing in
minimum value of objective function (OFV), which is proportional to minus twice the
log-likelihood, provided by NONMEM. The discrimination models were compared by
using a log-likelihood ratio test, which is the OFV for the two models and which was
referenced to its asymptotic 2 distribution (with n degrees of freedom equal to the
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difference in the number of parameters between different models). The OFV of ≥3.84
was required to indicate that the model with the lowest OFV was associated with the
better model (p < 0.05). The log likelihood ratio was used to simultaneously estimate
population values of fixed-effects parameters (e.g. CL, Vd) and values of random-
effects parameters (inter-individual and residual variability).
b) The plausibility of estimated parameters and their 95% confidence intervals
c) Quality of goodness of fit plots (GOF)
GOF plots included the following (all were presented as X vs. Y): (1) observed vs.
predicted concentrations, (2) predicted concentrations vs. weighted residuals
(deviations of predictions from observed concentrations) and (3) time vs. weighted
residuals. A more randomly distribution of predicted vs. observed concentration across
the line of unity and less systemic distribution of weighted residual compared with
those in the base model indicate a better fit.
3.8.1.2 Basic model building:
The mixed effects model consists of a structural, a statistical and a covariate model.
Building the basic model means choosing the structural and statistical model.
Concerning the structural model, initially the 5-FU concentration-time data were
modelled separately from 5-FUH2 without covariates in order to determine the initial
estimates of the pharmacokinetic parameters and to determine whether a one-, two-, or
three-compartment model best described the patient data. The model that best fit the
concentration-time profiles of 5-FU was selected for further analysis: i.e. to establish a
combined model (parent-metabolite structural model). The values of 5-FU
pharmacokinetic parameter [total clearance (CL), intercompartmental clearance (Q),
central and peripheral volume of distribution (Vc, Vp) obtained from this model were
used as inputs values to develop the combined pharmacokinetic model. Then, the values
of these parameters were “fixed”, allowing the first estimation for the 5-FUH2
pharmacokinetic parameters. Finally, the pharmacokinetic parameters of 5-FU and 5-
FUH2 were calculated simultaneously to refine the combined model. 5-FU was assumed
to be eliminated only from the central compartment; and 5-FUH2 was assigned to a
separate compartment (fig. 9).
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Figure 9 Structural pharmacokinetic model of 5-FU and 5-FUH2
i.v. dose
Vm
CLmet
Vc
Q
Vp
CLm CLres
Boxes indicate compartments. Arrows indicate first-order processes.
Vc = central volume of distribution of 5-FU, Vp = peripheral volume of distribution of 5-FU, Vm = volume of
distribution of 5-FUH2, CLmet = metabolic clearance of 5-FU converted to 5-FUH2, Q = inter-compartmental
clearance, CLres = elimination clearance of 5-FU other than intercompartment clearance and conversion to 5-FUH2
(residual elimination clearance), CLm = total clearance of 5-FUH2
In modelling 5-FU and 5-FUH2 simultaneously, several parameters could not be
globally identified under the conditions used in this study, mainly because no urine for
5-FU and 5-FUH2 quantification was collected. The following parameters were not
globally identifiable: residual elimination clearance (CLres) and metabolic clearance
(CLmet) of 5-FU, volume of distribution of 5-FUH2 (Vm), and total clearance of 5-FUH2
(CLm). However, combinations of these parameters were identifiable: CLmet/(Vc*Vp) or
(CLres + CLmet)/Vc : in which Vc and Vp is central and peripheral volume of distribution
of 5-FU, respectively.
Therefore, the combined model was parameterized in terms of clearance and volume of
distribution for 5-FU, while fraction of the metabolite and elimination rate constant
(K30) was parameterized for 5-FUH2. To aid the identification of pharmacokinetic
parameters of 5-FUH2, Vm was arbitrarily set to 100 L, so the model could be run in a
more stable fashion.
The statistical model accounts for interindividual and residual variability. Variability is
usually assumed to follow normal distribution with a mean of zero. The interindividual
variability () is described as the individual’s deviation from the population mean
(Ppop) of a kinetic parameter. As individual pharmacokinetic parameters (Pi) are usually
log-normally distributed, the interindividual variability in pharmacokinetic parameters
was estimated using an exponential error model: Pi = Ppop*eη
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Residual variability (), which includes the intra-individual variability, measurement
error and any model misspecification error, etc., corresponds to the differences between
observed (Cobs) and predicted (Cpred) concentration by individual parameters (Pi). The
residual variability was calculated separately for 5-FU and 5-FUH2 and was described
by a proportional error model used the following equation: Cobs = Cpred + Cpred*
3.8.1.3 Final model building (Covariate model):
After the basic model (combined pharmacokinetic model of 5-FU and 5-FUH2) was
constructed, individual estimates of the pharmacokinetic parameters were generated
from the basic model to assess whether additional patients’ covariates influenced the
pharmacokinetic parameters. The OFV obtained from the basic model was considered
as a starting value to test the significance of covariates. At first, relationships between
individual estimates of pharmacokinetic parameters and patient covariates were
explored graphically: scatter plots for individual pharmacokinetic parameter estimates
vs. continuous covariates or box and whiskers plots for pharmacokinetic parameters vs.
categorical covariates were evaluated. NONMEM used multiple linear regressions to
assess and quantify the relationship between the pharmacokinetic parameters and the
covariate(s). The selection of the covariates to be tested was based on their
physiological and clinical relevance. Age, weight, height, gender, body mass index,
body surface area1, co-medication, renal function (creatinine clearance)2, hepatic
function (ALT, AST, -GT, bilirubin), total protein, smoking status, DPD activity
(UH2/U), and the genotyping of DPD, TS and MTHFR were considered as covariates.
According to the literature, the DPD activity could be reduced by the mutations found
in the patients of this study. Based on this assumption, the patients in this population
pharmacokinetic study were divided into 3 groups depending on the presence of at least
one single-nucleotide polymorphisms (SNP) in the DPYD gene: wild-type (no
mutation), heterozygote (at least one heterozygous mutation), and homozygote mutants
(at least one homozygous mutation) with respect to different mutations.
Covariates that are continuous in nature (e.g. BSA, age) were centred on their medians.
The continuous covariates were entered into the population pharmacokinetic model
1 BSA = (body weight in kg/70 kg)0.73 x 1.73 m2
2 CLCr (male) (mL/min)=[140–age (yrs)][weight (kg)]/(72)[Crserum (mg/dL)], CLcr (female)=0.85x[140–age][weight]/(72)[Crserum]
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according to the following equation: P = θ1*[1 + (COV - CŌV)*θ2], in which P is the
individual estimate of the parameter, COV is the value of the covariate of respective
patient from the study population, and CŌV is the median value of the covariate in the
study population. θ1 is the typical value of the parameter in individuals with the
“median covariate” and θ2 is the percentage change in the typical parameter with each
unit change from the median covariate value.
Categorical covariates (e.g. sex) were included in the model by using the following
equation: P = θ1*θ2, where P is the individual estimate of the parameter, θ1 is typical
value of the parameter when the covariate is not present, and θ2 is the fractional change
in the value of P when the covariate is present. For some categorical covariates (e.g.
MTHFR C667T genotype), a typical value for respective pharmacokinetic parameter
was estimated separately for each subgroup of study subjects.
Once the selected covariates were included in the base model, the selected covariates
were tested for statistical significance one by one in NONMEM using a forward
addition development procedure. In this step, the OFV was also used to evaluate the
GOF upon inclusion of each covariate. The OFV was obtained by comparing a model
in which the tested covariate was absent to a model in which the covariate was
included. The OFV (decrease in OFV) of ≥ 3.84 (corresponding to a p-value < 0.05)
was required to identify a covariate as being significant. The most significant model,
i.e. the model with one covariate and lowest OFV, was kept in the next step and into
this model; each of the remaining significant covariates was again included, one at a
time. This continued until no additional covariate was judged to change the model
significantly. All significant covariates were then forced into a multivariate
intermediate model, and each was eliminated in a backward stepwise approach to
determine if its exclusion was statistically significant. The OFV obtained in
multivariate intermediate model was again used as reference value to evaluate the
decrease in GOF obtained upon independent deletion of each covariate: the OFV
(increase in OFV) of ≥ 6.63 with p <0.01, was required to achieve the level of
significance and to retain a covariate. The significant remaining covariates represented
the final model.
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The change in the extent of random variability in the presence of covariate(s) was used
as a further indicator of the GOF. A reduction in random variability and a less
systematic distribution of weighted residuals are generally accepted signs for model
refinement.
3.8.1.4 Model assessment
The stability of final parameter estimates was assessed by the jack-knife method. The
method assumes fitting model to the study population lacking one individual. This was
repeated until every individual had been excluded once from the analysis, which
resulted in 30 analyses. Unbalanced results were expected if the parameter estimates of
the model were highly determined by a single individual.
In order to identify the sensitivity of the final model for individuals that alone are
responsible for (driving) a covariate relationship, the final covariate model was re-run
ten times using only nine-tenth of each dataset at a time.
3.8.1.5 Calculation of additional pharmacokinetic parameters
The individual pharmacokinetic parameters estimated directly with the combined and
final pharmacokinetic model specifications were CL, Vc, Vp and Q of 5-FU, and
elimination rate constant and fraction of metabolite for 5-FUH2. Bayesian
pharmacokinetic estimates for individual subjects were obtained by specification of the
POSTHOC option to NONMEM. These POSTHOC Bayesian estimates of the
pharmacokinetic parameters were further used to calculate the additional
pharmacokinetic parameters of 5-FU and 5-FUH2 in the combined and final model. The
following parameters were calculated for 5-FU: metabolic CL of 5-FU converted to 5-
FUH2, residual elimination clearance, terminal elimination half-life (t1/2,z), total
volume of distribution (Vd), and area under the plasma concentration vs. time curve
from time point zero extrapolated to infinity [AUC(0-)]. For 5-FUH2 the total clearance,
t1/2,z and AUC(0-) were calculated. The following equations were used:
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Where t1/2,z is the terminal elimination half-life (h), K30 is elimination rate constant
(1/h), Vm is volume of distribution of 5-FUH2 (100 L), and Fm is the fraction of the
initial dose of 5-FU converted to 5-FUH2 divided by Vm of 5-FUH2
3.8.2 Statistical analysis
Clinical data of all patients were listed. Summary statistics of demographic data,
laboratory values, vital signs etc. were performed. A listing of all adverse events
reported was set up together with the clinical assessment of these adverse events. All
other data relevant to the clinical course of the study was reported either as listing of
individual findings or as summary statistics. Values were described by the arithmetic
mean and the relative standard deviation for continuous and normally distributed data
as well as by the median and range. The one-sample Kolmogorov-Smirnov test was
applied to check whether a parameter was normally distributed. A p-value < 0.05
indicated a significant difference between two distributions.
Concerning toxicity, since only few adverse events were observed and since all of them
were relatively mild, therefore adverse events were evaluated in term of the occurrence
of adverse events, regardless of the type, clustered into 2 groups: no adverse event
(grade 0) and 5-FU adverse event (grade 1-2). Additionally, due to hematological
toxicity being the main adverse effect, changes in blood cell counts for leukocyte,
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erythrocyte and thrombocyte was calculated as the safety test by using the following
equation:
  
countbloodntpretreatme
countbloodnadircountbloodntpretreatme 100
The following statistical analyses were evaluated: a) First, the search for factors of
influence on pharmacokinetics which pharmacokinetic variables were the dependent
variables, and genotypes and phenotype were the independent ones. To test the relevant
influence of DPD phenotype on pharmacokinetics, simple linear regression analysis
was used. The relevant influences of genotypes (DPD, TS, and MTHFR) on
pharmacokinetics were tested by using Kruskal-Wallis-test. b) Then, factors of
influence on adverse events which the pharmacokinetics were independent variables as
genotypes and phenotype were. Again, the simple linear regression was applied to
describe the functional relationship between the pharmacokinetics and the relative
decrease in blood cell counts as well as the DPD phenotype and the relative decrease in
blood cell counts. While Kruskal-Wallis-test was used to test the influence of genotypes
on the relative decrease in blood cell counts. Univariate analysis was carried out using
binary logistic regression for each individual genotype in DPD, TS, and MTHFR as a
predictor of adverse event. Parametric statistical tests using the pharmacokinetic
variables and DPD phenotype were performed to identify differences between
subgroups of patients categorized according to adverse event.
The pharmacokinetics used in statistical analyses were AUC of 5-FU (mgh/L), AUC of
5-FUH2 (mgh/L) and AUC ratio of 5-FU/5-FUH2.
For the association of DPYD-genotyping with any variable, each informative nucleotide
was tested separately assuming an additive allele effect.
Statistical significance was set at the p <0.05 level. Statistical analysis was performed
using SPSS for Windows version 11.0 (SPSS Inc. Chicago, IL, U.S.A.).
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4. Results
4.1 Patient characteristics
A total of 33 patients with colorectal or oesophageal carcinoma were enrolled in the
study of whom 30 completed the pharmacokinetic study. Three patients were removed
from the study for unrelated medical problems before the 5-FU started due to technical
problem in blood collection (2 patients) and personal reasons not related to the study (1
patient). The first patient entered the study in April 2003 and the last in April 2005. The
study finish lasted in October 2005. Baseline patient characteristics and pretreatment
values of relevant hematologic and biochemical parameters are listed in table 17. The
study included 25 male and 5 female patients with a median age of 59.5 years (range
37-73 years). The mean Karnofsky performance status was 100% (100-100). The most
prevalent primary tumor site was the oesophagus. The majority of patients had stage III
disease.
Table 17 Characteristics of patients (n = 30)
Characteristics Value
Tumor primary site
Oesophagus
Rectal
Colorectal
Anus
15
1
13
1
Disease stage
0
I
II
III
IV
1
5
6
9
6
Median height, m (range) 1.8 (1.6-1.9)
Median weight, kg (range) 75.5 (46-111)
Median body mass index (BMI), kg/m2 (range) 24.3 (18.7-33.2)
Median body surface area (BSA), m2 (range) 1.91 (1.48-2.35)
Median baseline laboratory values (range)
Hemoglobin (g/dL)
Platelets (x1E12/L)
Erythrocytes (x1E9/L)
Leukocytes (x1E9/L)
Albumin (g/dL)
Serum glutamic ocaloacetic transaminase (SGOT) (U/L)
Serum glutamic pyruvic transaminase (SGPT) (U/L)
Gamma-glutamyl transferase (-GT= (U/L)
Total bilirubin (mg/dL)
Creatinine (mg/dL)
13.7 (10.1-16.6)
277 (48-426)
4.6 (3.8-5.5)
6.90 (4.68-11.28)
42 (35-47)
18 (9-50)
15 (8-90)
24 (13-81)
0.45 (0.4-0.5)
0.85 (0.44-1.06)
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4.2 Adverse events
All 30 patients were evaluable for adverse events. Four patients had no adverse event
throughout the duration of treatment. The most frequently observed adverse events
during 5-FU therapy are listed in table 18. A total of 69 adverse events were recorded
during the course of the study, 54 of which were classified as grade 1 (78.26%), and 15
as grade 2 (21.74%). 5-FU-associated gastrointestinal adverse event were the most
common side effects observed. None of the 26 patients who experienced adverse event
had adverse event above grade 2.
Table 18 Adverse effects during 5-FU therapy
Grade I Grade II
Toxicity
Events Patients (n) Events Patients (n)
Hematologic
Leukopenia 1 1 1 1
Gastrointestinal
Nausea
Nausea with emesis
Emesis
Diarrhea
Soft stool
Blood in stool
Mucositis
Metal-like taste on the tongue
Gastric discomfort
Loss of appetite
Thirst
Abdominal pain
11
2
6
1
1
1
3
2
4
2
1
2
10
2
5
1
1
1
3
2
4
2
1
2
3
1
1
1
1
0
2
0
0
0
0
0
2
1
1
1
1
0
2
0
0
0
0
0
Pain
Rectal pain
Pain in hemorrhoids
0
1
0
1
4
0
1
0
Constitutional
Tiredness/fatigue/weakness
Sickness
Orthostatic symptoms
4
1
1
4
1
1
0
1
0
0
1
0
Cardiovascular
Tachycardia 1 1 0 0
Neurologic
Headache
Dizziness
Depressive mood
Feeling of warmness
Increased body temperature
Feeling of redhead
4
1
1
1
1
1
3
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
In this study, 69 total events were observed and 30 patients were evaluated
4.3 Changes in blood cell counts
Hematological changes were evaluated for 29 patients. For one patient no blood cell
count data were available. The hematological changes were defined as percentage
decrease in leukocyte, erythrocyte and thrombocyte counts. A median duration of
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follow-up for the hematological changes was 1 month (range 2-12 weeks). Mild
leukopenia (grade 1-2) was observed in 2 patients. One patient presented leukopenia
during the 5-FU infusion with a duration of adverse event of 1 month: the leukocyte
counts at that time were 2.46-4.13 x109/mL (baseline 5.01 x109/mL). In another
patient, leukopenia occurred on post-study day (day 10 after start of 5-FU infusion)
with duration of this adverse event of 2 weeks: the leukocyte counts at that time were
2.30-3.22 x109/mL (baseline 6.87 x109/mL). The hematological characteristics for all
patients are listed in table 19. The leukocyte, erythrocyte and thrombocyte counts
decreased by less than 50% (table 19).
Table 19 Hematological changes characteristic
Hematological
characteristics Blood cell counts type Mean Range Median SD
Leukocyte (x109/L) 6.94 4.00-13.66 7.22 1.95
Erythrocyte (x1012/L) 4.63 3.8-5.3 4.7 0.37Baseline (n = 30)
Thrombocyte (x109/L) 273.43 147-395 279 80.72
Leukocyte (x109/L) 3.80 1.72-8.11 3.30 2.02
Erythrocyte (x1012/L) 4.16 2.50-5.00 4.30 0.39Nadir (n = 29)
Thrombocyte (x109/L) 167.79 22-280 170 64.92
Leukocyte (%) 48.78 20.69-75.22 50.70 16.29
Erythrocyte (%) 13.98 6.00-49.02 10.42 4.86Percent decrease in blood
cell count
Thrombocyte (%) 39.32 2.00-74.00 42.74 17.84
SD = standard deviation
4.4 DPD phenotype
4.4.1 DPD phenotype distribution
DPD phenotype was assessed using the urinary ratio of dihydrouracil/uracil (UH2/U).
Concentrations of U and UH2 in urine samples of 30 patients were determined, and
their concentration ratios were calculated (table 20). One patient had unquantifyable
UH2 levels in urine. The UH2/U ratio was normally distributed as assessed by the
Kolmogorov-Smirnov test (p >0.05) with a mean ± SD of 1.18 ± 0.5 (table 20).
Table 20 Concentrations of U (µM), UH2 (µM) and the UH2/U ratio in urine
Analyte n Medium Minimum Maximum
Uracil 30 29.63 4.14 102.21
Dihydrouracil 29 32.85 12.90 62.49
Dihydrouracil/Uracil ratio 29 1.18 0.37 2.68
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4.5 Genotyping
4.5.1 DPYD polymorphisms
Analysis of the DPYD gene of 30 patients revealed the presence of 6 polymorphisms in
22 of 30 patients (table 21). In eight patients, no polymorphism was detected in any of
the 23 exons investigated. The mutation 85T>C (DPYD*9A) was detected in 10
patients (33.3%), with homozygous alleles in 2 patients and heterozygous alleles in 8
patients: allelic frequency of 20% (12/60). The 1627A>G (DPYD*5) was detected in 11
patients (36.7%), with homozygous alleles in 2 patients and heterozygous alleles in 9
patients: allelic frequency of 21.7% (13/60).
Other mutations were only present heterozygously (table 21): the allelic frequency of
these mutations was 20% (12/60). Of these polymorphisms, the mutations 1236G>A
and 1601G>A (DPYD*4), and 2194G>A (DPYD*6) were found in one and two
patients, respectively, whereas 496A>G was found in 8 patients. The DPYD
polymorphisms found in 22 patients are presented in table 22. In these patients, eight
had multiple mutations in the coding region of the DPYD gene.
Table 21 Allelic frequencies of polymorphisms in the DPYD gene in 30 patients
DPYD
polymorphism
nomenclature Exon
Effect (nucleotide
change)
Wild-
type
(n)
Heterozygous
mutant (n)
Homozygous
mutant (n)
Allelic
frequency (%)
DPYD*9A 2 Cys29Arg (85T>C) 20 8 2 12/60 (20%)
6 Met166Val (496A>G) 22 8 0 8/60 (13.33%)
11 Glu412Glu (1236G>A) 29 1 0 1/60 (1.67%)
DPYD*4 13 Ser534Asn (1601G>A) 29 1 0 1/60 (1.67%)
DPYD*5 13 Ile543Val (1627A>G) 19 9 2 13/60 (21.67%)
DPYD*6 18 Val732Ile (2194G>A) 28 2 0 2/60 (3.33%)
DPYD = dihydropyrimidine dehydrogenase gene, n = number of patients
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Table 22 DPYD polymorphisms detected in patients
Patient no. [sex, age] Primary cancer DPD genotype Effect Exon
1 [M, 68] Oesophageal 1627A>G Ile543Val 13
3 [M, 37] Rectal 496A>G
1627A>G
Met166Val
Ile543Val
6
13
4 [M, 46] Colon 85CC
496A>G
1236G>A
Cys29Arg
Met166Val
Glu412Glu
2
6
11
5 [F, 58] Oesophageal 85CC
496A>G
Cys29Arg
Met166Val
2
6
6 [M, 45] Oesophageal 1627A>G Ile543Val 13
9 [F, 50] Rectal 85T>C
496A>G
1627GG
Cys29Arg
Met166Val
Ile543Val
2
6
13
10 [M, 52] Oesophageal 1601G>A Ser534Asn 13
11 [M, 46] Oesophageal 85T>C
496A>G
1627A>G
Cys29Arg
Met166Val
Ile543Val
2
6
13
13 [M, 62] Oesophageal 1627GG Ile543Val 13
14 [M, 50] Rectal 85T>C Cys29Arg 2
15 [F, 60] Rectal 1627A>G Ile543Val 13
16 [M, 51] Rectal 85T>C Cys29Arg 2
17 [F, 70] Rectal 85T>C
496A>G
Cys29Arg
Met166Val
2
6
18 [M, 61] Rectal 1627A>G Ile543Val 13
19 [M, 58] Rectal 85T>C Cys29Arg 2
20 [M, 66] Oesophageal 85T>C
496A>G
Cys29Arg
Met166Val
2
6
22 [M, 66] Oesophageal 85T>C
496A>G
Cys29Arg
Met166Val
2
6
24 [M, 64] Rectal 1627A>G Ile543Val 13
26 [M, 52] Rectal 2194G>A Val732Ile 18
28 [M, 51] Oesophageal 2194G>A Val732Ile 18
29 [M, 66] Rectal 1627A>G Ile543Val 13
30 [M, 73] Anal 1627A>G Ile543Val 13
Age in year, 85T>C = DPYD*9A, 1601G>A = DPYD*4, 1627A>G = DPYD*5, 2194G>A = DPYD*6
4.5.2 Thymidylate synthase polymorphism
Among 30 patients analyzed for the TS genotype, 5 (16.70%) were homozygous for the
triple repeat (3R/3R), 19 (63.30%) were heterozygous (2R/3R), and 6 (20.00%) were
homozygous for the double repeat variant (2R/2R) within the human TS promoter
region.
4.5.3 Methylenetetrahydrofolate reductase (MTHFR) polymorphism
The MTHFR 677CT and MTHFR 677CC genotypes occurred with almost the same
frequency [43% (n = 13) and 40% (n = 12), respectively], while the MTHFR 677TT
genotype was only observed in 17% (n = 5) of the patients.
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4.6 Pharmacokinetics of 5-FU and 5-FUH2
4.6.1 Raw concentration-time data
The pharmacokinetic evaluation was carried out for all 30 patients. Plasma
concentrations of 5-FU and 5-FUH2 in 30 patients are presented in figures 10 and 11. A
large variability in 5-FU and 5-FUH2 concentrations were observed both between the
patients (median %CV = 60.43, range 17.61-76.12) and in the same patient (median
%CV = 34.70, range 3.40-93.85) during infusion (fig. 10). As shown in figure 11, 5-
FUH2 concentrations were consistently greater than those of 5-FU. The 5-FU plasma
concentrations decreased rapidly when the infusion was stopped, which may be
interpreted as that 5-FU accumulated during infusion, and was eliminated very fast,
while the concentrations of 5-FUH2 decreased more slowly (fig 11).
Figure 10 Plasma concentrations of 5-FU (a) and 5-FUH2 (b) in 30 patients
a)
b)
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Figure 11 Mean plasma concentrations of 5-FU and 5-FUH2 in 30 patients
4.6.2 Population pharmacokinetic analysis
4.6.2.1 Base model or covariate-free model
The population pharmacokinetic model was developed based on 199 and 251 plasma
concentrations of 5-FU and 5-FUH2, respectively, obtained from 30 patients. First, a
model for 5-FU pharmacokinetics alone was developed. The model best describing 5-
FU concentration-time data was an open two-compartment model with first-order
elimination (subroutine ADVAN3 TRANS3 in NONMEM), with interindividual
variability in total clearance. The mean population pharmacokinetic parameter
estimates for 5-FU and these 95% confidence intervals (95% CI) obtained from this 5-
FU model were the total clearance (CLtot) 238 L/h (198-278), central volume of
distribution (Vc) 11.4 L (5.5-17.3), intercompartment clearance (Q) 12.9 L/h (4.9-20.9),
and total volume of distribution (Vd) 30.4 L (17.8-43.0). Interpatient variability in CLtot
of 5-FU was about 9-fold, the coefficient variation (CV) was 44.3%.
For the development of a combined pharmacokinetic model of 5-FU and 5-FUH2, the
two-compartment model with first-order elimination was used to describe 5-FU
concentration-time data, whereas a one-compartment model gave the best fit for the 5-
FUH2 concentration-time data. These two models were then combined to describe the
pharmacokinetics of both analytes within one model (subroutine ADVAN5 TRANS1 in
NONMEM, general linear model).
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The combined pharmacokinetic model was parameterized in terms of CLtot, Q, central
and peripheral volume of distribution (Vc and Vp) for 5-FU, the fraction of the initial 5-
FU dose converted to 5-FUH2 divided by the volume of distribution of the 5-FUH2,
(Fm), and the elimination rate constant of 5-FUH2 (K30). By simultaneously analysis of
the 5-FU and the 5-FUH2 data, the model with inclusion of the interindividual
variability for the CLtot of 5-FU and elimination rate constant of 5-FUH2 gave the best
fit. By inclusion of interindividual variability () on such parameters as Q, V, Fm, the
fitting did not get better and the point estimate for  was very small. Because it is
important to keep the model simple as possible, the respective (s) were not included in
the model. The population mean estimate for CLtot of 5-FU was found to be 237 L/h
(95% CI, 197-227 L/h), the interpatient variability (expressed as %CV) was 44%. The
population mean estimate for K30 of 5-FUH2 was 1.17 1/h (95% CI, 0.90-1.43 /h) with
an interpatient variability of 31.8% (expressed as %CV). Other population
pharmacokinetic parameters are shown in table 23.
Table 23 Population pharmacokinetics of 5-FU and 5-FUH2 (combined base
model)*
Jack-knife validationPopulation estimate of
PK parameter (unit)
Point
estimate
SE of
estimate 95% CI
Interindividual
CV (%) Median Range
5-FU
CLtot (L/h) 237 20.6 197 – 227 44.0 236 230 – 251
Vc (L) 10.8 2.7 5.5 – 16.1 n.s.a 10.8 9.8 – 12.0
Vp (L) 19.4 5.6 8.5 – 30.3 n.s.a 19.4 16.4 – 21.5
Q (L/h) 12.2 3.9 4.5 – 19.9 n.s.a 12.5 9.8 – 13.1
5-FUH2
Fm/Vm (1/L)b 0.863 0.111 0.647 – 1.078 n.s.a 0.859 0.827 – 0.897
K30 (1/h) 1.17 0.13 0.90 – 1.43 31.8 1.17 1.11 – 1.21
* The values for the pharmacokinetic parameters represent estimates for a typical individual in the population.
a n.s. = inclusion of this element of inter-individual variation did not improve the model significantly
b Fm/Vm = the fraction of the initial 5-FU dose converted to 5-FUH2 divided by the volume of distribution of the 5-FUH2
PK = pharmacokinetic, SE = standard error, CLtot = total clearance, Vc = central volume of distribution, Vp = peripheral volume of
distribution, Q = intercompartmental clearance, K30 = elimination rate constant of 5-FUH2
The population pharmacokinetic parameter estimates of 5-FU in the combined model
were essentially equal to those previously calculated based on 5-FU concentration-time
data only (subroutine ADVAN3 TRANS3) (0.4% to 5.4% deviation), and their 95% CI
included the mean parameter estimates obtained from the former model during step 1
(see above).
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The additional pharmacokinetic parameters of 5-FU and 5-FUH2 were calculated from
the individual patient parameter estimates obtained by using NONMEM. These
parameters are presented in table 24. The mean values for CLtot of 5-FU and of 5-FUH2
were 237 (range 50-443) and 117 (range 67-217) L/h, respectively. The mean value of
5-FU metabolic clearance converted to 5-FUH2 (CLmet) was 205 L/h (range 43-383),
indicating that approximately 86.3% of 5-FU was catabolized to 5-FUH2. Additionally,
the AUC0-∞ of 5-FU and the terminal elimination half-life (t1/2z) of 5-FU and of 5-
FUH2 were also calculated for all patients (table 24).
Table 24 Pharmacokinetic parameters of 5-FU and 5-FUH2 calculated from
individual patient pharmacokinetic parameter estimates (combined base model)
PK parameter (unit) Formula Geometric mean ± SD Median Range
5-FU
CLmet (L/h) CLmet = K13*Vc
K13 = Fm*(CLtot/Vc)
205 ± 75 225 43 – 383
CLres (L/h) CLres = CLtot – CLm 33 ± 12 36 7 – 61
CLtot (L/h) - estimated n.a. 238 ± 87 261 50 – 443
t½,z (h) t ½,z = ln(2)/ Kel
Kel = (1 – Fm)*(CLtot/Vc) + K13
0.032 ± 0.024 0.029 0.017 – 0.15
AUC(0-) (mgh/L) AUC(0-∞) = Dose/CLtot 34.49 ± 23.62 33.56 16.61 – 150.80
5-FUH2
CLm (L/h) CLm = K30*Vm 117 ± 39 116 67 – 217
AUC(0-) (mgh/L) AUC(0-∞) = Dose * Fm/CLm 60.40 ± 19.61 62.88 30.73 – 97.51
t½,z (h) t ½,z = ln(2)/ K30 0.59 ± 0.19 0.60 0.32 – 1.04
PK = pharmacokinetic, SD = standard deviation, CLmet = metabolic clearance of 5-FU converted to 5-FUH2, CLres = residual
elimination clearance of 5-FU, CLtot = total clearance of 5-FU, t½,z = terminal elimination half-life, AUC(0-) = area under the
concentration-time curve from time 0 to infinity, CLm = total clearance of 5-FUH2, Kel = overall elimination rate constant of 5-FU,
K13 = formation rate constant of 5-FUH2, Vc = central volume of distribution, K30 = elimination rate constant of 5-FUH2, Vm =
volume of distribution of 5-FUH2, Fm = fraction of the initial 5-FU dose converted to 5-FUH2 divided by the volume of distribution
of the metabolite (1/L); point estimate for Fm = 0.863
The appropriateness of the combined base model was evaluated graphically by
goodness of fit (GOF) plots: the points on the model-predicted vs. observed plots for 5-
FU and 5-FUH2 concentrations and on the weighted residuals vs. predicted
concentrations plots (fig. 12-13) did not show distributions suggesting systematic
deviations.
Scatter plot of the individual predicted vs. the observed 5-FU and FUH2 plasma
concentrations, illustrated in fig. 12, indicated that the model adequately described the
concentration-time data of 5-FUH2, however, there was a tendency to overestimate 5-
FU plasma concentrations.
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Figure 12 Individual predicted vs. observed plasma concentrations of the base
model for 5-FU (a) and 5-FUH2 (b)
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Residual variability in the combined base model was calculated separately for 5-FU and
5-FUH2. The proportional error model for both substances yielded the lowest objective
function value and the best residual plots (fig. 13). The residual variability in the base
model was 64% and 43% for 5-FU and 5-FUH2, respectively. A combined proportional
and additive error models resulted in a significantly worse fit, and an additive error
model was also not superior to the proportional error model.
a)
b)
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Figure 13 Weighted residuals vs. predicted concentrations of the base model for 5-
FU (a) and 5-FUH2 (b) plasma concentrations
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4.6.2.2 Covariate analysis and final model
The effect of the covariates (see section 3.8 data analysis) on the pharmacokinetic
parameters of 5-FU and 5-FUH2 were tested in the combined pharmacokinetic base
model.
The preliminary separate testing of covariates in the model with 5-FU concentration-
time data developed in step 1 suggested that only some patient characteristics could
potentially explain the interindividual variability in the pharmacokinetics of 5-FU,
particularly, the CLtot of 5-FU was associated with BSA, BMI, body weight and height,
sex (2-fold lower clearance in females), while Q was affected by MTHFR C677T and
TS genotype and hepatic function represented by ALT, AST, and γ-GT values in the
model.
Using the addition development procedure and the elimination approach, a covariate
model for 5-FU data alone was obtained, in which the estimated value for 5-FU CLtot
a)
b)
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was affected by BSA and MTHFR C677T genotype. The effect of MTHFR C677T
genotype on CL has been modelled as a sum of clearance fractions, namely, a typical
value of CLtot (95% CI) for subjects with two T-alleles and increase in CLtot in the
presence of C-allele were 169 L/h (112- 226) and 72 L/h (21-123), respectively. Thus,
the point estimates for 5-FU CLtot were 169, 241 and 313 L/h for individuals with TT-,
CT-, and CC-haplotype of MTHFR gene, respectively. Addition of other covariates,
which have been significant factors of influence in univariate analysis, did not result in
significant improvements in the structural model in multivariate analysis.
In univariate analysis, the combined pharmacokinetic model was significantly improved
with the separate inclusion of the following covariates: CLtot was influenced by BSA,
body weight, BMI, sex, MTHFR and DPD genotype; Q was influenced by hepatic
function (γ-GT value), MTHFR C677T genotype, and age. The 5-FU CLtot increased
with increasing value of BSA, body weight, BMI, whereas Q increased with increasing
γ-GT values, but decreased with age. However, some of these models gave unstable
models, particularly, models describing the influence of body weight, and BMI on CLtot
as well as models describing the effect of MTHFR genotype, and γ-GT values on Q.
Therefore, these covariates were not included in the multivariate analysis.
The results of testing the influence of groups of DPYD genotypes, divided into 3 groups
depending on the presence of at least one single-nucleotide polymorphisms (SNP) in
the DPYD gene (homozygous wild-types, heterozygotes, and homozygotes mutants
with respect to different mutations), on pharmacokinetic parameters showed an impact
on 5-FU CLtot: i.e. point estimates were 263 L/h (95% CI, 231-295) and 175 L/h (95%
CI, 87-263) in patients with wild-type genotype and homozygous mutations,
respectively. The OFV decreased significantly (p < 0.05) by inclusion of patient’s DPD
genotype as co-factor in the combined model; however, the confidence intervals for
estimations on the CLtot were very broad with overlapping the values between the
groups. Thus, the covariance DPD genotype was not included in the final model
because of the lacking statistical significance and due to a very small number of
mutations in the DPYD gene found in the study population that would lead to
difficulties in interpreting the results.
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The inclusion of age as a covariate for Q in multivariate analysis resulted in a
significant reduction of the objective function value (OFV), but the level of
significance was not achieved in the backward elimination procedure. Therefore, this
cofactor was not included in the final pharmacokinetic model.
In multivariate analysis, the influence of BSA and sex on the CLtot in combination with
MTHFR genotype was tested in separate models because of the co-linearity of these
parameters. Inclusion of the parameters sex or BSA yielded a significant reduction in
the objective function value and in the random variability. The correlation between
BSA and CLtot was slightly stronger than the correlations between sex and CLtot. The
significant impact of BSA and MTHFR genotype on CLtot of 5-FU was confirmed by
multivariate analysis and by backward elimination. The remaining covariates after
having carried out the backward elimination procedure represented the final model.
The final equation including BSA and MTHFR C667T genotype as covariates, which
best described the CL of 5-FU in this study, was as follows:
BSA alone:
CL = 250*[1 + (BSA – 1.91)*0.85]
= 250*(0.85*BSA – 0.62) (p = 0.008, r2 = 0.224)
BSA and MTHFR genotype:
CL = 145*[1 + (BSA – 1.91)*0.85]
= 145*(0.85*BSA – 0.62), for patient with TT-haplotype
CL = 276*[1 + (BSA – 191)*0.85]
= 276*(0.85*BSA – 0.62)], for patient with CC- and CT-haplotype
(r2 = 0.415, p = 0.025)
The population pharmacokinetic parameter estimates obtained from this final covariate
model are summarized in table 25. As it has been done for the parameters obtained with
the base model, additional pharmacokinetic parameters of 5-FU and 5-FUH2 were
calculated from individual patient parameter estimates and are presented in table 26.
Results of the jack-knife analysis, that was used to assess the stability of final parameter
estimates are detailed in table 23. Median values for each parameter obtained from
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jack-knife analysis were in the same range as the parameter estimates obtained from the
model using the complete dataset. Similarly, the testing of final covariate model for its
sensitivity did not yielded any shortcoming of the model
Table 25 Population pharmacokinetics of 5-FU and 5-FUH2 (final covariate
model)*
Population estimate of PK parameter (unit) Point estimate SE of estimate 95% CI CV (%)
CLtot of 5-FU in patients with two T-alleles in
MTHFR gene (L/h)
145a 31.5 83 – 207 29.6
CLtot of 5-FU in patients with one- or two C-
alleles in MTHFR gene (L/h)
276a 13.4 250 – 302 29.6
Central volume of distribution of 5-FU (L) 11.1 2.8 5.7 – 16.5 n.s.b
Peripheral volume of distribution of 5-FU (L) 21.8 6.7 8.7 – 34.9 n.s.b
Intercompartmental clearance of 5-FU (L/h) 13.2 5.0 3.4 – 23.0 n.s.b
Fraction of metabolite (5-FUH2) (1/L) 0.863 c 0.110 0.647 – 1.079 n.s.b
Elimination rate constant of 5-FUH2 (1/h) 1.17 0.13 0.90 – 1.43 31.6
* values for the PK parameters represented estimates for the typical individual in the population. PK = pharmacokinetic, SE =
standard error, CI = confidential interval, CV = coefficient of variation
a CLtot was estimated separately for 2 subgroups of patients: patients with TT-alleles and patient with CT or CC in MTHFR gene
b n.s., inclusion of this element of inter-individual variation did not improve the model significantly
c fraction of the initial 5-FU dose converted to 5-FUH2 divided by the volume of distribution of the metabolite
Table 26 Pharmacokinetic parameters of 5-FU and 5-FUH2 calculated from
individual patient parameter estimates (final covariate model)
PK parameter (unit) Formula Geometric mean ± SD Median Range
5-FU
CLmet (L/h) CLmet = K13*Vc
K13 = Fm*(CL/Vc)
207 ± 75 230 43 – 381
CLres (L/h) CLres = CL – CLm 33 ± 12 36 7 – 60
CLtot (L/h) - estimated n.a. 240 ± 87 266 49 – 441
t½,z (h) t½,z = ln(2)/ Kel
Kel = (1-Fm)*(CL/Vc)+K13
0.032 ± 0.025 0.029 0.017 – 0.155
AUC(0-) (mgh/L) AUC0-∞ = Dose/CL 34.15 ± 23.98 32.74 17.52 – 152.46
5-FUH2
CLm (L/h) CLm = K30*Vm 117 ± 38 116 67 – 213
AUC(0-) (mgh/L) AUC0-∞ = Dose*Fm/CLm 60.29 ± 19.53 62.85 30.67 – 97.29
t½,z (h) t½,z = ln(2)/ K30 0.59 ± 0.18 0.60 0.32 – 1.04
PK = pharmacokinetic, CLmet = metabolic clearance 5-FU converted to 5-FUH2, CLres = residual elimination clearance, CLtot =
total clearance, t½,z = terminal elimination half-life, AUC(0-) = area under the concentration-time curve at time 0 to infinity,
CLm = total clearance of 5-FUH2, Fm = 0.863, K13 = formation rate constant of 5-FUH2 (1/h), K30 = elimination rate constant of
5-FUH2, Kel = overall elimination rate constant of 5-FU, Vc = central volume of distribution of 5-FU, Vm = volume of distribution
of 5-FUH2
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4.7 Factors influencing of additional pharmacokinetic parameters
The 5-FU AUC (AUC5-FU) and 5-FUH2 AUC (AUC5-FUH2) were calculated from the
base model, using the POSTHOC option of NONMEM. The mean AUC of 5-FU and of
5-FUH2 were 38.22 ± 23.62 mgh/L (range 16.16-150.80) and 63.40 ± 19.61 mgh/L
(range 30.73-97.51), respectively. The AUC5-FU/AUC5-FUH2 ratio (AUC ratio) was also
calculated which was 0.62 ± 0.28 (range 0.31-1.55).
4.7.1 DPD phenotype
Simple linear regression analysis showed that no correlations between the DPD
phenotype, expressed in term of UH2/U ratio, and AUC5-FU (adjusted r2 = 0.041, p =
0.149) or the AUC5-FUH2 (adjusted r2 = - 0.016, p = 0.465). There were also no
statistically significant correlation between DPD phenotype and AUC ratio (adjusted r2
= -0.14, p = 0.432).
4.7.2 DPYD polymorphisms
Using Kruskal-Wallis-test, neither significant correlation was found between AUC5-FU
nor AUC5-FUH2 and these DPYD polymorphisms. The same was true for the AUC ratio.
Statistical analysis is showed in table 27.
Table 27 Statistical analysis of the associations of DPYD and pharmacokinetics
AUC of 5-FU (mgh/L) AUC of 5-FUH2 (mgh/L) AUC ratioDPYD
polymorphisms

2 p-value 2 p-value 2 p-value
85T>C 4.460 0.108 0.967 0.617 4.540 0.103
496A>G 0.079 0.778 0.372 0.542 0.317 0.574
1236G>A 0.564 0.453 0.404 0.525 1.472 0.225
1601G>A 1.205 0.272 1.472 0.225 0.164 0.686
1627A>G 0.459 0.498 0.403 0.525 0.790 0.374
2194G>A 0.333 0.561 0.249 0.618 0.000 1.000
4.7.3 Thymidylate synthase polymorphism
A possible influence of TS polymorphisms on the pharmacokinetics was tested using
Kruskal-Willis-test. There was no relationship between the TS polymorphism and the
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AUC5-FU (2 = 2.015, p = 0.365) or the AUC5-FUH2 (2 = 2.586, p = 0.274) or the AUC
ratio (2 = 0.280, p = 0.869)
4.7.4 Methylenetetrahydrofolate reductase polymorphism
Using Kruskal-Willis-test, a significant correlation was observed between the AUC5-FU
and the MTHFR C677T polymorphism (2 = 6.585, p = 0.037; fig. 14). The AUC5-FU
was higher in patients homozygote for MTHFR 677TT than in patients with the wild-
type MTHFR 677CC or heterozygous carriers of the MTHFR 677CT allele. However,
no relationship was identified between the MTHFR polymorphism and the AUC5-FUH2
(2 = 1.154, p = 0.565) and the AUC ratio (2 = 4.202, p = 0.122).
Figure 14 The association of MTHFR C677T polymorphism and AUC of 5-FU
4.8. Factors influencing of adverse events and changes in blood cell counts
4.8.1 DPD phenotype
Four patients (13.33%) were defined as having no adverse event and 26 patients
(86.67%) had adverse events (grade 1-2). Of these 26 patients, one patient who had
unquantifyable UH2 levels in urine presented U concentrations of 4.14 µM. This patient
had mild adverse event (grade 1; nausea and vomiting).
The influence of the UH2/U ratio on the occurrence of adverse event was tested for 29
patients. The UH2/U ratio was not significantly different in patients with adverse event
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compared to patients who tolerated the treatment [1.17 ± 0.51 (range 0.37-2.68) vs.
1.29 ± 0.40 (0.83-1.69), respectively, p = 0.650].
An additional test was carried out to evaluate whether the DPD phenotype was
associated with changes in blood cell counts. The changes in blood cell counts for
leukocyte, erythrocyte, and thrombocyte served as the dependent variables here. Simple
linear regression analysis revealed no correlation between DPD phenotype and the
changes in leukocyte count (adjusted r2 = 0.05, p = 0.264), erythrocyte count (adjusted
r2 = 0.07, p = 0.182), and thrombocyte count (adjusted r2 = 0.01, p = 0.637).
4.8.2 DPYD polymorphisms
In 19 of the 26 patients who experienced adverse events, DPYD mutations were
detected; whereas no mutations were observed in 7 patients with adverse events, table
28. Three of four patients without adverse event had DPYD mutations. The frequency
of haplotypes was too small to reliably assess differences within and between haplotype
(fig. 15).
Figure 15 Haplotypes of the DPYD gene and adverse events of 5-FU
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Table 28 DPYD mutations in patients exhibiting adverse events
Patient no.
[sex, age ]
Primary
cancer
UH2/U DPYD genotype adverse events (grade)
1 [M, 68] Oesophageal n.d. 1627A>G nausea (1), emesis (1)
3 [M, 37] Rectal 0.77 496A>G, 1627A>G gastric discomfort (1)
4 [M, 46] Colon 0.61 85CC, 496A>G,
1236G>A
diarrhea (1), apthous oral (1), meterorism (1), weakness
(1), mucositis (2)
5 [F, 58] Oesophageal 0.58 85CC, 496A>G leukopenia (1)
6 [M, 45] Oesophageal 0.76 1627A>G dizziness (1), red head feeling (1), nausea and emesis (1)
7 [M, 41] Oesophageal 1.45 - tachycardia (1), nausea (1)
8 [M, 60] Rectal 1.09 - increased body temperature (1)
9 [F, 50] Rectal 1.20 85T>C, 496A>G,
1627GG
gastric pain (1), tiredness (1), mucositis (2), nausea and
emesis (1)
10 [M, 52] Oesophageal 1.23 1601G>A nausea (1)
12 [M, 64] Rectal 2.68 - Meterorism (1), nausea (1), mucositis (1)
13 [M, 62] Oesophageal 0.99 1627GG emesis (1), nausea (1), headache (1)
14 [M, 50] Rectal 1.41 85T>C depressive mood (1), soft stool (1), metal-like taste on
tongue (1), abdominal pain (1)
15 [F, 60] Rectal 1.39 1627A>G headache (1)
16 [M, 51] Rectal 0.86 85T>C leukopenia (2)
18 [M, 61] Oesophageal 0.37 1627A>G nausea (1)
19 [M, 58] Oesophageal 0.75 85T>C tiredness (1), nausea (1)
20 [M, 66] Oesophageal 1.17 85T>C, 496A>G nausea (1), emesis (1), mucositis (1)
21 [M, 71] Rectal 2.37 - rectal pain (2), nausea (2)
23 [M, 68] Oesophageal 0.95 - emesis (2), nausea (2),
24 [M, 64] Rectal 1.37 1627A>G orthostatic symptoms
25 [M, 70] Oesophageal 0.95 - warmness feeling (1), tiredness (1), sickness (1)
26 [M, 52] Rectal 1.17 2194G>A nausea (1), emesis (1), loss of appetites (1)
27 [F, 40] Rectal 1.20 - headache (1), diarrhea (2), thirst (1)
28 [M, 51] Oesophageal 1.67 2194G>A nausea (1), metal-like taste on tongue (1)
29 [M, 66] Rectal 1.43 1627A>G blood in stool (1)
30 [M, 73] Anal 0.92 1627A>G loss of appetite (1)
M = male, F = female, U = uracil, UH2 = dihydrouracil, age in years, DPD phenotype expressed as UH2/U ratio
The polymorphisms 1236G>A and 1601G>A were found in only 1 patient each (but
suffering from adverse event), and 2194G>A was found in 2 patients who both
presented adverse events (table 28). Thus, the number of patients with these mutations
was too low to identify an association with adverse event using logistic regression
analysis. For the polymorphisms 85T>C, 496A>G and 1627A>G, the evaluation of
associations between adverse event and allele frequencies showed that the 496A>G was
significantly correlated to the occurrence of adverse event [2 = 4.84, df = 1, p = 0.028,
odds ratio = 0.079 (95% CI = 0.007-0.933)]. Patients with the wild-type 496AA had
more frequently adverse event than carriers of the mutation. However, after correction
for multiple testing [by the Bonferroni correction technique; with 3 tests performed, a
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p-value must be < 0.05/3 (i.e., 0.016) to be statistically significant] it is did not prove to
be significant (p = 0.02). No influence on adverse event was seen for 85T>C (2 =
5.035, df = 2, p = 0.081) and for 1627G>A (2 = 8.39, df = 2, p = 0.658)
To evaluate the effect of the 6 polymorphisms detected in the study population on the
changes in blood cell counts, the Kruskal-Wallis-test was performed. None of the
polymorphisms showed an effect on changes in blood cell counts (table 29).
Table 29 The association between DPYD and changes in blood cell counts
Changes in blood cell counts
leukocyte erythrocyte thrombocyte
DPYD
polymorphisms

2 p-value 2 p-value 2 p-value
85T>C 1.503 0.472 1.891 0.389 0.403 0.818
496A>G 0.117 0.733 0.467 0.494 0.021 0.884
1236G>A 1.729 0.189 0.515 0.473 2.414 0.120
1601G>A 0.700 0.403 1.159 0.282 2.057 0.151
1627A>G 4.288 0.117 2.292 0.318 0.376 0.828
2194G>A 0.896 0.344 0.364 0.547 0.741 0.389
4.8.3 Thymidylate synthase polymorphism
In 26 patients experiencing adverse events, the 2R/2R and the 3R/3R were equally
distributed 15.38% (n = 4), and 2R/3R occurred in 69.20% (n = 18) of the patients
(table 30).
Table 30 TS polymorphism and adverse events in 30 patients
No adverse event 5-FU adverse event
TS polymorphism
No. of patients % No. of patients %
Total no. of patients
2R/2R 2 33.3 4 66.7 6
2R/3R 1 5.3 18 94.7 19
3R/3R 1 20 4 80 5
A possible influence of TS polymorphisms on the occurrence of adverse events was
tested using logistic regression analysis. No influence of TS genotype was observed on
the occurrence of adverse events (2 = 3.083, df = 2, p = 0.214).
A link between TS mutation and the changes in blood cell counts was tested with
Kruskal-Wallis-test. No association was observed for the change in leukocyte count (2
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= 0.390, p = 0.823), for the change in erythrocyte count (2 = 2.845, p = 0.241) and for
the change in thrombocyte count (2 = 0.995, p = 0.608).
4.8.4 Methylenetetrahydrofolate reductase polymorphism
All patients without adverse event (n = 4) were found to be heterozygous for the
MTHFR C677T polymorphism (CT). Patients experiencing adverse events were
homozygous (TT), heterozygous (CT), and wild-type (CC) for the MTHFR
polymorphism in 5, 8 and 13 cases, respectively (table 31).
Table 31 MTHFR C677T polymorphism and adverse events in 30 patients
No adverse event 5-FU adverse eventMTHFR C677T
polymorphism No. of patients % No. of patients %
Total no. of patients
CC 0 0 13 100 13
CT 4 33.3 8 66.7 12
TT 0 0 5 100 5
Analysis of the association between the MTHFR C677T and the occurrence of adverse
events by logistic regression showed that MTHFR C677T was not linked to the
occurrence of adverse events during 5-FU therapy (2 = 4.381, df = 2, p = 0.112).
Using Kruskal-Wallis-test, for the MTHFR mutation, there was no a significant effect
of MTHFR mutation on the changes in blood cell counts, either with respect to the
leukocyte (2 = 2.429, p = 0.297), or with respect to the erythrocyte (2 = 2.133, p =
0.344), or with respect to the thrombocyte (2 = 0.963, p = 0.618).
4.9 Influence of pharmacokinetics on adverse events and changes in blood cell
counts
The AUC5-FU and the AUC5-FUH2 generated from the final model were 37.93 ± 23.98
mgh/L and 63.30 ± 19.54 mgh/L, respectively. The AUC ratio was 0.62 ± 0.30.
Comparisons of the AUC5-FU, the AUC5-FUH2, and the AUC ratio were performed
according to adverse event groups of patients (table 32). No significant difference
between the AUC5-FU and the AUC5-FUH2 in the group of patients experiencing adverse
events compared to the group of patients not reporting adverse events was observed.
Similarly, no significant difference in the AUC ratio between these patient groups was
observed (p = 0.319).
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Table 32 Pharmacokinetic parameters categorized to the adverse event
Parameter Group n Mean ± SD Minimum Maximum t-test (p)
No 5-FU adverse event 4 22.70 ± 6.00 17.52 31.50 0.177AUC of 5-FU
(mgh/L) 5-FU adverse event 26 40.28 ± 24.89 20.00 152.46
No 5-FU adverse event 4 51.23 ± 21.34 30.68 73.43 0.190AUC of 5-FUH2
(mgh/L) 5-FU adverse event 26 65.13 ± 19.01 35.86 97.31
No adverse event 4 0.48 ± 0.12 0.35 0.64 0.319
AUC ratio
5-FU adverse event 26 0.64 ± 0.31 0.32 1.57
Using linear correlation analysis, for the pharmacokinetic parameters, no relationships
to the changes in blood cell counts was observed (fig. 16-18). Additionally, there were
also no significant correlation between other pharmacokinetic parameters (CL and t1/2
of 5-FU, CL and t1/2 of 5-FUH2) and the changes in blood cell counts in this study
population (all p-value > 0.05).
Figure 16 The relationship between pharmacokinetics and the change in leukocyte
count
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Figure 16 Cont.
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Figure 17 The relationship between pharmacokinetics and the change in
erythrocyte count
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Figure 18 The relationship between pharmacokinetics and the change in
thrombocyte count
r2 = -0.001, p = 0.334
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5. Discussion
In the present study, the pharmacokinetics of 5-FU and 5-FUH2 were investigated in 30
previously untreated colorectal or oesophageal cancer patients. The three main aims of
this study were hence to 1) identify factors of influence on 5-FU pharmacokinetics, 2)
identify factors influencing adverse events and blood cell count changes, and 3) evaluate
the influence of pharmacokinetics on adverse events and blood cell count changes. These
three aspects will be discussed separately.
The most common side effects observed in this study were gastrointestinal, consistent
with the know toxicity of 5-FU. Leukopenia, the most common hematologic toxicity
associated with 5-FU (Grem, 2000), was observed in only two patients with mild
intensity. In addition, other commonly occurring symptoms during i.v. 5-FU therapy
including mucositis, nausea, vomiting, anorexia, and diarrhea (Grem, 2000) also observed
in this study were tolerable with CDC common toxicity grading of ≤ 2. The lack of
serious toxicity of 5-FU may be attributable to the 5-FU regimen used. In comparison to
5-FU bolus administration, the long-term 5-day continuous infusion has a different and
more favourable spectrum of adverse events. The pattern of toxicity seems to be
dependent on the velocity of administration. An intravenous bolus typically causes
depression of both white blood cell and platelet counts, while a continuous intravenous
infusion often leads to more severe stomatitis, diarrhea, and hand-foot syndrome
(Gamelin et al., 1996; Meta-Analysis Group in Cancer, 1988; Thyss et al., 1986).
However, the sample of 30 patients may have been too small to observe more and also
severe adverse events.
5.1 Methodological aspect
It is important to realize that the result presented here should only apply when 5-FU is
administered as long-term continuous infusion for 5 days because of the relationship
suggested between 5-FU pharmacokinetics and both clinical response and toxicity (Diasio
& Harris, 1989; Gamelin et al., 996; Grem, 2000).
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5.1.1 Analytic methods
5.1.1.1 Determination of DPD phenotype
DPD expression can be phenotypically assessed by determining enzyme activity in an
accessible site such as peripheral blood mononuclear cells (PBMC), or by monitoring
catabolite formation of endogenous uracil in body fluids. Although determination of DPD
activity in PBMC is regarded as a global method to estimate the total DPD activity
(Etienne et al., 1994; Harris et al., 1990; Johnson et al., 1997; Lu et al., 1993), it is time-
consuming, requires a large volume of blood and radioactive labeled materials, making
the test difficult to be used in clinical routine. Since 5-FU and uracil have the same
metabolic pathway via DPD due to their similar chemical structures, the concentrations of
the naturally occurring pyrimidines in urine or plasma differ between patients with normal
and reduced DPD activity, respectively (Tuchman et al., 1985; Gamelin et al., 1999). So
analyzing endogenous uracil (U) and dihydrouracil (UH2) as well as their concentration
ratio (UH2/U) in biological fluids (plasma, urine) before administering 5-FU may be a
tool to prospectively identify patients with DPD deficiency. In this study, a simple LC-
MS/MS method was developed to determine simultaneously the urinary concentration of
uracil and its dehydrogenated metabolite (UH2). However, the purpose of the
measurement of UH2/U concentration ratios is not to determine the precise DPD activity.
The ratio serves as a tool to identify patients with a complete DPD deficiency, and to get
an impression of the overall pyrimidine metabolism, including other factors besides DPD
activity.
5.1.1.2 Assay method for 5-FU and 5-FUH2
A number of assays have been developed to measure 5-FU and its main metabolite, 5-
FUH2 in plasma. The assay used most often today in clinical pharmacokinetic studies is
HPLC with reverse phase column. Several different sample preparation techniques are
used with the HPLC and permit determination of 5-FU and of 5-FUH2 in the nanogram
range (6.5-75 ng/mL for 5-FU, 75-100 ng/mL for 5-FUH2, Ackland et al., 1997; Bocci et
al., 2000; Casale et al., 2002; Findlay et al., 1996; Maring et al., 2005). Thus, HPLC
methods are useful for measuring 5-FU and 5-FUH2 concentrations in the range observed
in patients receiving the drug via continuous infusion. In the present study, a HPLC
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method was developed to determine simultaneously the plasma concentration of 5-FU and
5-FUH2, which was an easily accessible technology in laboratory and allowed low 5-FU
(5 ng/mL) and 5-FUH2 (10 ng/mL) plasma concentrations to be determined.
5.1.2 The raw genotyping results
In the present study, the 23 coding exons of the DPYD gene were analyzed for the
presence of mutations/polymorphisms in order to associate the mutations and adverse
events. Analysis of the DPYD gene in 30 patients revealed 6 different polymorphisms
with an allelic frequency ranging from 1.67 to 21.67%. No unknown mutations were
identified. Five of the observed sequence variations have been described as common
polymorphisms in previous studies: (a) 85T>C (DPYD*9A, Cys29Arg); (b) 496A>G
(Met166Val); (c) 1601G>A (DPYD*4, Ser534Asn); (d) 1627A>G (DPYD*5, Ile543Val);
and (e) 2194G>A (DPYD*6, Val732Ile) (van Kuilenburg, 2004). One rare exonic
alteration has also been reported before: 1236G>A (Seck et al., 2005).
Additionally to the DPYD gene, far more information is available regarding
polymorphism of target enzyme TS. There 3 predominant genotypes of TS: (a) a
homozygous with double-tandem repeat (2R/2R), (b) homozygous with triple-tandem
repeat (3R/3R), and (c) heterozygous with both alleles (2R/3R). In the present study,
among 30 patients analyzed for the TS genotype, 5 (16.70%) were 3R/3R, 19 (63.30%)
were 2R/3R, and 6 (20.00%) were 2R/2R. The allele frequency of 3R/3R genotype in 30
Caucasian patients presently investigated was higher than that in reports of other studies
with Caucasian patients [32% (28 of 90 patients), Lecomte et al., 2004; 23.84% (21 of 88
patients), Jakobsen et al., 2005]. The difference in allele frequency of 3R/3R may be due
to the number of patients enrolled in the study.
Directly linked to the 5-FU-mediated inhibition TS is the presence of intracellular folate.
A polymorphism that may influence the efficacy of 5-FU by influencing folate pools is
that of methylenetetrahydrofolate reductase gene (MTHFR). The major nucleotide 677
polymorphism (C to T) at codon 22 (exon 4) is the most commonly linked with altered
enzyme activity (Maring et al., 2005). In the present study, the MTHFR 677CT and
MTHFR 677CC genotype occurred with almost the same frequency [43% (n = 13) and
40% (n = 12), respectively], while the MTHFR 677TT genotype was only observed in
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17% (n = 5) of the patients. The frequency distributions of MTHFR 677TT genotype
observed in the present Caucasian patients were in agreement in the Caucasians [11.4% (9
of 79 patients), Jakobsen et al., 2005; 18.4% (18 of 98 patients), Etienne et al., 2004].
5.2 Pharmacokinetics of 5-FU and 5-FUH2
5.2.1 Raw concentration-time data
In the thirty cancer patients studied here, plasma concentrations of 5-FU and 5-FUH2
varied considerably between and within patients during the 5-day infusion (fig. 10).
Variations in 5-FU and 5-FUH2 plasma concentrations were observed according to the
time of day (fig. 11). Similar observations were found in most studies on
pharmacokinetics of 5-FU administered by continuous infusion (Erlichman et al., 1986;
Hillcoat et al., 1978; Jiang et al., 2004b; Schneider et al., 1995; Vokes et al., 1996). The
circadian variations in plasma concentrations of both substances can be explained by the
existence of a circadian rhythm of the DPD activity, which has been suggested from both
human and animal investigations (Harris et al., 1990; Jaing et al., 2004a; Petit et al.,
1988). Petit et al. (1988) reported a 2.2-fold difference in 5-FU concentration at steady-
state (Css) during a 5-day infusion of 1,000 mg/m2/day (with i.v. cisplatin on day 1); the
peak value averaged 560 ng/mL and occurred at 1:00 a.m., whereas the minimum value
averaged 249 ng/mL and occurred at 1:00 p.m. With protracted continuous 5-FU
infusions of 300 mg/m2/day, Harris et al. (1990) observed a comparable variability, but
the time when the peaks occurred was different, with peak values (27.4 ng/mL) occurring
at 11 a.m. and trough values (5.6 ng/mL) at 11 p.m. The discrepancy between the times of
day at which peak and trough 5-FU levels occurred in these two studies suggests that
other factors, perhaps geographic, seasonal, individual sleep and wake habits,
administration of other drugs, or a combination of the four, and presumably other
unknown factors, may influence 5-FU clearance. There is evidence of consistency in the
timing of highest and lowest DPD activity within a given individual (Grem et al., 1997;
Harris et al., 1990) and it seems likely that each individual exhibits his or her own
circadian rhythm. This may lead to the variation in plasma 5-FU and 5-FUH2
concentrations from patient to patient. Sampling at different times of the day will
therefore yield different results. Since plasma samples in the present study were drawn
Discussion
______________________________________________________________________________________
83
randomly around few predefined time points relative to the start of the infusion, it was
likely that circadian variability in plasma concentrations would be visible (fig. 11).
It has to be noted, however, that in the present study, circadian differences could not be
detected, because a limited sampling scheme was used during the infusion which allowed
to get an impression of the overall intraindividual variability, but sampling was not
intense enough to determine the individual peaks and troughs.
The 5-FUH2 concentrations in the present study were consistently greater than of the
corresponding 5-FU plasma concentrations (fig. 11), which is in agreement with a small
study (n = 11) conducted by Ackland et al. (1997). These results may depend on the
volume of distribution of 5-FU which is relate to 5-FUH2.
5.2.2 Population pharmacokinetic analysis
Population pharmacokinetic approach is increasingly recognized as a valuable tool in drug
therapy optimization. The major advantages of this technique include the ability to
describe complex pharmacokinetic models, to quantify interindividual and intraindividual
variability, and to identify the quantitative relationships between patient characteristics
(covariates) and these variabilities. Furthermore, sparse and dense data, multiple dose
levels, and different treatment schedules can be analyzed simultaneously.
Data concerning the pharmacokinetic profile of 5-FUH2, which is dependent on systemic
(mainly hepatic) DPD activity rather than on the enzymatic activity in PBMCs, are still
needed. This investigation may add to that issue, because it investigates more extensively
the pharmacokinetics of this primary 5-FU metabolite and it is the first covariate-model
analysis that takes into account genetic polymorphisms in DPYD, TS, and MTHFR genes.
In addition, additional information on plasma concentrations after the end of the long-
term infusion is provided, which has not yet been investigated extensively in literature.
A population pharmacokinetic model was developed that described the plasma
concentrations of 5-FU and its metabolite, 5-FUH2, in 30 cancer patients receiving long-
term 5 days continuous infusion. In the present study, 5-FU plasma pharmacokinetics
were well described by a two-compartment open model with first-order elimination. The
point estimate for 5-FU clearance (238 L/h) was close to values previously reported
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during a 5-day continuous infusion (181 L/h: Milano et al., 1992, 287.71 L/h: Fleming et
al., 1992) or during a 3-day continuous infusion (270 L/h: Grem et al., 1993b), by non-
compartmental analysis. Interestingly, despite different models used in data interpretation,
numerical values of clearance were also similar in a study reported by Etienne et al.
(1998): a clearance value of 235 L/h was derived from a 1-compartment model with first-
order elimination. In addition, the point estimate values obtained for 5-FU clearance in the
present study were consistent with the mean values of the half-saturating plasma
concentration (Km) and the maximum rate of elimination (Vmax) previously observed in a
study in which a bolus of 400 mg/m2 was followed by a 22-hour infusion of 600 mg/m2
for 2 consecutive days (Terret et al., 2000). Indeed, the ratio Vmax/Km = 250 L/h
approximates the clearance when plasma 5-FU concentrations are far below Km, which is
the case for this schedule of administration.
The combined pharmacokinetics of 5-FU and 5-FUH2 were well described by an open
two-compartment model with first-order elimination for 5-FU and a one-compartment
model for 5-FUH2. This combined model proved to be robust: the median values obtained
during jack-knife analysis were in the same range as the respective model estimates for
every parameter analyzed (table 25). Besides, the parameters’ point estimates of 5-FU in
the combined pharmacokinetic model (table 25) were essentially equal to those generated
with the concentration versus time data of 5-FU only (0.4-5.4% deviation), and the 95%
confidence intervals included the mean parameters’ estimates obtained from the former
model of 5-FU. However, the model tended to overestimate plasma concentrations of 5-
FU (fig. 12a), indicating that the model had some limitations in describing the variability
of 5-FU concentrations observed in the study. Because of the limited amount of
concentration data, further model refinement was not possible. The pharmacokinetic
model was on average unbiased in predicting 5-FUH2 concentrations (fig. 12b).
The pharmacokinetics of 5-FU have been extensively studied, while the pharmacokinetics
of 5-FUH2 in human plasma are less well investigated, especially during long-term
continuous infusion. There are some studies published which investigated 5-FUH2
pharmacokinetics after 5-FU i.v. bolus injection (Bocci et al., 2000; Heggie et al., 1987;
Di Paolo et al., 2001; Di Paolo et al., 2002). In the present study, the pharmacokinetics of
5-FUH2 were modeled as a metabolite compartment connected to the central compartment
(fig. 9), and a one-compartment model best described 5-FUH2 pharmacokinetics.
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The parent-metabolite pharmacokinetic model was used to estimate pharmacokinetic
parameters for the individual patients (table 23). The total clearance of 5-FUH2 was
smaller than that of 5-FU, mean total clearance values were 117 L/h and 238 L/h for the
metabolite and the parent compound, respectively. These differences in clearance
translated to a longer elimination half-life (t1/2, z) of 5-FUH2: the t1/2, z of 5-FU averaged
2 min, whiles the t1/2, z of 5-FUH2 was on average 35.4 min. The longer half-life of 5-
FUH2 could be one explanation for the higher plasma concentrations of the metabolite
during continuous infusion (fig. 11). It is well known that the availability of 5-FU for
anabolism is regulated primarily by catabolism (Diasio & Harris, 1989). The average of
the metabolic clearance of 5-FU converted to 5-FUH2 was 205 L/h, indicating that
approximately 86% of 5-FU was catabolized to 5-FUH2. This result is in agreement with
previous studies which showed that most individuals eliminate around 85% of a 5-FU
dose via the catabolic pathway (Diasio & Harris, 1989). Additionally, up to 10% of the
dose is excreted unchanged by the kidneys (Diasio & Harris, 1989).
The estimate for the coefficient of variation of interindividual variability in total clearance
of 5-FU was high both in the base pharmacokinetic model for 5-FU (CV = 44.3%) and in
the base combined pharmacokinetic model for 5-FU and 5-FUH2 (CV = 44.0%).
Correspondingly, most studies on 5-FU pharmacokinetics demonstrated that the
interpatient variability in 5-FU pharmacokinetics was relatively large, with CV 20-31%
(Etienne et al., 1998; Sandström et al., 1996; Terret et al., 2000). Individual factors like
genotypes, sociodemographic variables, disease-related variables, concomitant treatments,
etc., could be sources of this interindividual variability. In the present study, besides
patient’s characteristics and other factors, mutations in three genes related to the
metabolism and the activity of 5-FU were tested as covariates for 5-FU pharmacokinetic
parameters in order to explain at least parts of the interindividual variability in 5-FU
pharmacokinetics.
5.2.3 Factors of influence on pharmacokinetic parameters
Among the variables that were tested by the NONMEM approach, it was found that the
full predictive model (final covariate model) included two independent variables which
were body surface area and the mutation at position 677 in the MTHFR gene. The final
model for covariables indicated that total clearance of 5-FU tended to increase with
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increasing body surface area and tended to be higher in patients harbouring the MTHFR
C677C (wild-type) or MTHFR C667T (heterozygous) genotypes. Other pharmacokinetic
parameters were not statistically significantly influenced by individual factors.
The present result shows that the total 5-FU clearance increases to 0.85% with 1%
increase in body surface area. Although several studies could not substantiate an influence
of body surface area on 5-FU clearance (Climente-Martí et al., 2003; Etienne et al., 1998;
Porta-Oltra et al., 2004), but a study supporting the present finding, pointed out that this
covariate can be the predictor of 5-FU clearance (Port et al., 1991). These suggest that
body surface area is, at least to certain extent that can be quantified, useful for dose
individualization.
If a relationship between body surface area and clearance of 5-FU is not surprising, an
opposite relationship would be more expected with MTHFR genotype. There is no clear
reason known at present which may serve as a scientific explanation of this finding. One
reason may be that the finding has arisen by chance. Recent studies suggested an
influence of the MTHFR C677T polymorphism on the folate pool in cancer tissue (which
influences the formation and stability of inhibitory ternary complexes between 5,10-
methylentetrahydrofolate, TS and 5FdUMP) and response to treatment. However, the
exact mechanisms by which an influence on 5-FU clearance may be explained are
unknown to date, and cannot be deduced from what is known about the enzymes and
metabolic pathways to date. Further in vitro studies to clarify a possible relationship and
in vivo studies to verify the present result are needed.
For the polymorphisms in the TS gene, no influence of the mutations studied here on the
pharmacokinetics of 5-FU and 5-FUH2 was observed. Thus, the possible impact of TS
polymorphisms on 5-FU pharmacology may rather occur on a pharmacodynamic than on
a pharmacokinetic level.
The significant interpatient variability in 5-FU clearance may be explained in part by
genetic differences in the enzyme activity of DPD (Milano & Etienne, 1994). Plasma
clearance of 5-FU is reported to be dependent on the catabolic pathway which is closely
linked to the activity of DPD (Diasio & Harris, 1989). To date, there are only very few
reports combining results of DPD genotyping with pharmacokinetics of 5-FU. It is known
that patients with complete deficiency of DPD activity demonstrate minimum catabolism
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of 5-FU, with a 10-fold longer half-life of 5-FU compared with patients with a normal
DPD activity (Diasio et al., 1988). In a patient with a partial deficiency of DPD, due to
heterozygosity for the IVS14+1G>A mutation (exon 14 skipping), the clearance of 5-FU
was 2.5 times lower and the AUC of 5-FU (24.1 mg.h/L) was 2.5 times higher, compared
with controls (Maring et al., 2002). However, the mutation reportedly leading to more
pronounced changes in 5-FU pharmacokinetics was not observed in the population study
here.
The present study is the first systemic analysis in which the results of a sequencing of the
DPYD gene were combined to pharmacokinetics of 5-FU. Since the small number of
mutations in the DPYD gene was observed in the present study population and since the
incidence of some DPD mutations was too low to reliably identify a possible relationship,
thus patients were divided into three groups depending on the presence of at least one
single-nucleotide polymorphisms (SNP) in the DPYD gene: wild-type genotype,
heterozygote, and homozygote mutants with respect to different mutations. The effect of
DPD genotype on the total clearance of 5-FU in our model were treated with that respect.
Although an apparent influence of DPD genotype on total clearance of 5-FU was also
observed in the present study: i.e. point estimates were 263 L/h (95% CI, 231-295) and
175 L/h (95% CI, 87-263) in patients with wild-type and homozygous mutations,
respectively, the confidence intervals for estimations of the total clearance of 5-FU were
very broad with overlapping values between the groups. Thus, the DPD genotype was not
included in the final model because of the lacking statistical significance to improve the
model. Accordingly, there was a lack of effect of the most mutations detected in the
present population study on pharmacokinetics of 5-FU (AUC of 5-FU) also in other
reports (Zhu et al., 2004).
No effect of DPD activity determined by the urinary UH2/U concentration ratio on any
pharmacokinetic parameters of 5-FU or 5-FUH2 was found in the present study. The lack
of correlation between 5-FU pharmacokinetics and the urinary UH2/U concentration ratio
suggests that this ratio may not predict systemic clearance of the drug. The urinary UH2/U
concentration may not be representative of the enzyme activity of DPD in the body,
particularly the liver.
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Other factors including sex, weight, and body mass index could potentially affect the total
clearance of 5-FU. Most of the models which described the influence of these covariables,
especially weight and body mass index, on 5-FU pharmacokinetics were not stable,
leading to an exclusion of these factors in multivariate analysis. In another study in 27
cancer patients who received 5-FU 450 mg/m2, 1 day per week for 48 doses, weight was
defined as a predictor of 5-FU clearance (Climente-Martí et al., 2002). However, the
authors indicated that adding this covariate to the basic model of 5-FU, interindividual
variability of clearance were reduced only from 76% to 71%, suggesting that weight could
not explain totally the interindividual variability in 5-FU clearance.
Contradictory results have also been reported on the influence of gender on 5-FU
clearance. A study of Milano et al. (1992) indicated that women showed median 5-FU
clearance values that were 10% lower than those found in men (p = 0.0005). In another
study, the average clearance in males was by 0.22 L/min higher than that in females (Port
et al., 1991). Correspondingly, DPD activity in women was about 15% lower than in men
(Milano & Etienne, 1994). In the present study, the separate testing of covariates in the
base pharmacokinetic model for 5-FU revealed a 2-fold lower 5-FU clearance in females.
However, this influence of sex on the 5-FU clearance was not retained in the final
covariate model for 5-FU. Similarly, in the parent-metabolite pharmacokinetic model
(combined pharmacokinetic model) sex was not included in the final covariate model
because in combination with other covariates, the body surface area was found to be a
statistically significantly better predictive factor for 5-FU clearance than sex. It should be
noted that the discrepancy with those previous studies can be consequences of a) the
relatively small patient population (n = 30), b) differences in 5-FU administration, since
5-FU pharmacokinetics are strongly dependent on the administration schedule (Larsson et
al., 1996), and c) the small number of women in our study population (female/male ratio
= 1:6). Clearly, the present study therefore did not have the power to detect small gender
differences. Moreover, this apparent discrepancy may also be caused by differences in
both the statistical approaches and the way of determining 5-FU clearance. In addition,
the previously found difference in 5-FU clearance between men and women was rather
small, since average values were 172 and 155 L/h/m2, respectively (Port et al., 1991).
However, the final result of the present study, i.e. that gender does not have an influence
on 5-FU pharmacokinetics, is corroborated by a large population analysis (n = 104). This
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analysis showed that gender was not an independent parameter in predicting 5-FU
clearance (Etienne et al., 1998).
Literature is contradictory concerning the influence of age on 5-FU pharmacokinetics. As
in the present study, age did not appear to influence the elimination of 5-FU (Climente-
Martí et al., 2002; Port et al., 1991; Porta-Oltra et al., 2004), while other studies suggested
that increased patient age lead to a moderate decrease in 5-FU clearance (Etienne et al.,
1998; Milano et al., 1992). This discrepancy may reflect different methods of statistical
analysis: age was considered as a continuous variable in most studies (as in the present
study), while age classes were examined both alone and in covariance matrices in others.
Additionally, in some studies, the age range examined may not have included sufficiently
patients with advanced age where the influence may have been more pronounced.
Likewise, as the present study reflects, other authors did not find a significant influence of
hepatic function and renal function tests on 5-FU pharmacokinetics (Climente-Martí et al.,
2002; Fleming et al., 1992; Porta-Oltra et al., 2004). These results are in agreement with
the findings obtained in two recent studies which enrolled patients with liver metastases
from gastrointestinal cancer (Maring et al., 2003) and patients with mild organ
dysfunction (hepatic or renal) (Fleming et al., 2003). The influence of liver metastases on
the pharmacokinetics of 5-FU and 5-FUH2 after bolus injection of 5-FU was studied in a
comparison between 16 patients with metastatic and 18 patients with nonmetastatic
gastrointestinal cancer. The patients in both groups displayed similar pharmacokinetics.
No effect of liver metastases on 5-FU clearance was observed (Maring et al., 2003).
Similarly, a trial on 24-h continuous infusion of 5-FU with leucovorin in patients with
elevated serum bilirubin or mild renal dysfunction (n = 64) showed that no association
between 5-FU clearance and either serum bilirubin (p = 0.517) or serum creatinine (p =
0.396) was present (Fleming et al., 2003). In a patient with colorectal carcinoma and end-
stage renal insufficiency on maintenance hemodialysis therapy, pharmacokinetic
parameters of 5-FU and 5-FUH2 were in the ranges reported in literature for patients with
normal renal function (Rengelshausen et al., 2002). Because renal elimination of
unchanged 5-FU accounts for only 10% of the injected dose (Diasio & Harris, 1989),
renal abnormalities should have, a priori, a minimal effect at least on pharmacokinetic of
parent compound 5-FU. Thus, these findings may be the explanation of why the
influences of hepatic and renal function test were not observed in the present study.
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Finally, we have shown that by using a statistical approach based on NONMEM analysis,
it is possible to identify several independent patient characteristics which have a
significant influence on 5-FU clearance during a 5-day continuous infusion. Previous
reports by others (Milano et al., 1994; Vokes et al., 1996) have identified target 5-FU
plasma concentrations at steady state or AUC values of 5-FU which were related to an
optimal 5-FU therapeutic index during 5-day continuous infusion. Given these findings,
there is a potential clinical interest for 5-FU dose tailoring. Although the two covariables
identified in the present investigation were significantly correlated to 5-FU clearance and
decreased the remaining interindividual variability from 44.0% to 29.6%, the so far
unexplained interindividual variability in 5-FU clearance remained high. Additionally, the
individual factors tested in the present study could not explain the interindividual
variability in the elimination rate constant of 5-FUH2 (CV = 31.8%). These may be
explained by the fact that the residual variability (64% for 5-FU and 43% for 5-FUH2)
included many sources of random variability, i.e. intraindividual variability, analytical
error, pre-analytical errors such as recording of sampling times, different ways of
handling the blood samples, and unidentified factors of potential influence such as further
mutations in genes. Finally, it is the hope of the present study to stimulate such future
investigations to clarify the influence of other factors on the pharmacokinetics of 5-FU.
5.3 Factor of influence adverse events and changes in blood cell counts
5.3.1 DPD phenotype
DPD is generally considered the rate-limiting step in the catabolism of the 5-FU (Diasio
& Harris, 1989). The activity of DPD may be an important determinant for predicting the
toxicity of 5-FU. Individuals can be screened for alterations in DPD activity by
phenotyping and/or genotyping before the first administration of 5-FU. Studies have
documented that patients with absent or reduced DPD activity show severe hematological,
neurological, and gastrointestinal toxicity upon standard 5-FU administration (reviewed in
Ploylearmsaeng et al., 2006) due to a reduced 5-FU clearance (Maring et al., 2002; van
Kuilenburg et al., 2000). In the present study, no impact of DPD phenotype on adverse
events and on changes in blood cell counts was seen. Since only mild adverse events were
observed, and no dramatically decreased DPD activity was present in the present study
population, thus no such relationship was found.
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The UH2/U concentration ratios in urine collected before the 5-FU infusion was started
were 1.18 ± 0.50 (mean ± SD) (n = 29). One patient had undetectable UH2 concentrations
in urine which made exact quantitative assessment of DPD activity impossible. This
patient experienced grade 1 toxicity (nausea and vomiting). With respect to the
concentrations of urinary uracil in patients with DPD deficiency, most of the DPD
deficient patients show extreme increases in urinary uracil concentrations (Milano &
Etienne, 1994). The uracil concentration in urine of this patient (4.14 µM) appeared to be
lower compared to the entire study population (median = 29.63 µM), which may have
caused that the UH2 concentrations were too low to be quantified.
Gamelin et al. (1999) showed in 152 patients that a low plasma UH2/U concentration ratio
(< 1.8), as expected in DPD deficiency, is associated with toxic effects after the first
weekly course of 5-FU treatment. In this study, toxic effects were observed only in
patients with initial UH2/U concentration ratios of less than 1.8. No adverse effects were
noted in patients with UH2/U concentration ratios greater than 2.25. Based on these
results, the authors speculated that plasma UH2/U concentration ratios could help to
identify patients with metabolic deficiency and to predict the occurrence of toxic side
effects of 5-FU, and thereby reduce the risk of 5-FU toxicity. In contrast, the present study
did not corroborate the existence of an association between the (urinary) pretreatment
UH2/U concentration ratios and the risk of developing side effects of 5-FU. In the present
study, the average pretreatment UH2/U concentration ratios were lower in patients who
presented 5-FU-related toxicity (1.17) than in patients who tolerated the treatment (1.29)
but this difference did not reach statistical significance (p = 0.65). In addition, the risk of
developing side effects was not linked to the pretreatment UH2/U concentration ratios (p =
0.646). This may be due to the small number of patients in this study (n = 30) and the fact
that most patients (n = 26) experienced mostly mild adverse events. Besides, the matrix
(urine versus plasma), the method of quantification (LC-MS/MS versus HPLC with diode
array detection) and the 5-FU treatment regimen (5-day continuous infusion versus 8-hour
infusion) investigated differed from the published study (Gamelin et al., 1999). To date,
no studies directly comparing the UH2/U ratio in plasma and urine have been performed.
Because blood dyscrasias, especially leukopenia, are the most common adverse effects of
5-FU therapy (Grem, 2000), the relationship between the pretreatment urinary UH2/U
concentration ratios and the relative decreases in blood cell counts (leukocyte,
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erythrocyte, and thrombocyte) were also investigated. No correlation between the
pretreatment UH2/U concentration ratios and the relative decreases in blood cell counts
were found. This indicated that different responses among patients were not associated
with the differences in the UH2/U concentration ratios in urine. In another clinical study in
40 gestational trophoblastic tumor (GTT) patients treated with 30 mg/kg of 5-FU or
prodrug floxuridine (FUDR) during 10 days per cycle, correlation analysis showed that
the pretreatment UH2/U concentration ratio in plasma were significantly correlated with
the absolute neutrophil count (r = 0.768, p < 0.01). The authors concluded that
pretreatment UH2/U concentration ratios were a key factor associated with the interpatient
variability in toxicity and efficacy (Jiang et al., 2004b). It may be speculated that the
absolute neutrophil count is a more sensitive parameter than the relative decrease in white
blood cells used in the present study or that the UH2/U ratio in plasma is more reliable
than the ratio determined in urine, however, there is no scientific endorsement for these
hypotheses.
These findings suggest that methods to estimate the DPD activity by using endogenous
pyrimidines may be imperfect to predict adverse effects caused by 5-FU.
5.3.2 DPYD polymorphisms
The mutations detected in our patients who presented 5-FU adverse events were 85T>C,
496G>A, 1236G>A, 1601G>A, 1627A>G and 2194G>A. Analysis of these 6 mutations
in relationship to adverse events revealed that only the 496A>G mutation was associated
with 5-FU adverse events (p < 0.028). Zhu et al. (2004) studied the association between
DYPD mutations and toxicity of 5-FU in 17 patients with colorectal adenocarcinoma.
Seven mutations in the DPYD gene, including 85T>C, 496A>G, 1627A>G, 3351T>C,
3649G>A, 3844A>G, and 3856T>C, were correlated to the 5-FU-related toxicity grouped
as grade 0-2 (n = 13) and grade 3-4 (n = 4). In this study, each informative nucleotide was
tested separately for an additive allele effect on the binary toxic response. None of the
nucleotides showed a statistically significant additive allele effect on the toxicity outcome
(all p > 0.05), either with respect to cycle 1 toxicity or with respect to the worst toxicity
during the entire study. The authors indicated that a combination of mutations may
explain a part of the toxicity, while each single mutation did not explain toxicity. It
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remains unclear which mutations exerted a particular influence on the occurrence of
severe toxicity.
The 496A>G mutation has been described in 3 patients who were suffering from severe 5-
FU toxicity but who also carried other variants including 85T>C (n = 1; van Kuilenburg et
al., 2000), 85T>C and 2846A>T (n = 1; van Kuilenburg et al., 2000), and IVS14+1G>A
(n = 1; Johnson et al., 2002). In the present study the 496A>G mutation was found in 7
patients, who also carried other variants (fig. 20), with an allele frequency similar to those
found in other populations (Sech et al., 2005; Zhu et al., 2004), however, three of these
patients did not experience adverse events. Hence, patients who were heterozygous for
496A>G mutation had a decreased risk for the occurrence of adverse events [odds ratio =
0.079 (95% CI, 0.007-0.933)]. It has to be emphasized that there was no patient
homozygous for the 496GG mutation in the present study. In addition, the odds ratio
showed a very broad confidence interval which almost included 1 and 0 that made the
result questionable. Several mutations were tested in this way in this study, thus the result
may have arisen by chance, but it may also be a hint that this mutation may have some
effect on the occurrence of adverse events. However, after a correction for multiple
testing by the Bonferroni correction technique; with 3 tests performed, a p-value must be
< 0.05/3 (i.e., 0.016) to be statistically significant, the result is no longer statistically
significant, so that the findings in the present study are lastly not contradicting literature
findings (van Kuilenburg et al., 2000; Johnson et al., 2002). This correction is very
conservative as it is not adjusted for linkage disequilibrium between the polymorphisms.
However, the present results also do not support the literature findings, because there was
no a statistically significant influence of the mutation in the direction that more adverse
events occur when the mutation is present (van Kuilenburg et al. 2000; Jonhson et al.,
2002). Since the numbers were too small to draw a definitive conclusion, since a
homozygous carrier of the mutation was not present in the study population, and since the
present results does not support the observed effect of this mutation in the literatures, it is
unlikely that such a relationship could be corroborated in a larger study.
Although the DPYD 85T>C and 1627A>G mutations have been identified in patients who
presented severe 5-FU toxicity (reviewed in Ploylearmsaeng et al., 2006), in the present
study, no association between these two mutations and adverse events could be assessed
(p > 0.05). The association between the presence of the 1601G>A and of 2194G>A
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mutations with 5-FU adverse events could not be investigated in our study, because these
mutations were found in only 1 and 2 patients, respectively. At the present, no study has
reported that patients carrying the 1236G>A mutation were at risk for 5-FU toxicity.
Since this mutation does not lead to an amino acid exchange, and the DPD activity is
reported to be normal (Seck et al., 2005), it is not expected that carriers of this mutation
differ from the general population in terms of 5-FU associated events. In our study, one
patient who experienced adverse events carried this mutation, but the toxicity was mild
(grade 1).
In 7 patients who experienced adverse events during the present study, no mutations in the
coding sequences of the DPYD gene could be detected. In 14 patients with severe 5-FU
toxicity, ten DPYD exons containing most of the known mutations were analyzed using
gene sequencing techniques, and in 3 patients, no mutations were detected at all (Collie-
Duguid et al., 2000). It cannot excluded, however, that genetic factors not identified in the
present study like a mutation in the promoter region of the DPYD gene may have been
present in the patients with adverse events who did not carry a mutation in coding regions.
Recently, Hasegawa et al. (2005) investigated polymorphisms in the 5´-flanking region of
DPYD gene, which are considered to control expression of DPYD gene, in genomic DNA
extracted from 37 kinds of human cancer cells. As the results, in DLD-1 cells, which have
C-insertion polymorphism in 5´-flanking region of the DPYD gene, the DPD activity was
below detection limit (≤ 0.5 pmol/min/mg protein). Furthermore, 50% of cytosine residue
on the CpG site generated by the C insertion was methylated at the 5 position which
might be associated with loss of the sequence of binding site for transcription factors. The
authors indicated that the prevention of binding a transcription factor with a methylated
newly generated CpG site that probably affects DPYD gene regulation (Hasegawa et al.,
2005). Considering the patients without 5-FU adverse events during the present study (3
of 4 patients), mutations were also detected in the DPYD gene. This finding indicates that
screening for coding mutations alone cannot unambiguously identify all patients at risk.
The most often described mutation in the DPYD gene associated with 5-FU-related
toxicity is a G to A point mutation within the 5´-splicing site of intron 14 (IVS14+1G>A,
known as DPYD*2A), which leads to skipping of exon 14 and consequently to DPD
enzyme deficiency (Raida et al., 2001; van Kuilenburg et al., 2001). In this study, we did
not find this mutation in any patient. However, the presence of IVS14+1G>A is not the
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only reason for severe 5-FU-related toxicity. Indeed, studies on populations of individuals
phenotypically deficient in DPD activity and of patients with 5-FU-related toxicity
detected the IVS14+1A mutation in only 14 of 22 (64%) (van Kuilenburg et al., 2002) and
in 6 of 25 (24%) subjects (van Kuilenburg et al., 2001). In a prospective study carried out
in 351 patients receiving 5-FU to assess the impact of DPYD mutations on 5-FU toxicity,
there was no evidence for a pivotal role of the exon 14 skipping mutation
(Kollmannsberger et al., 2001). However, although the precise role of this mutation as a
prognostic factor in the 5-FU-related toxicity still has to be fully established, there is some
evidence to suggest that patients with the IVS14+1G>A mutation are at increased risk for
the development of severe 5-FU-related toxicity (Raida et al., 2001; van Kuilenburg et al.,
2002). Some authors suggested to advise clinicians to screen all patients for the
IVS14+1G>A mutation prior to 5-FU therapy. If the IVS14+1G>A mutation is present,
dose reductions should be performed or alternative cytotoxic agents should be considered
(Omura, 2003; van Kuilenburg, 2004).
5.3.3 Thymidylate synthase polymorphism
The controversy regarding the association between the mutant genotype of DPYD gene
and 5-FU toxicity suggests a role for additional genomic variants or an influence of
epigenetic events. Polymorphism in drug targets are an important area in pharmacogenetic
studies, as interindividual differences in the expression of drug targets could lead to
resistance or toxicity towards standard chemotherapy regimens. Thymidylate synthase
(TS) is considered to be the main intracellular target of 5-FU. In addition to DPYD gene,
the TS gene (called TYMS) also contains a genetic polymorphism that may be also
involved in efficacy or toxicity of 5-FU-based chemotherapy.
Genetic polymorphisms in the TYMS gene in the promoter enhancer region have been
shown to influence toxicity of 5-FU based therapy (Lecomte et al., 2004; Pullarkart et al.,
2001), although protein expression levels were not linked to 5-FU pharmacodynamics
(Tomiak et al., 2001, Westra et al., 2005). In these studies, individuals who were
homozygous for the double repeat in the TYMS promoter region (2R/2R) had more severe
side effects to 5-FU (p < 0.05). In contrast, our results showed that no influence of the
TYMS tandem repeat promoter polymorphism on 5-FU adverse events (p = 0.214) and on
the changes in blood cell counts (all p > 0.05). Since only few toxic cycles and no serious
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toxicity was observed in the present study and since the sample size of 30 patients may be
too small, the statistical power of the investigation of the association may have been
insufficient. However, the present results are comparable to a previous study in 17
patients which also did not confirm an effect of the TYMS polymorphism in the promoter
region on 5-FU-related toxicity (p = 0.242; Zhu et al., 2004).
The difference in the correlation between TYMS promoter genotype and 5-FU adverse
events might be obscured by the fact that patients were treated with the different dose and
regimen. It should be noted that 5-FU may act as two different drugs according to mode
of administration (Grem, 2000). Bolus 5-FU may exert its major effect on RNA, whereas
continuous infusion may have a preferential effect on TS. The predictive value of TS gene
polymorphism may vary with mode of administration. However, analysis by type of 5-
FU-based therapy showed that the rate of toxicity is dependent on the number of patient
with a favorable TYMS promoter genotype included in each group rather than the specific
5-FU-based therapy. Furthermore, no significant heterogeneity concerning the toxicity
risk associated with the 2R/2R genotype was observed according to the different 5-FU-
based therapy regimens (Lecomte et al., 2004). However, to extend the understanding of
the relationship between polymorphism/mutation in TYMS gene and toxicity of 5-FU, it
will likely be necessary to take into account functional polymorphism outside the
promoter regions and haplotypes.
5.3.4 Methylenetetrahydrofolate reductase polymorphism
The MTHFR gene is highly polymorphic in the general population. A common C677T
transition in exon 4 of the MTHFR gene results in a thermolabile enzyme variant with
lower specific activity (reviewed in Maring et al., 2005). Since a loss in MTHFR activity,
due to the MTHFR C677T mutation, may theoretically favor an increase in intracellular
CH2FH4 concentrations, it can be hypothesized that patients exhibiting mutated MTHFR
genotype may be more sensitive to 5-FU cytotoxicity than patients with wild-type
genotype, and become at a risk of 5-FU-associated toxicity. Accordingly, MTHFR may
also be an important predictive factor of the toxicity of 5-FU.
To date, few data exist on the possible importance of MTHFR gene polymorphisms, and
most of them focused on the response rate of 5-FU. In the present study, the C667T
polymorphism in the MTHFR gene was correlated to adverse events and to the changes in
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blood cell counts. The MTHFR C677T mutation had no influence on adverse events and
on the changes in blood cell counts. Literature reports on the association of the MTHFR
C677T mutation and adverse outcomes of 5-FU based chemotherapy are conflicting.
Toffoli et al. (2000) reported that 5 of 6 patients who developed severe acute toxicity
(grade 4 leukopenia, mucositis, granulocytopenia, thrombocytopenia) in the first cycle of
adjuvant CMF (cyclophosphamide, methotrexate, and 5-FU) had the variant homozygous
genotype T677T (83%) and one patient had the homozygous C677C phenotype. The
authors suggested that patients with 677TT genotype in the MTHFR gene could have an
increased risk of developing severe acute toxicity. However, those serious toxicities may
result from the additive effect of adjuvant chemotherapy, especially from methotrexate
because the activity of both drugs is dependent of a competitive interaction with folate
metabolism. In addition, a combined effect of methotrexate and reduced activity of
MTHFR resulting from C677T mutation could occur, leading to toxicity.
In conclusion, further sufficiently powered clinical trials and additional mechanistic
investigations may be needed to elucidate the role of the polymorphisms in DPYD, TYMS
and MTHFR gene in explaining so far unexpected outcomes of treatments containing 5-
FU. Larger populations will be needed to clarify the effect of the mutations in these genes
on the 5-FU adverse events.
5.4 Influence of pharmacokinetics on adverse events and changes in blood cell counts
Previous investigations have indicated a positive association between the 5-FU exposure
(AUC) and the toxicity of a 5-day continuous infusion (Milano et al., 1988; Santini et al.,
1989; Thyss et al., 1986). In the present study, the AUC of 5-FU tended to be increased in
patients with adverse events which may have been addressed as 5-FU adverse events
(grade 1-2, table 32), although this relationship did not reach statistical significance. The
AUC of 5-FUH2 was almost identical in these two groups of patients. Some patients who
suffered from toxicity had a 5-FU AUC value similar to that of subjects belonging to non-
toxicity group.
In this study, the apparent lack of sensitivity of the AUC in detecting the subjects at risk
for 5-FU adverse events was compensated by the 5-FU/5-FUH2 AUC ratio. The results
were also not in agreement with the degree of adverse events. Additionally, no
statistically significant relationship between the AUC of 5-FU, the AUC of 5-FUH2 and
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the AUC ratio, respectively, and the changes in blood cell counts (fig. 16-18) was present
in the population studied here. The present results are in agreement with the findings
conducted with 18 patients (Casale et al., 2004), but do not confirm the results of two
previous studies who showed an association between an increased AUC ratio and severe
toxicity (mucositis, diarrhea, nausea, vomiting and hand-foot syndrome) (Di Paolo et al.,
2001, 2002). These observations may have been influenced by the small number of
subjects and/or the variability of data, and because the treatment was quite well tolerated
(≤ 2 toxicity grade).
5.5 Conclusion
The present study represents a further step toward a detailed modeling of the kinetics of 5-
FU and its main metabolite 5-FUH2. This study confirms the high individual variability of
5-FU pharmacokinetics administered in long-term infusion for 5 days. In addition, this
study suggests the influence of body surface area and MTHFR gene polymorphism in
position 677 on 5-FU clearance. To extend the present understanding of the influence of
this polymorphism on 5-FU pharmacokinetics, further studies aimed at confirming the
influence of this polymorphism on 5-FU pharmacokinetics in the larger population would
be useful.
Concerning the adverse events of 5-FU, although there was no overall relationship
between the polymorphisms in the DPYD, TYMS and MTHFR gene and adverse events of
5-FU, further investigations with a larger number of patients will be necessary to assess
the effect of the mutations in DPYD, TYMS and MTHFR gene on the 5-FU adverse events.
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6. Summary
The aims of this study were to characterise pharmacokinetics of 5-FU and its main
metabolite (5-FUH2) and to quantify factors of influence on pharmacokinetics as well as
to identify factors influencing adverse events and blood cell count changes. Additionally,
the relationship of pharmacokinetics on adverse events and blood cell count changes was
evaluated.
Thirty patients (5 females, 25 males) with colorectal or oesophageal cancer receiving 5-
FU 650 or 1000 mg/m2/day as 5-day continuous infusion were entered in this study. A
HPLC method was used for the simultaneous assay of 5-FU and 5-FUH2 in plasma
samples obtained at baseline and at multiple time points during infusion and after the end
of infusion. DPD phenotype was assessed as the UH2/U urinary concentration ratio using
LC-MS/MS. Genotyping assays were developed for DPYD gene (23 exons), the 5
promoter region of TYMS gene and the MTHFR gene in position 677. Population
pharmacokinetics of 5-FU and 5-FUH2 were tested with NONMEM using 199 and 251
quantifiable plasma concentrations of 5-FU and 5-FUH2, respectively. Patients’
covariables were included in the modelling process after the best basic model had been
identified.
An open two-compartment model with first-order elimination was found to best describe
5-FU concentration-time data, and a one-compartment model was suitable for 5-FUH2
data. The data showed that total clearance of 5-FU tends to increase with body surface
area and to be higher in patients with MTHFR 677CC or 667CT genotype in the MTHFR
gene. Point estimates for clearance (95% CI) were 145L/h (83-207) and 276L/h (250-302)
in patients with the 667TT and the 677CT or 667CC, respectively. No mutation in the
DPYD, TYMS or MTHFR gene was significantly associated with 5-FU adverse effect and
with the changes in blood cell counts served as parameters for adverse event, respectively.
There was also no significant impact of the pharmacokinetics (AUC of 5-FU, AUC of 5-
FUH2 and 5-FU/5-FUH2 AUC ratio) on the occurrence of adverse events and changes in
blood cell counts.
In conclusion, the present study provides pharmacokinetic data on long-term 5-FU
infusion and suggest a role of the MTHFR C677T polymorphism for 5-FU clearance,
which however needs to be further investigated.
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120
Plasma concentrations of 5-FU
Plasma concentrations at time point relative to 5-FU infusion (g/mL)Patient
# Predose +36h +48h +108h +120h +120.05h +120.30h +121h +121.30h
1 0 0.389 0.330 0.027 n.a. n.a. 0.018 n.d. n.d.
2 0 0.116 0.09 0.305 0.042 0.026 n.d. n.d. n.d.
3 0 0.764 0.291 0.532 n.a. n.a. n.d. n.d. n.d.
4 0 0.312 0.256 0.396 0.057 0.025 0.037 0.005 n.d.
5 0 0.622 0.1057 0.593 3.668 1.527 0.109 0.028 n.d.
6 0 0.256 0.292 0.219 n.d. n.d. n.d. n.d. n.d.
7 0 0.506 0.217 0.429 0.093 0.054 0.276 0.046 0.016
8 0 0.148 0.184 0.227 0.034 0.012 n.d. n.d. n.d.
9 0 0.648 0.365 0.644 0.083 0.038 0.578 0.036 0.007
0 0.333 0.025 0.398 n.a. n.a. n.a. n.a. 0.01610
121.45h = 0.009
11 0 0.038 0.245 0.552 0.036 0.019 2.329 0.103 0.105
12 0 0.462 0.302 0.497 0.475 0.104 0.018 0.006 n.d.
13 0 0.037 0.222 0.275 0.027 0.021 0.012 0.006 n.d.
14 0 0.140 0.211 0.317 n.a. n.a. n.a. n.d n.d
15 0 0.439 0.404 0.431 n.a. n.a. n.a n.a 0.016
16 0 0.190 0.251 0.236 0.492 0.076 0.010 n.d. n.d.
17 0 0.157 0.219 0.237 0.059 0.024 0.007 n.d. n.d.
18 0 0.179 0.271 0.401 0.205 0.025 0.011 0.008 0.007
19 0 1.180 0.309 0.052 0.008 0.006 n.d. n.d. n.d
20 0 0.107 0.437 0.384 0.021 0.014 0.007 0.005 0.005
21 0 0.520 0.176 0.214 0.011 0.007 0.005 n.a. n.a.
22 0 0.289 0.054 0.407 0.013 0.009 0.005 n.d. n.d
23 0 0.011 0.486 0.407 0.021 0.008 1.985 0.057 0.008
24 0 0.259 0.300 0.228 0.195 0.075 0.009 n.d. n.d
25 0 0.182 0.937 0.897 0.0043 0.012 0.122 0.011 n.d.
26 0 0.295 0.333 0.317 0.132 0.05 0.009 0.005 n.d.
27 0 0.283 0.265 0.258 0.625 0.276 0.028 0.005 n.d.
28 0 0.086 0.287 0.032 0.374 0.077 0.022 0.202 0.025
29 0 0.221 0.215 0.281 0.345 0.078 0.010 n.d. n.d
30 0 0.312 0.226 0.317 0.255 0.154 0.011 n.d. n.d.
n.a = no plasma available, n.d = not detectable
121
Plasma concentrations of 5-FUH2
Plasma concentrations at time point relative to 5-FU infusion (g/mL)Patient
# Predose +36h +48h +108h +120h +120.05h +120.30h +121h +121.30h
1 0 0.732 0.573 0.560 n.a n.a 0.018 n.d n.d
2 0 0.385 0.398 0.288 0.097 0.102 0.087 0.074 0.014
3 0 0.473 0.464 0.415 n.a n.a 0.019 0.019 0.013
4 0 0.449 0.342 0.262 0.152 0.127 0.112 0.099 0.087
5 0 1.041 1.849 0.784 0.393 0.772 0.684 - 0.295
6 0 0.462 0.538 0.536 0.075 0.082 0.034 0.027 0.019
7 0 1.331 0.708 0.925 0.289 0.341 0.849 - 0.300
8 0 0.371 0.374 0.303 0.157 0.265 0.159 0.110 0.064
9 0 0.833 0.622 0.634 0.150 0.170 0.265 0.149 0.036
0 1.089 0.479 0.753 n.a n.a n.a n.a 0.02110
121.45h = 0.246
11 0 0.310 0.397 0.483 - 0.158 0.414 0.410 0.251
12 0 0.781 0.786 0.819 0.725 0.709 0.409 0.216 0.164
13 0 0.356 0.336 0.212 0.298 0.224 0.146 0.135 0.046
14 0 0.345 0.303 0.483 n.a n.a n.a 0.059 0.054
15 0 0.522 0.503 0.524 n.a n.a n.a n.a 0.032
16 0 0.190 0.251 0.236 0.492 0.076 0.010 n.d n.d
17 0 0.469 0.547 0.458 0.132 0.152 0.115 0.093 0.066
18 0 0.346 0.412 0.352 0.381 0.243 0.181 0.090 0.078
19 0 0.612 0.712 0.680 0.310 0.283 0.226 0.178 0.175
20 0 0.605 0.858 0.632 0.248 0.175 0.148 0.142 0.138
21 0 0.829 0.864 0.951 0.247 0.236 0.169 n.a n.a
22 0 0.494 0.448 0.607 0.426 0.373 0.274 0.245 0.159
23 0 0.862 1.498 1.274 0.110 0.123 0.224 0.415 0.253
24 0 0.800 0.721 0.820 0.683 0.589 0.321 0.213 0.150
25 0 0.389 0.420 0.730 0.142 0.139 0.472 0.271 0.212
26 0 0.911 0.818 0.672 0.226 0.220 0.151 0.069 0.047
27 0 0.615 0.757 0.478 0.782 0.703 0.431 0.212 0.409
28 0 0.313 0.676 0.463 0.678 0.606 0.567 0.489 0.516
29 0 0.831 0.584 0.872 0.741 0.663 0.454 0.290 0.179
30 0 0.821 0.903 0.833 1.042 1.019 0.544 0.490 0.373
n.a = no plasma available, n.d = not detectable, - = plasma not enough
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DPD phenotype (UH2/U urinary concentration ratio)
Patient # concentration of U (µM) Concentration of UH2 (µM) UH2/U ratio
1 4.14 n.d -
2 16.93 26.65 1.57
3 43.84 33.59 0.77
4 54.31 33.01 0.61
5 28.49 16.54 0.58
6 38.55 29.15 0.76
7 38.21 55.29 1.45
8 28.82 31.55 1.09
9 27.60 33.11 1.20
10 25.25 31.13 1.23
11 35.73 60.46 1.69
12 8.27 22.19 2.68
13 52.95 52.38 0.99
14 20.53 28.62 1.39
15 43.39 37.35 0.86
16 27.22 29.30 1.08
17 102.21 38.12 0.37
18 34.15 25.76 0.75
19 28.14 32.85 1.17
20 17.05 40.45 2.37
21 57.73 45.80 0.79
22 15.68 21.50 1.37
23 30.44 28.92 0.95
24 32.77 38.40 1.17
25 10.73 12.90 1.20
26 37.51 62.49 1.67
27 22.42 32.01 1.43
28 40.31 37.02 0.92
29 25.90 36.47 1.41
30 34.24 28.38 0.83
U = uracil, UH2 = dihydrouracil
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DPD genotype in patient number 1-10
Patient #exon
1 2 3 4 5 6 7 8 9 10
1 x x x x x x x x x x
2 x x x 85CC 85CC x x x 85CC x
3 x x x x x x x x x x
4 x x x x x x x x x x
5 x x x x x x x x x x
6 x x 496AG 496AG 496AG x x x 496AG x
7 x x x x x x x x x x
8 x x x x x x x x x x
9 x x x x x x x x x x
10 x x x x x x x x x x
11 x x x 1236GA x x x x x x
12 x x x x x x x x x x
13 1627AG x 1627AG x x 1627AG x x 1627GG 1601GA
14 x x x x x x x x x x
15 x x x x x x x x x x
16 x x x x x x x x x x
17 x x x x x x x x x x
18 x x x x x x x x x x
19 x x x x x x x x x x
20 x x x x x x x x x x
21 x x x x x x x x x x
22 x x x x x x x x x x
23 x x x x x x x x x x
DPD genotype in patient number 11-20
Patient #exon
11 12 13 14 15 16 17 18 19 20
1 x x x x x x x x x x
2 x x x 85CC x 85TC 85TC x 85TC 85TC
3 x x x x x x x x x x
4 x x x x x x x x x x
5 x x x x x x x x x x
6 496AG x x x x x 496AG x x 496AG
7 x x x x x x x x x x
8 x x x x x x x x x x
9 x x x x x x x x x x
10 x x x x x x x x x x
11 x x x x x x x x x x
12 x x x x x x x x x x
13 1627AG x 1627GG x 1627AG x x 1627AG x 1601GA
14 x x x x x x x x x x
15 x x x x x x x x x x
16 x x x x x x x x x x
17 x x x x x x x x x x
18 x x x x x x x x x x
19 x x x x x x x x x x
20 x x x x x x x x x x
21 x x x x x x x x x x
22 x x x x x x x x x x
23 x x x x x x x x x x
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DPD genotype in patient number 21-30
Patient #exon
21 22 23 24 25 26 27 28 29 30
1 x x x x x x x x x x
2 x 85TC x x x x x x x x
3 x x x x x x x x x x
4 x x x x x x x x x x
5 x x x x x x x x x x
6 x 496AG x x x x x x x x
7 x x x x x x x x x x
8 x x x x x x x x x x
9 x x x x x x x x x x
10 x x x x x x x x x x
11 x x x x x x x x x x
12 x x x x x x x x x x
13 x x x 1627AG x x x x 1627AG 1627AG
14 x x x x x x x x x x
15 x x x x x x x x x x
16 x x x x x x x x x x
17 x x x x x x x x x x
18 x x x x x 2194GA x 2194GA x x
19 x x x x x x x x x x
20 x x x x x x x x x x
21 x x x x x x x x x x
22 x x x x x x x x x x
23 x x x x x x x x x x
TS and MTHFR genotype in 30 patients
TS genotype MTHFR genotypePatient # 2R/2R 2R/3R 3R/3R C677C C677T T677T
1 x x
2 x x
3 x x
4 x x
5 x x
6 x x
7 x x
8 x x
9 x x
10 x x
11 x x
12 x x
13 x x
14 x x
15 x x
16 x x
17 x x
18 x x
19 x x
20 x x
21 x x
22 x x
23 x x
24 x x
25 x x
26 x x
27 x x
28 x x
29 x x
30 x x
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Patient characteristics
#ID Amt(mg)
Rate
(mg/h) Sex
Age
(yr.)
Ht
(cm)
Wt
(kg)
BMI
(kg/m2)
BSA
(m2) Co-med CLcr
GGT
(U/L)
ALT
(U/L)
AST
(U/L)
1 8804.07 76.17 M 68 170 76 26.3 1.79 1 95 38 27 19
2 6342.96 53.93 M 59 180 79 24.4 1.99 1 123.44 44 13 15
3 8856.94 74.36 M 37 181 79 24.1 1.91 0 144.89 13 13 16
4 8855.17 75.31 M 46 186 75 21.7 1.98 0 108.8 74 90 36
5 7535.4 63.44 F 58 162 49 18.7 1.502 1 81.78 13 16 15
6 9105.72 77.38 M 45 182 105 31.7 2.259 1 153.94 30 40 24
7 9004.36 75.27 M 41 186 68 19.7 1.91 1 108.72 16 15 18
8 8820.97 75.12 M 60 180 82 25.3 1.996 0 96.93 24 10 13
9 7848.13 65.58 F 50 161 57 22 1.594 0 99.28 21 22 23
10 9003.88 77.8 M 52 183 80 23.9 2.021 1 113.7 15 14 20
11 7944.56 66.52 M 46 172 53.5 18.1 1.609 1 114.5 31 8 18
12 7907.88 65.97 M 64 169 54 18.9 1.614 0 53.77 22 15 17
13 8929.91 74.57 M 62 184 111 32.8 2.358 0 93.22 28 19 17
14 8940.83 75.88 M 50 179 93 29 2.12 0 110.71 50 45 20
15 7944.23 67.9 F 60 164 59 21.9 1.591 0 76.33 24 14 16
16 8640.33 72.81 M 51 176 76 24.5 1.911 0 110.52 17 11 24
17 4688.15 39.93 F 70 165 46 16.9 1.482 0 86.4 33 8 10
18 8801.76 75.21 M 61 174 84 27.7 1.989 1 119.7 24 19 9
19 8681.78 71.38 M 58 167 75.8 27.2 1.786 1 90.59 24 14 14
20 8843.28 74.61 M 66 175 70 23 1.85 1 74.17 16 16 18
21 8860.5 75.23 M 71 173 99 33.1 2.124 0 111.62 16 12 10
22 8828.39 74.65 M 66 178 77 24.3 1.95 1 94.21 38 13 23
23 8844.7 74.4 M 68 176 66 21.3 1.81 1 76.74 22 10 19
24 8877.42 74.55 M 64 176 103 33.18 2.17 0 124.97 45 34 50
25 5816.28 49.03 M 70 172 68 23 1.8 1 74.28 23 15 18
26 8742.91 74.3 M 52 175 65 21.2 1.79 0 149.9 24 20 20
27 8368.03 69.48 F 40 165 62 22.8 1.68 0 82.24 16 14 19
28 9157.61 75.44 M 51 173 91 30.4 2.05 1 133.91 20 13 15
29 7645.053 63.72 M 66 180 89 27.5 2.09 0 120.36 18 24 18
30 7650 63.41 M 73 183 81 24.2 2.03 2 100.5 81 31 32
Amt = real dose (without remaining volume in device), rate = infusion rate (dose/duration of infusion), calculated from
real dose, sex: F = female, M = male, Ht = height, Wt = weight, BMI = body mass index, BSA = body surface area, Co-
med = co-mediation: 0 = without cisplatin, 1 = with cisplatin, CLcr = creatinine clearance, GGT = gamma-glutamyl
transaminase, ALT = alanine transaminase (SGPT, Serum glutamic pyruvic transaminase), AST = aspartate
transaminase (SGOT, Serum glutamic ocaloacetic transaminase)
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Pharmacokinetic data of 5-FU and 5-FUH2 for each patient (combined base model)
ID CL K30 K10 K13 CLres CLmet KEL
AUC of
5-FU
t1/2 of
5-FU CLm
t1/2 of 5-
FUH2
AUC of
5-FUH2
1 238.3 1.2 3.0 19.0 32.7 205.6 22.0 36.94 0.031 121 0.571 62.581
2 317.9 1.8 4.0 25.4 43.6 274.3 29.4 19.95 0.024 178 0.389 30.730
3 198.1 2.2 2.5 15.8 27.2 170.9 18.3 44.71 0.038 217 0.320 35.299
4 209.2 1.6 2.7 16.7 28.7 180.5 19.3 42.34 0.036 159 0.437 48.145
5 50.0 0.7 0.6 4.0 6.9 43.1 4.6 150.80 0.150 67 1.039 97.507
6 363.7 2.1 4.6 29.0 49.9 313.9 33.6 25.03 0.021 206 0.336 38.075
7 266.3 0.8 3.4 21.2 36.5 229.8 24.6 33.81 0.028 80 0.863 96.754
8 443.4 1.6 5.6 35.4 60.8 382.6 41.0 19.89 0.017 158 0.437 48.034
9 200.8 1.3 2.5 16.0 27.5 173.2 18.6 39.09 0.037 128 0.543 53.042
10 198.1 0.9 2.5 15.8 27.2 170.9 18.3 45.45 0.038 86 0.810 90.804
11 281.8 0.9 3.6 22.5 38.6 243.2 26.0 28.19 0.027 93 0.748 74.012
12 214.1 1.0 2.7 17.1 29.4 184.8 19.8 36.93 0.035 98 0.706 69.504
13 282.5 1.6 3.6 22.5 38.7 243.7 26.1 31.62 0.027 164 0.423 47.077
14 348.7 1.7 4.4 27.8 47.8 300.9 32.2 25.64 0.022 166 0.417 46.473
15 178.9 1.5 2.3 14.3 24.5 154.4 16.5 44.40 0.042 148 0.467 46.230
16 259.4 1.2 3.3 20.7 35.6 223.8 24.0 33.31 0.029 116 0.600 64.509
17 282.2 1.1 3.6 22.5 38.7 243.5 26.1 16.61 0.027 114 0.608 35.509
18 260.1 1.6 3.3 20.7 35.7 224.4 24.0 33.84 0.029 159 0.437 47.854
19 150.7 1.2 1.9 12.0 20.7 130.0 13.9 57.62 0.050 119 0.584 63.184
20 338.5 1.2 4.3 27.0 46.4 292.1 31.3 26.12 0.022 123 0.565 62.178
21 387.4 1.1 4.9 30.9 53.1 334.3 35.8 22.87 0.019 110 0.629 69.351
22 395.0 1.2 5.0 31.5 54.2 340.9 36.5 22.35 0.019 116 0.597 65.629
23 309.1 0.8 3.9 24.6 42.4 266.7 28.6 28.62 0.024 82 0.846 93.158
24 274.4 1.1 3.5 21.9 37.6 236.7 25.4 32.36 0.027 109 0.637 70.467
25 118.5 0.9 1.5 9.4 16.2 102.2 10.9 49.09 0.063 90 0.774 56.041
26 281.7 1.4 3.6 22.5 38.6 243.0 26.0 31.04 0.027 139 0.500 54.470
27 156.6 0.9 2.0 12.5 21.5 135.1 14.5 53.43 0.048 86 0.803 83.707
28 198.8 0.9 2.5 15.9 27.3 171.6 18.4 46.06 0.038 90 0.774 88.283
29 261.3 0.9 3.3 20.8 35.8 225.5 24.1 29.26 0.029 92 0.749 71.349
30 194.8 0.7 2.5 15.5 26.7 168.0 18.0 39.28 0.039 72 0.967 92.076
min 50.0 0.7 0.6 4.0 6.9 43.1 4.6 16.61 0.017 67 0.320 30.730
mean 255.3 1.2 3.2 20.4 35.0 220.3 23.6 38.22 0.035 123 0.619 63.401
mean* 237.7 1.2 3.0 19.0 32.6 205.1 22.0 34.49 0.032 117.1 0.592 60.397
median 260.7 1.2 3.3 20.8 35.8 224.9 24.1 33.56 0.029 115.8 0.598 62.882
max 443.4 2.2 5.6 35.4 60.8 382.6 41.0 150.80 0.150 216.5 1.039 97.507
SD 86.7 0.39 1.10 6.91 11.89 74.80 8.01 23.62 0.024 39.1 0.187 19.607
* = geometric mean, min = minimum value, max = maximum value, SD = standard deviation
CL = total clearance of 5-FU, K30 = elimination constant of 5-FUH2, K10 = residual elimination constant of 5-FU, K13 =
metabolic constant of 5-FU to 5-FUH2, CLres = residual elimination clearance of 5-FU, CLmet = metabolic clearance of
5-FU to 5-FUH2, CLm = clearance of 5-FUH2
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Pharmacokinetic data of 5-FU and 5-FUH2 for each patient (final covariate model)
ID CL K30 K10 K13 CLres CLmet
t1/2 of
5-FU
t1/2 of
5-FUH2
CLm
AUC of
5-FU
AUC of 5-
FUH2
1 246.9 1.22 3.05 19.26 33.8 213.1 0.031 0.570 121.6 35.66 62.50
2 324.7 1.78 4.01 25.33 44.4 280.3 0.024 0.388 178.5 19.53 30.68
3 172.0 2.13 2.13 13.41 23.5 148.4 0.045 0.325 213.2 51.51 35.86
4 222.7 1.59 2.75 17.37 30.5 192.2 0.034 0.436 159.0 39.77 48.08
5 49.4 0.67 0.61 3.86 6.8 42.7 0.155 1.037 66.8 152.46 97.31
6 392.9 2.07 4.86 30.65 53.7 339.2 0.020 0.335 206.6 23.18 38.05
7 272.6 0.80 3.37 21.27 37.3 235.3 0.028 0.861 80.5 33.03 96.58
8 441.0 1.59 5.45 34.40 60.3 380.7 0.017 0.435 159.2 20.00 47.84
9 196.4 1.28 2.43 15.32 26.9 169.5 0.039 0.542 127.9 39.96 52.96
10 216.5 0.86 2.68 16.89 29.6 186.9 0.035 0.810 85.6 41.59 90.81
11 255.0 0.93 3.15 19.90 34.9 220.2 0.030 0.742 93.4 31.15 73.43
12 215.1 0.98 2.66 16.78 29.4 185.7 0.036 0.704 98.4 36.76 69.36
13 299.6 1.64 3.70 23.37 41.0 258.6 0.026 0.423 163.9 29.81 47.04
14 368.1 1.66 4.55 28.71 50.3 317.7 0.021 0.417 166.3 24.29 46.41
15 185.0 1.48 2.29 14.43 25.3 159.7 0.041 0.467 148.4 42.95 46.21
16 266.2 1.16 3.29 20.77 36.4 229.8 0.029 0.598 115.8 32.46 64.40
17 267.7 1.14 3.31 20.88 36.6 231.1 0.029 0.606 114.3 17.52 35.41
18 272.1 1.59 3.36 21.23 37.2 234.9 0.028 0.435 159.2 32.34 47.74
19 164.1 1.19 2.03 12.80 22.4 141.7 0.047 0.585 118.5 52.91 63.23
20 344.2 1.23 4.26 26.85 47.1 297.1 0.022 0.563 123.1 25.69 62.03
21 393.8 1.10 4.87 30.72 53.9 339.9 0.019 0.628 110.4 22.50 69.28
22 390.4 1.17 4.83 30.46 53.4 337.0 0.020 0.595 116.5 22.61 65.42
23 300.6 0.82 3.72 23.45 41.1 259.5 0.026 0.844 82.1 29.43 92.94
24 266.5 1.09 3.29 20.79 36.4 230.0 0.029 0.636 108.9 33.32 70.37
25 111.7 0.90 1.38 8.71 15.3 96.4 0.069 0.766 90.4 52.06 55.51
26 285.8 1.39 3.53 22.30 39.1 246.7 0.027 0.500 138.6 30.59 54.46
27 150.0 0.87 1.85 11.70 20.5 129.5 0.051 0.797 86.9 55.79 83.08
28 209.8 0.90 2.59 16.37 28.7 181.1 0.037 0.773 89.6 43.65 88.22
29 272.5 0.93 3.37 21.26 37.3 235.3 0.028 0.748 92.6 28.05 71.27
30 204.4 0.72 2.53 15.94 28.0 176.4 0.038 0.965 71.8 37.44 91.96
min 49.4 0.67 0.61 3.86 6.8 42.7 0.017 0.325 66.8 17.52 30.68
mean 258.6 1.23 3.20 20.17 35.4 223.2 0.036 0.618 122.9 37.93 63.28
mean* 240.1 1.17 2.97 18.73 32.8 207.2 0.032 0.591 117.4 34.15 60.30
median 266.3 1.16 3.29 20.78 36.4 229.9 0.029 0.597 116.2 32.74 62.87
max 441.0 2.13 5.45 34.40 60.3 380.7 0.155 1.037 213.2 152.46 97.31
SD 88.8 0.39 1.10 6.93 12.2 76.7 0.025 0.186 38.8 23.98 19.53
* = geometric mean, min = minimum value, max = maximum value, SD = standard deviation
CL = total clearance of 5-FU, K30 = elimination constant of 5-FUH2, K10 = residual elimination constant of 5-FU, K13 =
metabolic constant of 5-FU to 5-FUH2, CLres = residual elimination clearance of 5-FU, CLmet = metabolic clearance of
5-FU to 5-FUH2, CLm = clearance of 5-FUH2
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Hematology response in 30 patients
Leukocyte count Erythrocyte count Platelet count
ID
# baseline
(x109/L)
nadir
(x109/L)
Change in
leukocyte
count (%)
baseline
(x1012/L)
nadir
(x1012/L)
Change in
erythrocyte
count (%)
baseline
(x109/L)
nadir
(x109/L)
Change in
platelet
count (%)
1 6.93 5.05 27.13 4.4 3.9 11.36 189 71 62.43
2 10.31 2.88 72.07 4.1 3.4 17.07 393 157 60.05
3 8.47 4.06 52.07 4.6 4.3 6.52 242 169 30.17
4 5.59 4.42 20.93 5.4 4.9 9.26 150 147 2.00
5 6.87 2.3 66.52 4.7 4.2 10.64 278 73 73.74
6 6.09 4.83 20.69 4.9 4.3 12.24 48 22 54.17
7 6.24 3.13 49.84 5.1 2.6 49.02 285 115 59.65
8 6.94 4.3 38.04 4.3 3.9 9.30 245 195 20.41
9 7.74 2.75 64.47 4.2 3.7 11.90 274 197 28.10
10 5.25 2.16 58.86 4.7 4.3 8.51 280 247 11.79
11 12.64 8.11 55.86 4.6 4.1 10.87 321 280 14.64
12 7.34 4.88 33.51 5.0 4.7 6.00 322 236 26.71
13 8.32 2.34 71.88 4.3 2.5 41.86 349 147 57.88
14 11.28 5.19 53.99 4.7 4.3 8.51 309 170 44.98
15 7.15 5.84 18.32 4.4 4 9.09 302 206 31.79
16 4.99 2.46 50.70 4.8 4.3 10.42 249 175 29.72
17 9.02 4.27 52.66 3.8 3.3 13.16 365 209 42.74
18 7.55 2.81 62.78 4.7 3.7 21.28 223 111 50.22
19 6.94 1.72 75.22 4.6 4 13.04 293 238 18.77
20 4.74 3.04 35.86 4.1 3.1 24.39 277 106 61.73
21 7.13 4.2 41.09 4.7 4.3 8.51 344 180 47.67
22 7.2 1.8 75.00 4.3 3.58 16.74 256 115 55.08
23 6.71 4.19 37.56 4.4 4.1 6.82 364 214 41.21
24 6.39 3.3 48.36 5.3 5 5.66 258 170 34.11
25 13.66 5.0 215
26 6.00 3.88 35.33 5.1 4.6 9.80 293 239 18.43
27 7.36 3.05 58.56 4.3 3.8 11.63 426 229 46.24
28 3.99 2.35 41.10 4.9 4.4 10.20 172 98 43.02
29 6.24 3.39 45.67 4.8 4.3 10.42 375 201 46.40
30 6.09 3 50.74 4.7 3.7 21.28 147 108 26.53
